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In sub-Saharan Africa previous efforts to control malaria have proved less successful mostly 
due to prolonged use of less efficacious mono-therapy drugs to which Plasmodium falciparum 
has developed drug resistance. In most parts of malaria endemic regions chloroquine (CQ) 
was found to be poorly effective for several decades but it was still being prescribed until 
recently. In Tanzania, for instance, P.falciparum was already resistant to CQ in more than 60% 
of all P. falciparum positive patients back in the late 80’s but was still used until when it was 
possible to replace it  by sulfadoxine-pyrimethamine (SP)  in 2001. SP is anti-folate sulfa 
based anti-malaria drug that was adopted as an interim first line drug by many malaria 
endemic countries as there was no affordable immediate alternative to CQ. Elsewhere in sub-
Saharan Africa Zambia was the first African country to embrace policy change with efficacious 
anti-malaria combination therapy using Artemisinin-based Combination Therapy (ACT) back in 
2004 after support from global funds.   
 
Until 1990, the past three decades have had a sustained global focus on malaria control 
strategy with the aim of intensifying developing intervention tools. This was preceded by 
specific eradication efforts of the 1940s, which were intensified in most parts of Southern 
Europe and America.   It was during this period that the global focus on malaria sustained a 
great deal of change.  In that same period therefore, the main focus was on technical issues 
as well as research and development for new tools, that could lead to advances in drug and 
vaccine development alongside vector control strategies. There were medium term gains 
during this period but at the same time some challenges were recorded. Key among these 
challenges was the fragmented global efforts, whereby there was total loss of a broad based 
global focus to a joint strategy on the fight against malaria. This resulted in little global support 
with no clear roadmap for developing states, mostly in Sub Saharan Africa, to establish 
adequate health systems and primary health care for comprehensive malaria management.  
These challenges resulted in to overuse of ant-malaria mono-therapies that were cheaply 
available in most of these countries and led to development of parasite resistance to drugs 
with far reaching consequences. Towards the mid of 1990s, the combination of a worsening 
malaria situation and emerging positive  technical developments led to renewed global focus 
on malaria control.  It is for the same reason that in 2000 the global head of states developed 
a joint position to address the global disease burden most affecting developing countries as 
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part of the Millennium Development Goals (MDG) of global programme on development to be 
achieved by 2015. Two goals were developed to improved health for the Under Five (U5e.i, 
MDG4 and MGD6.  MGD4 sets target to reduce child mortality by two third by 2015 while 
MGD6 aims at combating malaria and other major infectious diseases (HIV and TB) by year 
2015 as compared to baseline 1990.  
 
As the results of the launch of these global initiatives, a number of new strategies and tools 
against malaria have been developed and existing ones sharpened to better address the 
problem. Not later than beginning of last decade, Artemisinin-based Combination Therapy 
(ACT) emerged as potential therapeutically efficacious proven tool to combat malaria. In the 
face of growing anti-malarial drug resistance due to the use of mono-therapies, ACT has 
placed itself as a novel treatment for malaria treatment. Use of insecticide Treated Mosquito 
bed-Nets (ITN) has also been advocated. With the support of Global Health Partners, ITN 
have been made available to the vulnerable persons within endemic communities. Support to 
control malaria has exceeded $ 1000 million a year but malaria still exerts a threat to the U5 
and expectant mothers. 
 
In Tanzania ACT as the first line anti-malaria drug was introduced in late 2006, scaled for 
country wide use in 2007. The ACT implementations in Tanzania bear some similarities with 
approaches in other African countries but there are still major differences. Tanzania has a 
homogenous health system that facilitated the rolled out of the malaria control programme as 
part of the primary Health Care (PHC) system. This was also supported by the evidence 
generated from the North-South research collaborations that informed policy makers. 
Government and non-state collaboration within Tanzania was key in informing the above 
process. In some cases cross boarder collaboration among economic blocks of East Africa 
and Southern African Development Community (SADC) have provided insights into the control 
of malaria in the continent. 
Some of the novel implementation tools developed and tested in Tanzania have been applied 
in the rest of Sub-Saharan malaria endemic states and often supported the global campaign 
against malaria.  In Tanzania, political stability and peace for over four decades has also made 
it easy for quick policy change and scale up of control interventions using ACT this could have 
been different in neighboring nations like Uganda, Sudan, Mozambique and Democratic 
republic of Congo which have experienced civil strife during this period. Tanzania has 
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emerged as one of the few African countries that provided the ground to test some of the most 
successful malaria control interventions for the rest of the world to up-scale.  
 
 The Kilombero River basin in Ifakara Tanzania is a known cradle for malaria endemicity. 
Several novel interventions have been tested for efficacy and then evaluated for impact during 
roll out as programmes. Most findings presented in this thesis have been largely derived from 
the Ifakara Demographic surveillance system among other study sites in Tanzania. This work 
has provided major insights into the policy change for ACT and its implementation at the 
national scale.   
 
The aim of the PhD work presented here was to contribute to a better understanding of the 
impact of the ACT introduction on malaria morbidity and mortality in rural Tanzania and to 
monitor its long-term safety when used at country wide. 
 
Availability of baseline efficacy profile, mobilization of stakeholders including participating 
communities and preparedness among researchers accelerated policy implementation in most 
part of Tanzania right from the on-set of policy inception. Findings from the Interdisciplinary 
Monitoring Project of Anti-malaria Combination Therapy (IMPACT) and East African Network 
for Monitoring Anti-malaria Treatment (EANMAT) programmes as described in this thesis have 
provided evidence that informed policy. The invivo studies have shown that artemether-
lumefantrine (AL) was nearly 100% efficacious after controlling for re-infection by Polymerase 
Chain Reaction (PCR) in children U5 years in the years prior policy change.  We have also 
shown that in real life situation it is possible to build comprehensive researchers-policy 
makers-pharmaceutical industry partnership to implement strategies for monitoring safety and 
proper use of anti-malaria drugs as reported in the programme Artemether-Lumefantrine In 
Vulnerable patients: Exploring health Impact (ALIVE). We were able, for the first time in the 
ALIVE project to describe a compliance of more than 95% using a complex six-dose regimen 
for AL in a randomized study conducted at community level. We have report the establishment 
of a pharmacovigilance system in a rural community that also tested for the first time the use 
of mobile phone technology with SMS to report anti-malarial serious adverse events (SAE). 
The ALIVE project provided an assessment of the impact of ACT and other malarial 
interventions on child mortality as well as on malaria transmission.  It demonstrated that for 
every 10% increases in ITN coverage, there was a 48% reduction in the annual community 
parasitaemia [IRR=0.52; 95% CI=0.38 to 0.73]. It also showed that, compared to a period 
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when anti-malaria first line was SP, ACT was responsible for nearly 11% annual decreases in 
under five mortality when adjusted for other key factors [IRR= 0.89; 95% CI=0.79 to 1.0].  
ALIVE also showed the relationship of key contextual factors with malaria interventions and U5 
child mortality. Food security was major determinant of under five child mortality; notably the 
rice yields was responsible for nearly 36% reduction in annual mortality [IRR=0.64; 95% 
CI=0.54 to 0.75]. As far as malaria transmission is concerned, we observed parallel a 65% 
reduction of parasite prevalence in asymptomatic community members of study area as 
compared to baseline in 2006 before ACT was introduced in the study population. 
 
Lastly, these effects are likely to be sustainable since the efficacy of AL, as evaluated with an 
invivo study conducted one year after implementation has remained above 96% in the 
Kilombero valley in spite of its wide scale use. The findings of this thesis attest the importance 
of policy change in malaria control supported by evidence gathered from operational 
researches. The lessons learned from this work will be relevant to similar interventions locally 
and on a global scale in most malaria affected communities. We have also learnt that safety 
and compliance issues of medicinal products that are deployed at large scale such as ACT 
should be monitored and managed by strong partnership involving the Ministry of Health and it 
allied departments, the pharmaceutical industries when possible, the researchers and most 
importantly with full participation and support of local leadership and communities. We, 
recommend that this partnership gain support from other global health partners to ensure 
safety of drugs through rigorous monitoring of its use and long life span. Capacity building of 
market and policy implementers is another critical aspect that should be given priority. We also 
recommend that resources be made available to strengthen the health system (human 
resource, Health Information System and Infrastructure) in order to gain sustained results in 
malaria control. This will further create enabling environment and a critical mass of scientists 
and public health experts to spearhead anti-malaria policy implementations properly and 
monitor it on timely basis.  
 
As outlined in this work, a successful campaign against malaria can be realized through 
combining efforts of researchers, policy makers, global health development partners and 
communities. This partnership has lead to real life time achievements related programmes, 
such as the 1940s malaria elimination campaign in Sardinia Island of Italy.  
 
 





In Subsahara-Afrika haben sich die bisherigen Bemühungen zur Bekämpfung von Malaria als 
wenig erfolgreich erwiesen, da vor allem auf eine Mono-Medikamente-Therapie gesetzt wurde, 
gegen welche Plasmodium falciparum inzwischen Resistenzen entwickelt hat. Obwohl sich 
Chloroquin (CQ) in den letzten Jahrzehnten in den meisten Malariagebieten als nur teilweise 
wirksam erwies, wurde es noch bis vor kurzem eingesetzt.  
Bereits in den späten 1980er Jahren wurden beispielsweise in Tansania in über 60% der 
P.falciparum-positiven Patienten Resistenzen gegenüber CQ festgestellt. Trotzdem wurde CQ 
erst im Jahre 2001 durch Sulfadoxin-Pyrimethamin (SP) ersetzt. SP ist ein Malaria-
Medikament, das in vielen Malaria-endemischen Ländern als Zwischenlösung eingeführt 
wurde, da noch keine erschwingliche Alternative zu CQ zur Verfügung stand. Etwa zur selben 
Zeit erlebte Sambia als erstes afrikanisches Land einen Politikwandel und führte 2004 mithilfe 
globaler Fördermittel die effizientere Artemisinin-based Combination Therapy (ACT) ein. 
 
Zwischen 1960 und 1990 wurde der Fokus auf eine nachhaltige Malaria-Kontroll-Strategie 
gelegt, die zum Ziel hatte, die Interventionsstrategien der Entwicklungsländer zu fördern. 
Vorangegangen sind in den 1940er Jahren spezifische Maßnahmen zur Ausrottung, wobei der 
Schwerpunkt auf technische Fragen sowie auf die Forschung und Entwicklung von neuen 
Werkzeugen gelegt wurde, die zu Fortschritten in der Medikamenten- und 
Impfstoffentwicklung, sowie in der Vektorkontrollstrategie hätten führen sollen. Es gab 
mittelfristig einige Errungenschaften, gleichzeitig entstanden aber in diesem Zeitraum auch 
neue Herausforderungen. Eine Hauptherausforderung lag in den globalen Bemühungen, die 
eine fokussierte, breit angelegte Strategie zur Bekämpfung von Malaria erschwerte. Dies war 
auch der Grund, weshalb es den Ländern südlich der Sahara nicht gelang, eine angemessene 
Gesundheitsversorgung aufzubauen. Sie waren deshalb immer noch von veralteten Mono-
Therapien abhängig, die zwar in den meisten Ländern zu günstigen Preisen zur Verfügung 
standen, aber wegen deren chronischen Überbeanspruchung zur Entwicklung von 
Resistenzen beitrugen. Mitte der 1990er Jahre führte die verschlechterte Situation bezüglich 
Malaria zusammen mit den sich abzeichnenden positiven technischen Entwicklungen dazu, 
dass die Kontrolle von Malaria wieder in den globalen Fokus rückte. 
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Aus dem gleichen Grund versuchten im Jahr 2000 verschiedene Staatschefs eine 
gemeinsame Position bezüglich der Strategie zur Bekämpfung der wichtigsten Krankheiten zu 
finden. Zwei Ziele wurden in Form der Millennium Development Goals (MDG) konkret 
formuliert und sollten bis 2015 erreicht werden. Das MGD 4 bestand darin die 
Kindersterblichkeit bezogen auf das Jahr 1990 um zwei Drittel zu senken, während MGD 6 
darauf abzielte die Bekämpfung von Malaria und anderen schweren Infektionskrankheiten 
(z.B. HIV und TB) bezüglich der Situation in 1990 deutlich zu verbessern. 
 
Diese globalen Initiativen vermochten einige bereits bestehenden Interventionsstrategien 
gegen Malaria zu verbessern und halfen zur Entwicklung einer Reihe neuer Instrumente und 
Strategien bei. Erst zu Beginn des letzten Jahrzehnts kam die „Artemisinin-based Combination 
Therapy“ (ACT) als eine Alternative zu den Mono-Therapien auf, welche wegen der 
wachsenden Resistenz immer mehr an Wirksamkeit einbüsste. Des Weiteren wurde auch für 
den Einsatz von „insecticide treated mosquito bed-nets“ (ITNs) plädiert. Dank der 
Unterstützung von Global Health Partnern, konnten die ITNs nun für viele in Malaria-
endemischen Gebieten lebende Personen zugänglich gemacht werden. Obwohl bisher jährlich 
über 1000 Millionen US$ für die Bekämpfung von Malaria ausgegeben wurden, stellt Malaria 
weiterhin eine grosse Bedrohung vor allem für Kinder unter 5 Jahren und für schwangere 
Frauen dar.  
 
ACT wurde als Haupt-Malaria-Medikament in Tansania gegen Ende 2006 eingeführt und 2007 
auf das ganze Land ausgeweitet. Die Realisierung dieses Projekts hatte einige Ähnlichkeiten 
mit Ansätzen in anderen afrikanischen Ländern, jedoch gibt es nach wie vor grosse 
Unterschiede. Das homogene Gesundheitssystem in Tansania im Allgemeinen und das 
„Primary Health Care“ (PHC) System im Speziellen erleichterten die Realisierung dieser 
Malaria-Programme erheblich. Auch die Erkenntnisse, die im Rahmen der Nord-Süd-
Forschungskooperationen gewonnen wurden, die Kollaborationen zwischen NGOs und der 
Regierung, sowie die Bereitstellung der erforderlichen Nachweise durch die politischen 
Entscheidungsträger, führten schliesslich zu einer erfolgreichen Umsetzung. Zusätzlich 
ermöglichte die Zusammenarbeit zwischen den wirtschaftlichen Blöcken Ostafrikas und der 
„Southern African Development Community“ (SADC) neue Einblicke in die 
grenzüberschreitende Kontrolle von Malaria. 
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Einige dieser in Tansania neu entwickelten und praxis-erprobten Instrumente wurden auch in 
anderen Staaten südlich der Sahara angewandt und dabei oft von globalen anti-Malaria 
Kampagnen unterstützt.  
 
Die politische Stabilität und der Frieden in Tansania während mehr als vier Jahrzehnten haben 
ein schnelles Umdenken in der Politik und die landesweite Ausdehnung der ACT-
Kontrollstrategie überhaupt erst ermöglicht. Viele benachbarte Länder wie Uganda, Sudan, 
Mozambique und die Demokratische Republik Kongo erlebten im gleichen Zeitraum viele 
Unruhen. Tansania hat sich als eines der wenigen afrikanischen Länder nicht gescheut sich 
dem Rest der Welt für Grossversuche der heute erfolgreichsten Interventionen gegen Malaria 
zur Verfügung zu stellen. 
 
Der Kilombero River Basin in Ifakara Tansania wird als Wiege von Malaria bezeichnet. Etliche 
neue Interventionen wurden auf ihre Wirksamkeit getestet und evaluiert. Die in dieser Arbeit 
präsentierten Ergebnisse wurden hauptsächlich aus verschiedenen Studienzentren in 
Tansania zusammengetragen, wobei der grösste Teil aus dem „Ifakara Demographic 
Surveillance System“ stammt.  Die vorliegende Arbeit gewährt Einblicke in das von Tansania 
verfolgte Programm zur landesweiten Umsetzung der ACT. 
 
Das Ziel der Doktorarbeit ist es, einen Beitrag zum besseren Verständnis der Auswirkungen, 
welche die Einführung der ACT auf die Malaria Morbidität und Mortalität hatte, beizutragen 
und die langfristige Sicherheit im landesweiten Einsatz zu überwachen. 
 
Die erfolgreiche Einbindung der Akteure, insbesondere der teilnehmenden Communities, 
sowie die grosse Bereitschaft unter den Forschern beschleunigten die Umsetzung der neuen 
Richtlinien von Beginn an. Die auf Beweisen basierten Erkenntnisse, die aus dem 
“Interdisciplinary Monitoring Project of anti-malaria Combination Therapy” (IMPACT) und dem 
“East African Network for Monitoring anti-malaria Treatment” (EANMAT) gewonnen wurden, 
werden in die Entwicklung von neuen Richtlinien einfliessen. Die in vivo Studien haben 
gezeigt, dass Artemether-Lumefantrin (AL) nach Kontrolle der Reinfektion durch Polymase 
Chain Reaction (PCR) bei Kindern unter fünf Jahren nahezu 100% wirksam war. Wir haben 
ebenfalls bewiesen, dass es durch eine intensive Zusammenarbeit zwischen Forschung, 
Politik und der pharmazeutischen Industrie möglich ist, auch unter Realbedingungen 
Strategien für die Überwachung der Sicherheit und dem sachgemäßen Gebrauch von Anti-
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Malaria-Medikamenten umzusetzen. Das „Exploring Health Impact“ Programm (ALIVE) war als 
erstes Programm überhaupt in der Lage, in einem randomisierten Beurteilungsdesign auf 
Community-Level eine Compliance von mehr als 95% zu einer komplexen 6 Dosen Therapie 
von Artemether-Lumefantrin (AL) aufzuzeigen. In Kapitel 5 wird berichtet, dass „ALIVE-
pharmacovigilance“ afrikaweit die erste community-based Pharmakovigilanz-Studie ist, welche 
auch die Verwendung von SMS als Überbringer von schweren Nebenwirkungen untersucht. 
Das Projekt ALIVE gewährt sowohl einen Einblick in die Auswirkungen von ACT und  anderen 
Interventionen auf die Kindersterblichkeit und die Prävalenz. ALIVE hat gezeigt, dass eine 
Erhöhung der ITN Abdeckung um 10% eine Verringerung von 48% jährlicher Malaria-
bedingten Parasitämie auf kommunaler Ebene erzielt [IRR=0.52; 95% CI=0.38 to 0.73]. Es 
wurde ebenfalls gezeigt, dass im Vergleich zu der Zeit, als in erster Linie noch SP verwendet 
wurde, ACT für ungefähr 11% der jährlichen Reduktion der Mortalität verantwortlich war, wenn 
man für andere wichtige Faktoren stratifiziert [IRR = 0,89, 95% CI = 0,79 bis 1,0]. Des 
Weiteren wurde beobachtet, dass die Erhöhung der Ernährungssicherheit, insbesondere der 
Reiserträge, für fast 36% der Reduktion der jährlichen Mortalität von Kindern unter 5 Jahren 
verantwortlich war [IRR = 0,64, 95% CI = 0,54 - 0,75]. Hinsichtlich der Übertragung von 
Malaria wurde parallel eine Parasiten-Prävalenz Reduktion von 65% bei asymptomatischen 
Community-Mitgliedern im DSS in Ifakara aufgezeichnet, im Vergleich zum Ausgangswert im 
Jahr 2006 als ACT eingeführt wurde. 
 
 
Darüber hinaus wurden diese Auswirkungen als nachhaltig beurteilt, da die Wirksamkeit von 
AL, wie anhand einer in vivo Studie ein Jahr nach Umsetzung gezeigt, im Kilombero-Tal bei 
über 96% liegt.  
Die Ergebnisse dieser Arbeit unterstreichen die Bedeutung des politischen Wandels in der 
Malariabekämpfung. Dazu gehört die Forschung als systematischer Weg, um das 
Gesundheitssystem zu stärken und sich in der Malaria Bekämpfung innerhalb eines 
endemischen Entwicklungslands zu engagieren. Die Erfahrungen aus dieser Arbeit werden 
relevant sein für Malaria-betroffene Gebiete vor Ort und auf globaler Ebene. Wir haben auch 
gelernt, dass die Sicherheit und Compliance von Arzneimitteln, die, wie ACT, im großen 
Maßstab eingesetzt werden überwacht und verwaltet werden muss. Dabei sollten das 
Gesundheitsministerium und verwandte Fachbereiche sowie die pharmazeutische Industrie 
und Forschungspartner, als auch die örtliche Führung miteinbezogen werden. Wir empfehlen, 
dass diese Partnerschaft von globalen Gesundheitsorganisationen unterstützt wird. Die 
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rigorose Überwachung der ordnungsgemässen Verwendung von Medikamenten würde zu 
einem besseren Verständnis betreffend der Fragen der Sicherheit von Arzneimitteln führen, 
sowie deren Lebensdauer verlängern. Ein weiterer kritischer Aspekt, welcher den Vorrang 
eingeräumt werden sollte, ist der Aufbau von Kapazitäten. Wir empfehlen, dass Ressourcen 
zur Verfügung gestellt werden um das Gesundheitssystem in Malaria-endemischen Gebieten 
zu stärken (human resources, Health Information und Infrastruktur), um nachhaltige 
Ergebnisse in der Malariabekämpfung zu erreichen. Damit werden günstige 
Rahmenbedingungen geschaffen um eine wirksame, regelmässig überwachte, Anti-Malaria-
Politik zu implementieren. 
 
Wie in dieser Arbeit erläutert, kann eine erfolgreiche Kampagne gegen Malaria durch die 
Bemühungen der Forscher, politischer Entscheidungsträger, globaler Entwicklungs-Partnern 
und der lokalen Gemeinden realisiert werden. Eine solche Partnerschaft hat bereits Erfolge 
erzielt, wie das Beispiel in den 1940er Jahren der Malaria Eliminationskampagne in Sardinien, 
Italien zeigt. 





Juhudi za kupambana na malaria katika Afrika Kusini mwa jangwa la Sahara zimeonyesha 
kuwa na mafanikio madogo kutokana na matumizi ya muda mrefu ya madawa yenye ufanisi 
hafifu yasiyo mseto ambayo wadudu wa malaria wamejenga usugu. Katika sehemu nyingi 
zinazo athiriwa na malaria, dawa ya chloroquine ilionekana kutofanya kazi vizuri kwa miongo 
kadhaa, lakini bado iliendelea kutolewa kwa ajili ya matibabu ya malaria mpaka katika siku za 
karibuni. Kwa mfano katika Tanzania, vijidudu vya malaria vilikuwa tayari vimejijenga usugu 
kwa dawa ya chloroquine kwa zaidi ya 60% kwa wagonjwa wengi waliokuwa na malaria katika 
miaka ya mwishoni mwa 1980 hivi lakini iliendelea kupewa wagonjwa mpaka pale 
ilipowezekana kupata mbadala na kuanza kutumika dawa ya SP (sulfadoxine-pyrimethamine) 
katika mwaka 2001. SP ni dawa ya kutibu malaria inayotokana na salfa iliyotumika kama dawa 
ya mstari wa mbele kutibu malaria katika kipindi cha mpito katika nchi nyingi zinazoathiriwa na 
malaria kwa kuwa hakukuwa na dawa yenye gharama nafuu mbadala wa chloroquine. 
Kwingineko katika Afrika Kusini mwa Sahara, Zambia ilikuwa nchi ya mwanzo ya Afrika 
kubadili mkakati kwa kutumia dawa ya malaria ya mseto yenye Artemisini tangu mwaka 2004 
kwa msaada kutoka mfuko wa dunia. 
 
Mpaka mwaka 1990, miongo mitatu iliyopita ilikuwa na mikakati yenye kuendelea katika 
kupambana na malaria ambapo mpango kamambe ulikuwa kutafuta na kendeleza mbinu 
mpya za kupambana na malaria. Hii ilitanguliwa na mpango wa kuondoa kabisa malaria ya 
miaka ya 1940 iliyokuwa na nguvu sana sehemu za kusini mwa Ulaya na Marekani. Katika 
kipindi hicho ndipo mikakati ya ulimwengu ya kupambana na malaria ilipata mabadiliko na 
chachu kubwa. Kwa hivyo, katika kipindi hicho hicho nguvu kubwa ilielekezwa kwenye mambo 
ya kiufundi na utafiti na ugunduzi wa zana mpya ambazo zinapelekea maendeleo zaidi katika 
kupambana na malaria kwa kupata dawa bora na chanjo sambamba na kupata mbinu za kuua 
na kujikinga na mbu. Mafanikio ya muda yalipatikana na pia kulikuwepo na changamoto 
zilizorekodiwa. Changamoto kubwa kabisa ilikuwa ni kukosekana juhudi za pamoja za 
kiulimwengu,  ambapo mwelekeo, mkakati na nguvu za pamoja vilikosekana katika 
kupambana na malaria. Matokeo yake yalikuwa uwepo wa uungwaji mkono hafifu 
ulimwenguni  na kutokuwepo mwelekeo na mipango thabiti hasa kwa ajili ya nchi 
zinazoendela hasa Afrika kusini mwa Sahara kuweza kuimarisha miundo mbinu na afya ya 
msingi kwa ajili ya kudhibiti malaria kiujumla wake. Changamoto hizi zilipelekea kuendelea 
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kwa matumizi makubwa ya dawa zisizo mchanganyiko zinazopatikana kwa kiurahisi katika 
nchi nyingi za Afrika kusini mwa Sahara iliyopelekea vijidudu vinavyosabisha malaria kujijenga 
usugu kwa dawa na kusababisha madhara makubwa. Kuelekea miaka ya 1990 hivi, mjumuiko 
wa hali mbaya ya malaria na kuibuka kwa maendeleo chanya ya kiufundi yalipelekea kuwepo 
kwa nguvu mpya ya kiulimwengu katika kuelekeza nguvu katika kupambana na malaria. Na 
kutokana na sababu hizo hizo, mwaka 2000 wakuu wa nchi wa ulimwengu walitengeneza 
mkakati wa pamoja kutatua matatizo makubwa ya magonjwa ulimwenguni hasa yanayoathiri 
nchi zinazoendelea unaoitwa mkakati wa Milenia unaotakiwa kufikiwa 2015. Katika malengo 
yaliyomo, mawili yanaelekeza nguvu kuimarisha afya ya watoto chini ya miaka mitano (Lengo 
4 na 6). Lengo namba 4 linapanga kupunguza vifo vya watoto kwa 2/3 mpaka 2015, wakati 
lengo namba 6 linalenga kupambana na malaria na magonjwa mengine ya kuambukiza 
(Malaria na Ukimwi) ifikapo 2015 ukilinganisha na kiwango cha kuanzia cha 1990.    
 
Matokeo ya kuanzishwa kwa malengo ya Milennia ya kiulimwengu, imepelekea mikakati mingi 
mipya ya kupambana na malaria imebuniwa na ile iliyokuwepo kutengenezwa vizuri kuweza 
kufanya kazi vizuri zaidi kupambana na tatizo la malaria. Sio kipindi kirefu katika mwanzo wa 
mwongo uliopita ambapo dawa mseto yenye Artemisinin (ACT) imeibuliwa na kuwa tegemeo 
kubwa na inayofanya kazi vizuri kupambana na malaria. Katika hali ya kukua kwa usugu wa 
madawa ya malaria kutokana na kutumia dawa zisizo za mseto, ACT imekuwa ugunduzi mpya 
na mzuri  katika kutibu malaria. Matumizi ya vyandarua vyenye viuatilifu (vilivyowekwa dawa) 
pia vinatiliwa mkazo. Kwa kuungwa mkono na msaada wa Kiulimwengu wa kiafya, vyandarua 
vyenye dawa vimewezeshwa kupatikana kwa watu walio kwenye hatari zaidi katika jamii 
zinazoathiriwa zaidi na malaria. Msaada katika kupambana na malaria imefikia zaidi ya $1000 
milioni kwa mwaka lakini malaria bado ni tatizo kubwa kwa watoto chini ya miaka mitano na 
akina mama wajawazito.  
 
Katika Tanzania ACT kama dawa ya mstari wa mbele katika kutibu malaria ilianza mwishoni 
mwa mwaka 2006, na utekelezaji wake ulienea mwaka 2007. Utekelezaji wa matumizi ya ACT 
unafanana na ule wan chi nyingine za Afrika ingawa kuna utofauti. Miundo mbinu ya afya ya 
Tanzania ni ya aina moja katika wilaya zote ambayo inawezesha utekelezaji kuenezwa kama 
sehemu ya afya ya msingi. Hii ilisaidiwa na ushahidi uliotokana na utafiti wa kiumoja wa nchi 
za Kaskazini- Kusini (utafiti wa ushirika wa nchi zilizoendelea za kaskazini na zinazoendelea 
za Kusini) ambapo majibu yake yaliwafikia na kuwasaidia watunga sera. Ushirikiano wa 
Serikali ya Tanzania pamoja na mashirika yasiyo ya kiserikali yalisaidia sana kufahamisha na 
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kuwezesha utekelezaji wa sera kama ilivyoelezwa hapo mwanzoni.  Wakati mwingine, 
ushirikiano wa umoja wan chi mbalimbali katika masuala ya kiuchumi kama Jumuiya ya Afrika 
Mashariki na ile ya nchi za kusini mwa Africa imesaidia kutoa mwanga na mwelekeo katika 
juhudi za kudhibiti malaria katika bara la Afrika. 
 
Baadhi ya mbinu mpya za utekelezaji zilizobuniwa na kufanyiwa majaribio nchini Tanzania 
zimefanyiwa pia majaribio pia katika nchi nyingine Afrika kusini mwa Sahara zenye tatizo la 
malaria na kusaidiwa na harakati za kilimwengu za kupambana na malaria. Katika Tanzania, 
hali ya utulivu wa kisiasa katika miongo minne imesaidia kurahisisha kubadilisha sera na 
kueneza utekelezaji wa kutumia ACT suala ambalo lingekuwa na ugumu katika nchi za jirani 
kama  Uganda, Sudani, Msumbiji na Kongo ambazo zimekuwa na matatizo ya vita vya 
wenyewe kwa wenyewe katika kipindi hicho. Tanzania imetokea kuwa ni sehemu chache 
muhimu katika nchi za Afrika  ambapo majaribio ya mikakati ya kudhibiti malaria imefanyika 
kisha kunakiliwa sehemu nyingine duniani.  
 
 Bonde la Mto Kilombero lililopo Ifakara Tanzania linajulikana kwa kuathiriwa sana na malaria. 
Mbinu mpya nzuri zimejaribiwa kuangalia ufanyaji kazi katika uangalizi maalumu na baadaye 
kufanyiwa tathimini zaidi ya kufanya kazi katika hali ya kawaida ya utekelezaji mkubwa. 
Sehemu kubwa ya matokeo ya kitabu hiki cha kazi ya masomo ya juu ya philosofia 
yametokana na shughuli za ufuatiliaji wa kuendelea wa maisha ya watu ya kila siku katika 
bonde la Ifakara ambayo ni moja ya ufuatilia unaoendelea Tanzania. Kazi imeonesha 
mabadiliko ya sera ya ACT na utekelezaji wake katika ngazi ya kitaifa.   
 
Lengo la kazi hii ya kwa ajili ya shahada yangu ya philosofia inayoelezwa hapa ni kuchangia 
uelewa wa matokeo ya matumizi ya dawa ya ACT katika kupunguza kuugua na vifo 
vinavyotokana na malaria katika maeneo ya vijijini katika nchi ya Tanzania na kufuatilia 
matokeo yake ya kiusalama katika muda mrefu inapotumika katika nchi nzima. 
 
Upatikanaji wa taarifa za awali za ufanyaji kazi wa dawa katika hali ya uangalizi wa kitaalam, 
kuwaleta pamoja washika dau mbalimbali wakiwemo wanajamii wanaoshiriki, hali ya 
maandalizi inayofanywa na watafiti imerahisisha utekelezaji sera katika sehemu nyingi za nchi 
ya Tanzania pale tu mabadiliko ya sera ya matumizi ya dawa ya ACT kwa malaria ilipofanyika. 
Matokeo ya utafiti wa malaria mkubwa wa Tanzania (The Interdisciplinary Monitoring Project 
of Anti-malaria Combination Therapy-(IMPACT) na nchi za Africa Mashariki (East African 
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Network for Monitoring Anti-malaria Treatment –EANMAT programmes) kama ilivyoelezewa 
katika kitabu hiki cha kazi, imesaidia kutoa takwimu na taarifa kwa wakati kwa ajili ya utungaji 
sera. Matokeo ya utafiti wa mwanzoni wa dawa kwa matumizi ya binadamu (invivo studies) 
yameonyesha kuwa dawa ya ACT inafanya kazi vizuri sana karibu 100% ukishaondoa tatizo la 
kurudiwa kupata maambukizi mapya kwa watoto wa chini ya miaka mitano katika kipindi cha 
miaka kabla ya kubadilisha sera.  
 
Vilevile tumeweza kuonesha kuwa katika maisha ya kawaida inawezekana kujenga kundi la 
umoja imara unaojumuisha watafiti, watunga sera na watengenezaji dawa kutekeleza mikakati 
ya kufuatilia usalama na matumizi sahihi ya dawa za kudhibiti malaria kama kwenye utafiti 
uliojulikana kama ALIVE (Artemether-Lumefantrine In Vulnerable patients) ulioangalia afya za 
makundi maalumu katika jamii. Kwa mara ya kwanza, tuliweza katika mradi wa ALIVE kuona 
kwamba kutumia dawa kwa wakati kwa 95% kwa dawa yenye kutumika mara sita katika utafiti 
uliotumia uchaguzi wa kaya kwa bahati nasibu katika jamii ya vijijini. 
 
Tumetoa taarifa ya kuanzisha mtandao wa kufuatilia matumizi ya dawa katika jamii ya vijijini 
kwa ujumla (pharmacovigilance system) ambayo pia imefanya majaribio ya mwanzo ya 
matumizi ya simu za mkononi  kwa kutuma ujumbe mfupi kutoa taarifa iwapo kuna maafa 
katika kutumia aina yoyote ya dawa (SAE). Mradi wa ALIVE umetoa nafasi ya kutathmini 
matokeo ya matumizi ya ACT na pia matumizi ya aina nyinginezo za mikakati ya malaria 
katika kupunguza vifo vya watoto wadogo na uambukizaji wa malaria. Imeonywsha kuwa kila 
matumizi ya vyandarua vilivyowekwa dawa yanapoongezeka kwa 10%, maambukizo ya 
malaria katika jamii yanapungua kwa 48% kwa mwaka [IRR=0.52; 95% CI=0.38 hadi 0.73]. 
Pia tumeonyesha kuwa, ukilinganisha na kipindi cha matumizi ya dawa ya SP kama dawa ya 
mstari wa mbele kutibu malaria, ACT imepunguza malaria kwa karibu 11% kwa mwaka kwa 
watoto chini ya miaka mitano baada ya kuzuia athari za sababu nyinginezo [IRR= 0.89; 95% 
CI=0.79 hadi 1.0].  ALIVE pia imeonyesha uhusiano wa mambo mengineyo yanayoathiri vifo 
vya watoto chini ya miaka mitano. Upatikanaji wa chakula imeonekana una mchango mkubwa 
katika vifo vya watoto chini ya miaka mitano; hasa mchele ulichangia karibu 36% kupunguza 
vifo kwa mwaka [IRR=0.64; 95% CI=0.54 hadi 0.75]. Kuhusu uambukizaji wa malaria, 
tumeona kuwa kuna usambamba wa kupunguza maambukizo kwa 65% ya malaria katika jamii 
kwa malaria iliyotambuliwa kwa homa tu ukilinganisha na taarifa za awali za mwaka 2006 
kabla ya kuanza matumizi ya ACT katika jamii iliyofanyiwa utafiti. 
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Mwisho, matokeo haya yanawezakuwa endelevu kwani ufanisi wa ALU, kama ulivyofanyiwa 
tathmini kwa kutumia study ya invivo uliofanyika mwaka mmoja uliopita baada ya 
utekelezaji,umebakia juu ya 96% katika bonde la Kilombero licha ya matumizi ya kiwango 
kikubwa. 
 
Matokeo ya kazi hii yameonesha umuhimu wa badiliko la sera ya kudhibiti malaria yakitiwa 
nguvu na ushahidi kutoka tafiti zinazoendeshwa. Mafunzo yaliyotokana na kazi hii yatafaa 
katika hatua za ndani ya nchi na kwa kiwango cha kimataifa katika jamii nyingi zinazoathirika 
na malaria. 
Tumejifunza pia kwamba usalama na kukubalika kwa bidhaa za dawa ambazo zinatumika kwa 
kiwango kikubwa kama vile MSETO/ACT hazina budi kufuatiliwa na kudhibitiwa kwa 
ushirikiano thabiti unaojumuisha Wizara ya Afya na idara zake shirikishi,viwanda vya madawa 
itakapowezekana, watafiti na muhimu zaidi kwa ushiriki kamili na msaada wa viongozi wa 
ndani ya nchi na jamii. 
 
Tunapendekeza kwamba, ushirikiano huu upate kuungwa mkono na washirika wengine wa 
afya kuhakikisha usalama wa dawa kupitia ufuatiliaji mkali wa kisheria wa matumizi yake na  
muda mrefu wa maisha/matumizi.Ujengaji uwezo wa soko na watekelezaji sera ni kipengele 
muhimu cha kupewa kipaumbele.Tunapendekeza pia kwamba rasilimali ziwepo tayari 
kuimarisha mfumo wa afya (rasilimali watu,Mfumo wa Taarifa za Afya na Miundombinu) ili 
kupata matokeo endelevu katika udhibiti wa malaria.Hii itazalisha zaidi mazingira ya 
uwezeshaji na umma makini wa wanasayansi na wataalamu wa afya ya umma kuongoza 
kikamilifu utekelezaji wa sera dhidi ya malaria na kuufuatilia kwa muda maalum. 
 
Kama ilivyoanishwa katika kazi hii, kampeni yenye mafanikio dhidi ya malaria inaweza kupitia 
kuunganisha juhudi za watafiti,watunga sera,washiriki wa maendeleo/uendelezaji afya wa 
kimataifa na jamii.Ushirikiano huu umewezesha mafanikio ya maisha halisi yanayohusiana na 
mipango,kama vile kampeni ya kuondoa malaria katika kisiwa cha Sardinia Italia, katika miaka 
ya 1940.
 1 | P a g e  
 
 
PART I: BACKGROUND 
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CHAPTER 1: INTRODUCTION 
 
1.1.0 Global burden of malaria  
 
Beginning of current decade, African continent inhabits nearly 11% of the global 
population and yet contributes to nearly 19% of the global mortality. A great chunk of 
the global mortality due to malaria 87% (963,000/1,124,000) and its consequences is 
happening in Africa and this is 17% part of the globally overall cause mortality putting 
Africa to the most vulnerable continent of malaria disease burden (WHO ; Zucker, 
Lackritz et al. 1996).  
Depending on the geopolitical presentation in Sub-Saharan Africa, most of the disease 
burden (94-72%) is occurring in rural setting where the poorest of the world population 
resides. It is estimated that nearly 58% of this population are at most risk to this burden 
due to them being the least population group receiving the worst health care as a result 
of poor health care infrastructures in their settings (Breman, Alilio et al. 2004). In sub-
Saharan Africa, malaria is too a leading cause of outpatient and inpatient admission 
(Maegga, Cox et al. 2005) and malaria due to Plasmodium falciparum is an important 
cause of fatal illness and disability in most vulnerable population groups. It is estimated 
that almost 3% of disability adjusted life years (DALYs) are due to malaria mortality 
globally whereas 10% of similar DALYs stands for Africa (Breman, Alilio et al. 2004).   
 
1.1.1 Global initiatives to combat malaria burden 
The 20th century witnessed comprehensive programmes that led to not only reduced 
malaria vectors but the eliminations of plasmodium parasites in most invaded Southern 
European states. Sardinia Island in Italy in mid 1940s eradicated malaria encounter 
through massive campaign ranging from vector control to sustaining vigilance at 
malaria detection and management for long term eradication campaign in the island 
(Tognotti 2009). Today, more than half century after Sardinia achievements, most 
malaria endemic countries are still struggling on how to best come to common terms in 
order to address malaria eradication programme globally. Lack of common approach to 
address malaria burden in most endemic states has been due to various genuine 
bottlenecks. During the past two decades in the aftermath of 1940s eradication in years 
1969-1991 the global focuses on malaria was mainly on technical issues as well as 
research and development for new tools, that could lead to advances in drug and 
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vaccine development alongside vector control strategies. It is during the same period 
also that better understandings of the natural variation on experience among different 
malaria endemicity in a variety of epidemiological settings have been developed. 
However, because this period was short of a joint global focus on region-wide based 
plan to fight malaria, there was as a result little global support and clear roadmap 
provided for the malaria endemic but also newly emerged independent states of Africa. 
These states at that time were struggling to establish adequate health systems and 
primary health care (PHC) system. As a result of these hurdles, reliance on use of 
historical anti-malaria monotherapies that were cheaply available in most of these 
countries was rampant and resulted in to development of drug resistance. Towards the 
mid of 1990s, the combination of a worsening malaria situation and emerging 
promising technical developments led to renewed global focus on malaria control 
(Tanner and de Savigny 2008). It is for the same reason that, in 2000 the global head 
of states forged a scheme of goals that can best address the global diseases burden 
most affecting developing countries to be achieved  by 2015 and these goals are 
known as; eight Millennium Development Goals (MDG) (Nations 2010). Among these 
goals two that aim to improve health reflect under five (U5) survival and combat malaria 
illness; MDG4 and MGD6.  MGD4 set target to reduce child mortality by two third 
during 2015 while MGD6 aims at combating malaria and other major infectious 
diseases (HIV and TB) by year 2015 as compared to baseline 1990. To date as the 
results of these global initiatives a number of new strategies and tools against malaria 
have been developed and existing ones sharpened to better address the problem. Not 
later than beginning of last decade artemisinin based combination therapies (ACT) 
emerged as potential therapeutically efficacious proven tool among the key other 
existing in the fight against malarial. Use of insecticide mosquito bed-net (ITN) have 
also been advocated and where possible funding for their availability for free 
distribution to vulnerable persons within endemic countries have been developed within 
current funding mechanism from global health financing partners. Global support to 
control malaria has exceeded 1000 billion US Dollar to date, but malaria still exerts a 
threat to the U5 and pregnant women (Snow, Guerra et al. 2008; Perry 2010). Another 
parallel key tool in the fight against malaria that was successfully implemented in the 
past with better outcome is indoor residual spraying (IRS) with insecticide. IRS was the 
best tool ever shown good results in the past century before it was intermittently 
abandoned following environmental campaign against the use of [dichloro-diphenyl-
trichloethane]-DDT as well as the shift in the global focuses to malaria control 
strategies. IRS has proven to be a major tool for vector control alongside ITN, in place 
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where it has been jointly implemented with bed-net and chemotherapy has resulted in 
to tremendous achievements (AFM 2008).  
 
Country like South Africa in the KwaZulu-Natal province were all measures were 
implemented jointly we do observe a reduction in malaria related outpatients and 
mortality cases by 99% and 97% respectively (Barnes, Durrheim et al. 2005). In 
Zambia and parts of Ethiopia following massive deployment of ACT in areas where ITN 
use and IRS were underway a reduction in overall and malaria specific mortality has 
gone down to the level close to the MGD bench marks (Barnes, Chanda et al. 2009). 
Despite the low pace to implement key tools for malaria combating strategies, 
Tanzania is in the right direction towards addressing MGDs goals. Over the past 5-10 
years Tanzania has reduced infant mortality from 100 in 1995-1999 to 68 deaths per 
1000 live births in 2004 [Tanzania National Bureau of statistics & Macro International 
Inc. Calverton,2005] (Masanja, de Savigny et al. 2008). Key to these strategies 
includes the use of efficacious anti-malarial in the first line policies for therapies and 
chemoprophylaxis and improving financing the health system. Use of vector control 
strategies such as insecticide treated mosquito bed nets and indoor residual spraying 
strategies in combination with ACT has rendered Zanzibar; part of united republic of 
Tanzania a territory close to malaria elimination (AFM 2008).  
 
1.1.2 Use of artemisinin based combinations ant malarial chemotherapy 
The legacy of inadequate global translations of achievements gained in years post 
1940s eradication campaigns in Europe, America and Northern Africa has accounted 
for huge impedance in the fight against malaria today in sub-Saharan Africa and South-
Eastern Asia. Major among impedance, were the use of failing anti-malaria therapy as 
a result of consistent use of non-efficacious but cheaply available first line monotherapy 
drugs. In place of  inadequate monitoring programme to advocate to the change of 
treatment policies on timely bases has resulted to subjecting available mono-therapies 
to high drug pressures (Mutabingwa 2005). Beyond control however, it has been 
unavailability of real time efficacious anti-malarial drug alternatives as well as 
insufficient knowledge of health care staff to promptly diagnosis and management of 
malarial illness in some parts of malaria endemic regions (Nosten, McGready et al. 
2007). In most part of malaria endemic regions chloroquine was found unfit nearly quite 
long ago. In Tanzania for instance P.Falciparum was already resistant to chloroquine in 
more than 60% of all P. Falciparum positive slides towards the end of the last decade 
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(Hatz, Abdulla et al. 1998) . Despite the obvious failure of chloroquine to such 
magnitude there was little effort to change policy to a more efficacious first line until in 
2001.  The emergence and rapid spread of resistance to anti-malarial drugs over the 
past recent years has led to the intensification of search for new efficacious anti-
malarial alternatives by researchers and pharmaceutical companies (MMV 2009) as 
well as emergence of concerted global initiatives. In late nineties for instance the World 
Health Organization (WHO) launched a Roll Back malaria campaign whereas by then 
malarial vector control strategy was high on agenda in many malaria endemic 
countries. During the same period the uptake and strategy to make available of most 
efficacious anti-malarial therapy in many endemic countries was very slow. In the 
aftermath of ACT availability at scale in the beginning of the current decade, a cluster 
sampling surveys in most sub-Saharan African countries, Tanzania inclusive was done. 
It was evident that in more than 53% of under five children with febrile illnesses who 
sought health care were being treated with Chloroquine despite of it being inadequate 
to treat P. falciparum (Breman, Alilio et al. 2004). Thanks to an article that was 
published in the Lancet in 2004 by prominent scientists with criticism on lack of policy 
change at the global level, 2004 became the turning point resulting in many endemic 
countries changing their policy to ACT (White, Nosten et al. 2004). Thanks to 
increasing availability of fixed-dose ACT options by 2009, nearly 77 of 81 P. falciparum 
malaria-endemic countries and territories had adopted ACTs for use in their national 
drug policies (WHO). WHO is monitoring the global supply of and demand for the ACT 
fixed-dose and to date artemether-lumefantrine (AL) fixed-dose combination as part of 
the requirements of the Memorandum of Understanding signed with the manufacturer, 
Novartis Pharma AG, Basel Switzerland, in 2001, to make Coartem® available at cost 
price for distribution in the public sector of malaria-endemic developing countries AL 
has reached more than 78 million treatment courses in 2008 (WHO). 
 
1.1.3 Insecticide treated bed-nets 
Insecticide treated mosquito bed net is another very important vector control tool that 
has not only  demonstrated effect on individual using it directly but also the community 
at large in places where high coverage is achieved in a given malaria endemic 
community (Maxwell, Msuya et al. 2002; Hawley, Phillips-Howard et al. 2003). By the 
year 2008 nearly 31% of African household was estimated to own at least an 
insecticide-treated bed net (ITN) or a long lasting insecticidal treated Mosquito net 
(LLITN). More children aged less than 5 years were also sleeping under ITN on an 
average of 24% as compared to 17% in the previous 2 years (WHO). In some countries 
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in African region where high coverage of ITNs has been achieved a fall of malaria 
cases and deaths by more than 50% has been reported (Nations 2010). Such 
developments are encouraged and may suggest that overall attainment of MGD to 
reduce child mortality by two third ahead of the target 2015 in some countries is 
possible (WHO ; Barnes, Chanda et al. 2009). 
It is worth mentioning here that a good coverage of vector control in some part of the 
continent has resulted from funding commitments for malaria control from Global Fund, 
the World Bank and other international donor communities.  The main challenge in the 
future will therefore remain to be the sustaining public funding by endemic countries at 
the time of weaning this global support. 
 
Now that ACT is widely available and in many areas a combination of malaria control 
tools have been implemented widely and widely supported by global health partners, 
there is an ample need to assess the impact of these interventions. In general this has 
to be assessed by individual health authorities with commitments to strengthen their 
health system that have to be scaled up in the framework of these assessments. Full 
implementation of ACT is fundamental and routine monitoring and surveillance for the 
safe use of these drugs as well as emergence of resistance signals is too vital to mirror 
out the intended impact overtime. 
 
1.1.4 Tanzania country specific initiatives to combat malaria burden  
The Tanzania Mainland has an estimated population of 40 million for the year 2008 as 
projected from the 2002 population Census (nbs 2002). It has an annual population 
growth rate of 2.9% and total fertility rate of 5.5 children per woman. The national crude 
death rate and infant mortality rate stands at 12.9 and 100.3 deaths per 1000 persons 
per year respectively (in 2000). Only 23% of the population resides in urban areas 
whereas the majority (77%) of population is rural dwellers. On average 35.7% of the 
population is below the poverty line with Gross Domestic Product (GDP) per capita of 
US$280 (in 2000). Malaria in Tanzania is a leading cause of outpatients’ attendances 
and a leading cause of deaths in children less than five years old.  
In 1993 the Tanzanian government approved the health sector reform act that gave 
rise to the adoption of the current nationwide health reforms. The main focus of this 
reform is to address burden of disease existing in a particular local setting with 
evidence based tools and strategies. This approach is in line with requirement laid 
forward by World Bank report in 1993 that emphasized on: (a) the suggestion to look 
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beyond the health sector for the answers to many of the problems of disease (b) the 
identification of certain challenges for the future: HIV, malaria, child mortality, fertility 
rates, and ageing populations (c) the recommendation to create a cost-effective 
national public health package and a national clinical services package (WORLD-
BANK 1993). As the results, in 1999 at the time when global malarial control initiatives 
were at revival, Tanzania ministry of health defined and launched the National Package 
of Essential Health Interventions. This package addresses communicable diseases 
among other diseases that burden Tanzania and emphasized on control and 
management of common diseases such as malaria. It encouraged the use of locally 
available evidence on interventions and funding mechanisms at district level to facilitate 
the decentralization of health management structure as key to strengthen health 
system.  
Aimed at supporting evidence based interventions at district level for guiding to policy, 
Ifakara Health Institute in collaboration with other local and international health partners 
has consistently maintained the implementation of several key interventions to address 
the burden of malaria at the district level in Kilombero and Ulanga (K/U) Districts.  In 
late nineties and early 2000 most of the interventions that were implemented in K/U 
Districts have mainly focused on improving child health. These programmes include; 
the integrated management of childhood illness (IMCI) that introduced a set of 
guidelines for management of sick children seen at different level of health care 
facilities country-wide beginning of 1996 and up scale of WHO and UNICEF expanded 
IMCI strategy later in K/U 2002.   
 
In 1997 a project that socially-marketed subsidized Insecticide Treated Mosquito bed-
nets in K/U Districts (KINET) was implemented (Schellenberg, Abdulla et al. 1999). The 
KINET project was implemented until 1999 and achieved a community ITN ownership 
of nearly 37% by the year 2000. Through this programme the coverage of ITN for 
infants in the area rose from less than 10% at baseline to more than 50% 3 years later 
(Schellenberg, Abdulla et al. 1999; Schellenberg, Abdulla et al. 2001) . The ITN model 
has been up-scaled nationwide in the programme named after-NATNETS (Tanzania 
National Insecticide Treated Net).  
The KINET project did set the grounds for the Ifakara Health Demographic Surveillance 
System (IHDSS) that was initiated in 1996 (Armstrong Schellenberg, Adam et al. 2004) 
The DSS infrastructure is being used to assess different intervention at community 
level. Another intervention in the area that has been implemented through support of 
the IHDSS infrastructure is the ACCESS programme. The ACCESS was launched in 
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K/U Districts to addresses programmatic issues of improving access to effective 
malaria treatments since 2003 
(http://www.novartisfoundation.org/page/content/index.asp: Cited on 21 July). This 
project was integrated in the community and local health system structure with a set of 
interventions including: A social marketing campaign that aimed at sensitizing 
community for more effective health care seeking. The other component of ACCESS 
was training of public health care staff on key guidelines of IMCI and the up-scaling 
Accredited Drug Dispensing Outlets (ADDOs) in collaboration with other partners-
Tanzania Food and Drug Authority.  The ACCESS project has witnessed an increase 
of 87% coverage of anti-malarial retails outlet as compared to 71% at baseline and 
number of anti-malaria dispensation to increase by 78% (Alba, Hetzel et al.). 
 
It is therefore imperative to note here that during the implementations of all the above 
mentioned initiatives the ministry of health of the Tanzania mainland at the same time 
has gone through a period of succession for two anti-malarial first line treatment policy 
changes. It is during the same period that the national level up scaling most of 
interventions that were confirmed efficacious in research settings has been 
implemented. In 2001, Tanzania switched the first line anti-malarial policy from CQ to 
SP and later at the end of 2006 from SP to AL. The use of SP for prevention of malaria 
during pregnancy was also launched as policy in mid 2001. In 2002 the nation-wide 
social marketing campaigns on ITN began whereby subsidized ITNs to pregnant 
women and children under five years through a Swahili connoted voucher scheme 
“HATI PUNGUZO” was implemented. Alongside this implementation, a free distribution 
long lasting ITN pilot scheme was introduced in some areas where the most poor social 
economical quartile in Tanzania belongs; namely Rufiji District, Mtwara and Lindi 
regions in the South Eastern coast of Tanzania. In the K/U Districts both periods of first 
line policy transition; first with SP and later with AL have been under successions of 
two research programmes of impact assessment. In 2001 the policy change was 
monitored by the IMPACT (Interdisciplinary Monitoring Project for Artemisinin 
Combination Therapy) –as a byproduct of comparative assessment of a pilot 
implementations of ACT in Rufiji district and K/U districts were considered as non-
implementation comparator districts. In that set-up Rufiji district was being compared to 
the National first line policy with SP in K/U. As second phase of assessment  beginning 
in  2007 during the aftermath of ACT introduction countrywide, in K/U the policy was 
privileged again to be closely monitored by a community based study ALIVE 
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[Artemether-Lumefantrine In Vulnerable patients: Exploring health Impact] project that 
is implemented in the region toward the end of  2011 
 
The next two chapters of this thesis state the overall goal, main objectives and details 
of methodologies to address most questions regarding first line policy with ACT 
implementation in Tanzania. Beginning from the fourth chapter the thesis sheds light on 
plans and research activities that were implemented ahead of the policy uptake and it 
gives insight on further steps undertaken to monitor ACT when the policy was 
implemented. Chapter 4 describes the assessment of safety and efficacy of ACT as the 
means of accumulating evidence to prepare a room for evidence based policy change. 
The fifth chapter describes the extension of assessment strategies to include policy 
monitoring strategies during the implementation period. The sixth chapter looks closely 
at the descriptive parameters of medium term impact of the first line anti-malarial policy 
on morbidity and mortality in children under five years. The seventh chapter describes 
programmatic issues of the patients’ acceptability and compliance to the treatment 
policy. Finally in chapter eight a general discussion and conclusion is articulated 
whereas at the end of the discussion key message and recommendations from the 
thesis are made hence future research agenda is set forwards. 
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PART II: GOAL AND OBJECTIVES 
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CHAPTER 2: OBJECTIVES 
2.1.1 Goal 
To assess the impact of ACT introduction on malaria morbidity and mortality in rural 
Tanzania and to monitor its long-term safety when used at country scale. 
 
2.1.2 General objective 
 
To evaluate the impact of the introduction of AL on i) malaria transmission (in two 




2.1.3 Specific objective   
 
1. To evaluate efficacy of ACT in children under five years before implementation as first 
line policy in Tanzania. 
2. To monitor efficacy of AL one year after the introduction of AL as first line anti-malarial 
policy in Tanzania. 
3. To evaluate the feasibility of using demographic surveillance system framework to 
record early anti-malarial drug exposure during pregnancy. 
4. To monitor safety of AL using a programmatic pharmacovigilance system in rural 
endemic population in Tanzania. 
5. To assess the impact of anti-malarial first line policy on malaria transmission and under 
five mortality in rural area with high ITN coverage in Tanzania 
6. To describe programmatic issues of the proper use of AL as 1st line anti-malarial 
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PART III: METHODOLOGY 
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CHAPTER 3: METHODS  
3.0 Methodology 
3.1 Thesis framework 
This thesis describes the before and after strategies that were implemented to prepare 
the room for  first line anti-malarial policy with ACT and thereafter outlines research 
activities that were implemented to monitor its impact. Data that has been used in this 
thesis include datasets collected prospectively in three projects. Two projects were 
implemented in a period before the introduction of ACT in years 2004-2006. The 
reminder project was implemented during the introduction of ACT as first line anti-
malarial policy. The three projects are East African Network for Monitoring Anti-malarial 
Treatment (EANIMAT), the IMPACT project implemented before policy and ALIVE 
project that was implemented thereafter.  The major components of evaluation 
completed before the introduction of ACT include; invivo studies conducted in 2004/5 
under EANMAT .Community surveys that assessed asymptomatic carrier of malaria 
parasites and mortality in children under five years in rural Tanzania was conducted 
under the IMPACT project for which this thesis uses surveys that were conducted 
between 2004-2006 as baseline. In the same framework we assessed safety of anti-
malarial in pregnant women at community level. The ALIVE study that was 
implemented in 2007 in the aftermath of the ACT introduction countrywide evaluated 
the ACT post implementation strategies and gave platform for further assessment of 
the impact of ACT in three years after the first line policy adaptation as compared to 1st 
line policy with SP during the IMPACT project.    
3.2 Design of studies involved and study population 
 
3.2.1 invivo efficacy studies 
EANMAT platform represent a sub-regional anti-malarial efficacy monitoring that was 
founded in 1998 to provide reliable and current estimates of malaria treatment efficacy 
representative to Eastern Africa region. The network is composed mainly of staff from 
national malaria control programmes (NMCPs) of participating sub-regional ministries 
of health. EANMAT started with three member countries: Kenya, Tanzania (mainland) 
and Uganda. Rwanda joined the network in 1999, Burundi and Zanzibar; a 
semiautonomous region within the United Republic of Tanzania, both joined in 2001 
(2003). Each country in the network decides which treatments should be monitored, 
according to their respective anti-malarial first line drug policies. The WHO invivo test 
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protocol was adopted for this monitoring as the central tool of all networks whereas 28 
days follow up studies were being conducted in children under five years that were 
being recruited from outpatient department of involved health facilities. In Tanzania IHI 
is one of the NMCP technical country member of the EANMAT and was mandated to 
lead assessment of anti-malarial at two NMCP/EANMAT sentinel sites; Ipinda in the 
Kyela District in Mbeya region and Mlimba in the Kilombero District in Morogoro all in 
the South-Eastern and Southern Tanzania respectively. It is through this framework 
that AL was assessed as a candidate ACT for the Tanzania first line anti-malaria policy. 
Details of this invivo assessment are given in Chapter 4.1 of this thesis. 
 
 
3.2.2 Safety of anti-malarial monitoring in pregnant women 
This is a pilot study that evaluated the possibility for the conduct of pregnancy test at 
household level to evaluate safety of anti-malarials that were reported to be used 
during pregnancy. This methodology was implemented in the Ifakara Health 
Demographic Surveillance system (IHDSS) in 2006 during the IMPACT project. The 
IMPACT project was implemented in K/U and Rufiji Districts beginning of 2001 towards 
2006 to evaluate the impact of SP plus artesunate; an artemisinin drug on the 
prevention and reduction of malaria transmission and the spread of resistance (Malisa, 
Pearce et al.). SP plus artesunate was introduced to pilot ACT policy implementation in 
Rufiji District while in Kilombero river valley SP was used as a comparator. During the 
lifespan of the IMPACT project, cross-sectional household surveys in the Rufiji and 
IHDSS were periodically conducted in May-August after every each year and malaria 
indicators were collected throughout. During these survey level of anaemia among 
under five children and community parasitaemia in all age groups were being 
assessed. Alongside these, mortality data were collected using verbal autopsy and a 
questionnaire listing the use of anti-malaria in the previous two weeks was applied. 
Ascertainment of pregnancy status and further assessment of anti-malarial drug safety 
was introduced in this set up in 2006 in the IHDDS. In this study women who reported 
exposure to anti-malarial while pregnant and those who were not certain if they were 
pregnant when exposed were identified and offered a (rapid) urinary pregnancy test 
(UPT) to confirm presence of pregnancy. A professional IHDSS field interviewer was 
trained on how to perform UPT and to give to women the test results. Pregnancy 
outcome among women who tested positive were followed up through the IHDSS 
framework. The DSS field interviewers were used to document pregnancy outcomes 
and the survival of the woman child pair in the subsequent IHDSS household visits that 
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occurs at home during periodic surveys after every four months. Details of this 
evaluation are given in chapter 4.2 of this thesis. 
 
3.2.3 ACT policy with AL implementation; monitoring of policy and assessment of its 
impact- The ALIVE study. 
The ALIVE study is a prospective, community-based, longitudinal surveillance study 
including demography and morbidity surveillance systems. The primary objective of this 
project is to assess the impact of the introduction of AL on all-cause mortality in 
infants/children ≥ 3 months [and > 5 kg] and < 5 years of age in a rural area of southern 
Tanzanian Districts (Kilombero and Ulanga) in comparison with historical data when SP 
was used. Key indicators of ALIVE are being collected within the existing demographic 
surveillance system (DSS) and the ACCESS project. The secondary objectives are to 
assess the impact of the introduction of AL on malaria-specific mortality in 
infants/children using ‘verbal autopsy’ reports, all-cause health facility attendance rate 
of patients overall, malaria-related health facility attendance rate of patients.  In 
particular the level of haemoglobin concentration in children under five years and 
parasitaemia in the general population are collected annually during a community 
household survey at the peak of malaria transmission in May-August of every year 
beginning 2008. In addition, patient satisfaction and drug adherence was conducted in 
March - April 2008. Furthermore, safety assessments of anti-malarial at the moment of 
country-wide deployment in the community have been introduced since September 
2007. 
Given the good efficacy of AL as first line and policy it is expected that AL should be 
more effective than SP to treat clinical malaria and clear Plasmodium parasites, and 
hence should ultimately reduce the incidence of severe malaria and death among the 
most at risk for malaria; children under five years. Furthermore it is expected that 
occurrences of malaria attack could be less frequent and eventually transmission 
dwindle with time thanks to the effect of AL on gametocytes clearance in the 
community. The expectation is therefore to observe a lower overall mortality and 
morbidity in Tanzania from 2007 onwards, when compared to the previous period of 
2002-2006 when SP was used as standard anti-malarial first line treatment during the 
IMPACT project. Details of this evaluation are given in chapter 5, 6 and 7 of this thesis 
3.3 Statistical methods 
Most of findings presented in this xx are descriptive of disease burden and percentage 
coverage of most applied intervention in the region. For drug efficacy studies, clinical 
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and molecular failure or efficacy rates are presented. Most of the data were managed 
on a tailored Visual FoxPro version 9 programme in Ifakara whereas analysis was 






























 17 | P a g e  
 
 
PART IV: EVALUATION OF EFFICACY AND SAFETY OF ACT BEFORE THE 














































CHAPTER 4.1: Efficacy and safety of artemisinin-based anti-malarial in the 
treatment of uncomplicated malaria in children in Southern Tanzania 
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Tanzania switched the anti-malarial first line to sulphadoxine-pyrimethamine (SP) in 
2001 from ineffective chloroquine (CQ). By 2003 higher levels of SP resistance were 
recorded, prompting an urgent need for replacing the first line drug with ACT, as 
currently recommended by the World Health Organization. Despite this 
recommendation country-specific evidence-based data to support efficacy and safety 
profile of ACT is still limited. A study on the efficacy and safety of artesunate plus 
amodiaquine (AS+AQ) and artemether plus lumefantrine (Coartem®) was carried out in 
2004 with the view of supporting the National Malaria Control Programme in the review 
of the policy in mainland Tanzania.  
Methods 
An invivo efficacy study was conducted at Ipinda and Mlimba health facilities between 
May and November 2004. The study recruited children aged 6-59 months presenting 
with symptoms of uncomplicated malaria, history of fever or an axillary temperature 
≥37.5oC; mono infection with Pasmodium falciparum (2,000-200,000 parasites/µl). 
Patients were randomized to receive either SP or amodiaquine monotherapy or treated 
with standard doses of AS+AQ in Mlimba and Coartem in Kyela and followed-up for 28 
days to assess treatment responses. This study reports results of the combination 
therapies. 
Results 
A total of 157 children (76 in Mlimba and 99 in Kyela) who were enrolled in to the study 
and treated with either Coartem or AS+AQ were successfully followed-up. Both 
combinations were tolerated and effected rapid fever and parasite clearance. The 
crude ACPRs were 80 (87 %) and 41 (63%) for Coartem and AS+AQ respectively. 
However, after PCR adjustments the corresponding figures raised to 100% (n=86) and 
93.8% (n=45) in Coartem and AS+AQ groups, respectively. The mean haemoglobin 
improved moderately from day 0 to day 28 by 1g/dl in Coartem and 0.4g/dl in AS+AQ 
treatment group and was statistically significant (p<0.001 both).  
Conclusion 
These findings provide substantial evidence that Coartem is highly efficacious in areas 
of high resistance of SP and supported the country’s decision to switch from SP 
monotherapy to Coartem.  
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4.1.2 Background 
The emergence and spread of Plasmodium falciparum resistance to commonly used 
anti-malarial such as chloroquine (CQ) and sulphadoxine/pyrimethamine (SP) has 
posed major challenges to malaria control in sub-Saharan Africa. In the face of 
escalated resistance to these widely used and long utilized anti-malarial l the World 
Health Organization (WHO) currently recommends the use of artemisinin combination 
therapies (ACTs) as the first line treatment of malaria in sub-Saharan Africa (WHO 4-5 
April 2001; WHO/UNICEF 2003; Koram, Abuaku et al. 2005). Several countries in the 
region have started implementing the use of ACTs as the first line drug. Despite these 
recommendations, country specific evidence-based data to support anti-malarial l first 
line treatment policy change to ACTs is still limited(Coleman, Morel et al. 2004).  
 
In 2001, the Tanzanian Ministry of Health and Social Welfare switched its first line drug 
from CQ to SP Prior to this change, CQ has remained in use as the first line drug for 
over 45 years and had recorded day 14 parasitological cure rates of 10.3%(Hatz, 
Abdulla et al. 1998). A number of lessons were, therefore, learnt after this policy 
revision. Some of these include, poor acceptability of the new policy as health services 
providers and the general public at large were short of preparedness to adopt the new 
policy(Eriksen, Nsimba et al. 2005; Mubyazi and Gonzalez-Block 2005). In addition, 
there were very few efficacious, safe and cheap drugs to be considered for first line. At 
the same time efficacy and safety data on the few available drugs were missing. In the 
aftermaths of interim policy inception, several major steps were taken including 
conducting invivo studies on efficacy of SP and other newly registered anti-malarial 
geared to increase choices and preparedness should the need for policy revision arise 
(Tarimo, Minjas et al. 2001; Mugittu, Ndejembi et al. 2004; Hetzel, Msechu et al. 2006). 
In this framework, therefore, an invivo study was carried out on the efficacy of some 
ACT drugs with a view of supporting the National Malaria Control Programme (NMCP) 
in reviewing the anti-malarial l drug treatment policy in Tanzania.  
4.1.3 Methods 
 
Study site and design  
The study was conducted within the invivo efficacy testing framework of the Tanzania 
NMCP/East African Network for Monitoring Anti-malarial (EANMAT).Two health 
facilities took part in the study; Ipinda in Kyela District at the border with Malawi and 
Mlimba in Kilombero District in South-eastern Tanzania. This study was conducted in 
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2004 between January - June and March - October at Ipinda and Mlimba health 
facilities, respectively. At both sites malaria transmission is perennial and peaks 
between May and July, after the long seasonal rainfall. 
 
The WHO standardized protocol for the assessment of therapeutic efficacy of anti-
malarial  drugs (WHO 2000) was used and the study included sick children who were 
6-59 months age if they presented with history of fever in the past 24 hours or axillary 
temperature of ≥ 37.5°C, and mono-infection of P. falciparum count of 50-5,000/200 
white blood cells (WBC) assumed to be 2,000-200,000parasites/µl. Patients were 
excluded from the study if they present with repeated convulsion, inability to take 
anything orally, severe anaemia i.e. Hb≤5gm/dl, difficulty in breathing or patient with 




The patients were randomized to receive either monotherapy or the ACT according to 
the NMCP schedule of sentinel testing. At Ipinda sentinel site SP and amodiaquine 
were used as the monotherapies and artemether/lumefantrine (Coartem®) was used 
as the ACT while Artesunate and Amodiaquine (AS+AQ) in an ad-hoc as ACT and the 
same monotherapies were given at Mlimba. This study reports only the outcome of 
both combination therapies. Coartem was given to children according to bodyweight as 
follows 20/120 mg tablet to those weighing 5-14kg and two tablets 40/240 mg to 
children with 15-24 kg. The full course of treatment for all study patients in this group 
consisted of 6-doses of Coartem that was given at 0, 8 and 16 hours, the remaining 
doses were given at 12-hourly intervals for a total of three days. At Mlimba sentinel site 
AS+AQ was given at a dose of 4mg/kg and 10mg/kg body weight respectively. AS+AQ 
was given on day 0, 1 and 2 with only amodiaquine’s dose reduced to 5mg/kg body 
weight on day 2. All treatments were supervised by study nurse and patients were 
observed for 30 minutes in the aftermath of drug intake. All patients who vomited within 
30 minutes intervals were re-administered another full dose of the same medicine. All 
treated patients were followed for 28 days to assess clinical and parasitological 
responses. Patients that did not turn up for scheduled dose were visited at home by the 
study nurse on the same day. Treatment outcomes were classified as early treatment 
failure (ETF), late clinical failure (LCF), late parasitological failure (LPF) and adequate 
clinical and parasitological responders using the (WHO 2003) guidelines. Clinical 
therapeutic outcomes were adjusted by genotyping the P. falciparum merozoite surface 
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protein 2 (msp2) and glutamate rich protein (glurp) on admission (Day 0) and any day 
of infection recurrences (Day 7, 14, 21 or 28). Recrudescence was differentiated from 
new-infections as described by Mugittu et al 2006 (Mugittu, Adjuik et al. 2006) only for 
patients who received ACTs due to cost limitation. Under this assessment, only 
parasitaemia that was confirmed by PCR as recrudescence was considered as 
treatment failure and conversely, was considered as new infection and counted as the 
ACPR.  
 
Clinical and laboratory procedures 
Patient follow up were scheduled on days 1, 2, 3,7,14, 21 and 28. On each visit, 
including day 0 under which patient were enrolled. Clinical, parasitological and 
haematological examinations were performed. Haemoglobin level (Hb) was assessed 
using HemoCue® (Angelholm, Sweden) and the Hb of ≤5g/dl was considered as 
severe anaemia. Parasitological examinations involved preparation of thick and thin 
blood smears from each patient and examined by specialized microscopist from Ifakara 
Health Research and Development Centre (IHRDC). Parasitaemia was expressed as 
count per 200 WBC of blood assuming a normal leucocytes level of 8,000/µl.  
 
Analysis 
Data generated in patient’s case record forms were entered on FoxPro® database 
software version 7 (Microsoft Corporation, Redmond USA 2001) at Ifakara Health 
Research and Development Centre (IHRDC). Data analysis was performed using 
STATA® statistical analysis software package version 8 (Stata corporation, Collage 
Station TX, USA, 2003). Descriptive analysis was done and differences in proportions 
of treatment outcome were compared using chi square test for proportions. Student’s t-
test was applied for continuous variables. Data on patients that were excluded for 





Study profile and patient’s records  
A total of 99 and 76 patients were enrolled at Ipinda and Mlimba health facilities, 
respectively. Table 1.4 summarizes patient’s mean age, body weights, clinical and 
haematological parameters at admission/enrollments. There were 18 patients who 
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were loss to follow up; 7/99 (7%) in Ipinda and 11/76 (14.5%) in Mlimba. Overall 92/99 
(92.9%) patients in Ipinda (Coartem arm) and 65/76 (85.5%) in Mlimba (AS+AQ arm) 
were available for the assessment of therapeutic endpoints.  
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Both drugs were tolerated; there was no report of significant Adverse Drug Reaction 
(ADR).Table 2.4 shows crude and PCR corrected treatment rates of the test drugs. The 
crude ACPRs were 80/92 (87 %) and 41/65 (63%) for Coartem and AS+AQ, 
respectively. After PCR adjustment however, the corresponding figures rose to 100% 
(86/86) and 93.8% (45/48) in Coartem and AS+AQ respectively.  Most of the recurrent 
infections at both sites were due to LPF. Interestingly, after genotyping all these were 
found to be due to new infection. The study recorded only two recrudescent infection, 
both of which in the AS+AQ. No recrudescence was observed in the Coartem arm. 
Moreover, a total of 10 recurrent infections (six in Coartem and four in AS+AQ) could 
not be unresolved even after repeated DNA extraction and PCR amplification. When 
these 10 recurrent infections were assumed to be recrudescence in the final analysis 
together with the PCR corrected ones however, the ACPRs were 93.3% (83/89 ) in 
Coartem and 87.1% (54/62) in AS+AQ. 
 
Sentinel site Measured parameters –Means (Standard Deviations [SD]) 
  Age in years  Body weight in Kg  Temperature in °C Hb in g/dl Parasites/µl  
      
Ipinda (n=99) 2.3 (1.2) 11.9 (2.7)  38.9 (0.98) 9.7 (1.4) 43114.5 (40130.4) 
      
Mlimba (n=76) 2.1 (1.2) 11.3 (2.5) 38.2 (1.2)   8.7 (1.7)  49347.8 (48194.1) 
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Table 2.4: Clinical and parasitological therapeutic outcome 
 
 
The mean haemoglobin improved moderately from day 0 to day 28 by 1g/dl in Coartem 
and 0.4g/dl in AS+AQ treatment groups. The mean haemoglobin recovery after day 28 
was statically significant in both groups (p<0.001 both).  
 
4.1.5 Discussion  
 
The main goal of this invivo ACT efficacy study was to support the establishment of 
evidence-based results that can be used to change malaria treatment policy in 
Tanzania. This study has demonstrated high therapeutic efficacy and tolerability for a 
six dose regimen of Coartem and a 3-day course of AS+AQ in southern Tanzania. Both 
crude and PCR-corrected ACPRs for Coartem (87% and 100%) were higher than those 
recorded in the AS+AQ (63.2% and 93.8%) arm. The Coartem crude and PCR-
corrected cure rates are more or less similar to those recorded in Muheza Tanzania in 
2005 (79% and 97.2%), (Mutabingwa, Anthony et al. 2005) and in mult-country 
(Tanzania inclusive) Coartem efficacy study (86.5% and 93.9%) (Falade, Makanga et 
al. 2005).  
The testing of each drug independently for each site was due to the arrangements in 
place that required testing each individual drug as part of anti-malarial l nationwide 
drug testing allocation. This allows accumulation of evidence of the performance of the 
ACT in different settings. It can be argued that there are differences from place to place 




After PCR corrections 
Before PCR 
corrections 














ETF 0 (0.00) 0 (0.00) 0 (0.00) 1 (1.5) 1 (1.6) 1 (2.0) 
LCF 1 (1.0) 1 (1.1) 0 (0.00) 4 (6.1) 3 (4.8) 2 (4.2) 
LPF 11 (12.0) 5 (5.6) 0 (0.00) 19 (29.2) 4 (6.5) 0 (0.00) 
ACPR 80 (87.0) 83 (93.3) 86 (100) 41 (63.2) 54 (87.1) 45 (93.8) 
Total 92 89 86 65 62 48 
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related to the response to treatment that is observed but treatment policies are 
formulated at regional or sub-regional level hence the need to get regional summary 
estimates. The sentinel system is a good approach toward addressing that need. 
Secondly it will be very difficult to sample all possible places where variation is being 
expected and under the current malaria transmission intensity in Tanzania, it is hard to 
follow up enough patients for  all treatment groups in a single site during the same 
transmission year(Schellenberg, Menendez et al. 2004).  
 
An interpretation of the comparative efficacy of the two drugs was not considered in our 
analysis. The reasons for this approach are; first this study was not designed to 
measure the differences between two test drugs but only to get point estimates of the 
efficacy which also allows monitoring of their performance overtime. Second, both ACT 
drugs have high efficacy profiles in the region that in principal would require huge 
sample size to be able to show a comparative difference(Adjuik, Agnamey et al. 2002; 
Mutabingwa, Anthony et al. 2005). For this same reason the direct comparison of the 
two ACTs in a randomized trial is not an optimal approach of monitoring drug efficacy 
in the programme’s implementation setting and the reliance of sentinel sites in a 
country therefore becomes an efficient solution.  
 
4.1.6 Conclusion  
 
According to the current malaria treatment policy revision guidelines (changing policy at 
>10% failure rate), both Coartem and AS+AQ would be considered suitable drugs for 
first line purpose since both recorded high PCR-corrected efficacies i.e. 100% and 
93.8%, respectively. However, it was more rational to adopt Coartem as its efficacy is 
far above the cut-off point, whereas AS+AQ efficacy is just 3 units higher from the 
policy revision cut-off point and its useful therapeutic life might be compromised sooner 
following widespread use. In addition, the policy revision process took into account the 
suggestion that apart from reasonably high efficacies of partner drugs, an effective 
combination therapy should comprise of drugs that have not been deployed previously 
in the area for use as monotherapies (Watkins, Sibley et al. 2005). Prior to the 2006 
policy change AQ was being used as a second line anti-malarial drug in Tanzania. 
Finally, Coartem was highly recommended based on its extra privileges such as being 
the only co-formulated ACT at the time of policy change and good effectiveness 
 27 | P a g e  
 
parameters in the country(Mulligan, Mandike et al. 2006). All these experience have 
paved the way for adoption of Coartem as the first line anti-malarial drug in Tanzania.  
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CHAPTER 4.2 Using a Demographic Surveillance System to evaluate the 
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Background: The risk of malaria infection and its severity tends to increase during 
pregnancy and for this reason WHO recommends the use of anti-malarial for case 
management and intermittent prevention of malaria during pregnancy. Coverage of 
recommended programs is still low in sub-Saharan Africa.  Anti-malarial self treatments 
is common hence exposure in early periods of pregnancy despite the absence of 
infrastructure to monitor drug safety. 
Methods and findings: A list of women of child bearing age who were exposed to 
anti-malarial s, with or without knowing they were pregnant four weeks preceding 
household surveys was generated from the Ifakara health demographic surveillance 
system (IHDSS) database in 2006.  Women who reported exposure to anti-malarial s 
while pregnant were offered a urinary pregnancy test.  This test was performed by a 
female, none-medical, professional IHDSS field interviewer trained on testing and to 
give test results.  Pregnancy outcome among women who tested positive was followed 
up through the IHDSS framework.  The IHDSS field interviewers documented 
pregnancy outcomes and the survival of women in the regular household surveys.  
Overall 268 women were identified and almost 98% reported use of one or two types of 
anti-malarial drug in the two to four weeks prior to the interview.  Nearly all agreed to 
undergo urinary pregnancy tests.  The test showed 38 women were pregnant at any 
early gestation age. 26% of positive cases thought they were not pregnant before the 
test was done. Thirty seven women had a live birth; one woman had a non-live birth.   
Conclusions: This assessment has provided useful information on the feasibility of 
monitoring early drug exposure in pregnancy. The methodology can be further 
extended to include a close follow-up of pregnancy and newborns. Detailed information 
about pregnancy status and subsequent offspring developmental safety milestones can 
be recorded through extended form of pharmacovigilance reporting system.  
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4.2.2 Introduction 
The risk of malaria infection and its severity tends to increase during pregnancy and for 
this reason the frequency of anti-malarial  exposure during pregnancy also tends to 
increase (Steketee and Nahlen 2001). It is for this reason that the World Health 
Organization (WHO) currently recommends a three-pronged approach for the 
management of malaria during pregnancy: use of insecticide-treated mosquito bed 
nets, use of intermittent preventive treatment of malaria and proper malarial case 
management (World Health Organization. WHO Regional Office for Africa 2004).  The 
last two approaches require the use of anti-malarial drugs.   
 
Despite these recommendations, the coverage of these programs is still very low and 
in sub-Saharan Africa, where malaria is highly endemic, anti-malarial  self treatment is 
common (Ndyomugyenyi, Neema et al. 1998). The occurrence of new malaria 
episodes in an endemic setting tends to increase with transmission intensity and 
therefore correlates with a significantly high number of anti-malarial  exposures (Hetzel, 
Alba et al. 2008). Of all population groups pregnant women have a reduced immunity 
to malaria infection and, in the rural setting, they are frequently exposed to malaria 
vectors and therefore often self-medicate with anti-malarial  drugs (Ndyomugyenyi, 
Neema et al. 1998). It is therefore expected that in sub-Saharan Africa anti-malarial  
exposure in the early critical periods of pregnancy, and untoward pregnancy outcome, 
is likely to account for most of the unrecorded drug exposures in the absence of an 
adequate infrastructure to monitor and efficiently record drug safety assessments 
(Dellicour, Ter Kuile et al. 2008). This problem is likely to be even more acute following 
the use of different new anti-malarial products that are easily available in private 
pharmaceutical outlets (Goodman, Kachur et al. 2004; Hetzel, Dillip et al. 2008).  
 
To understand these challenges, we piloted a procedure on how to identify and monitor 
early drug exposure during pregnancy in women of reproductive age in the Kilombero 
river valley where the Ifakara Health Institute (IHI) runs a Demographic Surveillance 
System (IHDSS). The IHDSS is a longitudinal health- and population- based 
surveillance system that records vital demographic information including births, 
migration, death and causes of deaths through verbal autopsy. Details of the IHDSS 
are given elsewhere in the literature (Schellenberg, Abdulla et al. 2001; Kabanywanyi, 
Macarthur et al. 2008).  




Ascertainment of women exposed to anti-malaria.  
A list of women of child bearing age who were exposed to anti-malarial, with or without 
knowing they were pregnant, in the four weeks preceding subsequent household 
surveys was generated from the Ifakara health demographic surveillance system 
(IHDSS) database in 2006. Women who reported exposure to anti-malarial drugs while 
pregnant, and those who were not certain if they were pregnant, were both identified 
and were offered a urinary pregnancy test  
 
Procedures 
Details of these women, including demographic parameters and morbidity status of 
their household, were routinely recorded during preceding household surveys.  In 
addition, women were asked about their current reproductive status and if they had 
used any anti-malarial drugs in the two to four weeks prior to the date of interview.  
Women who reported being pregnant was asked to ascertain the actual gestation age 
and all women were offered confirmatory pregnant tests. Pregnant women with 
gestation age above two months at the moment of drug exposure also were offered a 
test, but were not included in the subsequent follow-up. All eligible women were asked 
for informed consent to undergo urinary pregnancy tests. A female, none-medical 
professional IHDSS interviewer was initially trained on how to perform the test. She 
could then provide respondents with the test results. All women unaware of their 
pregnancy status were given the results of the confirmatory test.  For those women 
who were pregnant the estimated date of conception was ascertained by the reported 
last date of menstrual cycle.  Test results were kept confidential between the 
interviewer and the women tested, unless a request was made for the results to be 
disclosed to other household members.  
 
Ethics consideration. 
All of the data presented in this paper was obtained as part of the IHDSS initial surveys 
that obtained ethical approval from the Ifakara Health Institute’s Institutional Ethics 
Committee. This study was implemented in the same framework of these surveys that 
record vital demographic parameters (births, deaths out migration and in migration). 
For each participant in this study we obtained a verbal consent that was sought after 
detailed explanation about the aim of the study.  
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4.2.4 Results 
Overall, 268 women were identified with nearly 98% of them reporting use of one or 
two types of anti-malarial drug in the two to four weeks prior to the interview.  More 
than half (n=166) used sulfadoxine-pyrimethamine (SP), 38 (14%) used amodiaquine, 
29 (11%) used quinine, 9 (3%) used SP plus quinine, while 11 (4%) used SP plus 
amodiaquine. Fifteen women could not clearly state which type of anti-malarial drug 
they used. Nearly all agreed to undergo urinary pregnancy tests. The test revealed that 
38 women were pregnant and had been exposed to an anti-malarial during their early 
period of pregnancy. Another three women in whom the test result was positive had 
been exposed to an anti-malarial at a late gestation stage. In about 26% positive result 
cases the women had not thought they were pregnant before the test was made.   
It had been planned in this pilot study to follow up pregnancy outcome at the time of 
delivery, but woman-child pair follow-ups were not included in the plan of assessment.  
In women that were identified as pregnant during this survey all gave birth to live 
offspring with the exception of one stillbirth. The long-term survival and health status of 
the 37 children born to the women who were exposed to anti-malarial drugs whilst 
pregnant was not systematically assessed during subsequent surveys.  
 
4.2.5 Discussion 
The methodology in the study provides new important information on the feasibility of 
performing urinary pregnant tests among reproductive age group women at household 
level.  In addition, this approach shows how this methodology can be used to record 
any untoward teratogenic medical outcome attributable to early medical inadvertent 
exposure in pregnancy.  
This pilot study was designed to identify the risks of anti-malarial exposure during early 
pregnancy and describe the usefulness and practicability of urinary pregnancy tests in 
the routine household surveys. IHDSS has the potential for follow-up of pregnant 
women through its routine longitudinal household visits, where vital demographic 
parameters (birth, migration, death and cause of death through verbal autopsy) are 
routinely documented.  
This study was not designed to record the occurrence of rare, adverse events, but, 
rather to test the hypothesis that a urine pregnant test could be done that was 
acceptable at community level. It was also designed to asses any untoward pregnancy 
outcome in all women who were exposed to anti-malarial drugs in early pregnancy.  It 
is important to note here that this approach allows early drug exposure during critical 
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stages of pregnancy to be tracked with follow-up pregnancy outcome for recording 
safety signals. This type of follow-up, however, is not routinely implemented at 
Reproductive and Child Health clinics. One of the major reasons for the failure of these 
clinics to implement this follow-up could be the late antenatal booking that is routine 
practice in most sub-Saharan settings (Fekede and A 2007; Ouma, van Eijk et al. 
2007).  
 
Drug exposure during pregnancy is based on information supplied by pregnant women.  
This presents limitations to the findings on the association of drug exposure and 
pregnancy outcome as there was no attempt to quantify this source of information.  
Another limitation is that this study was only able to follow up on hard outcomes such 
as birth or abortion at the end of pregnancy. This type of follow-up does not take 
account of the incidence of short-term, mild to moderate adverse drug reactions 
experienced whilst the embryo is developing.  It is for this reasoning that short-term 
symptoms and problems that regress with gestation age might have gone undetected 
through our surveys.   
 
Although this study applied a close follow-up plan of pregnancy outcome, the actual set 
up was less stringent than would be applied in a clinical controlled trial. This study has 
provided the research community with ample evidence that in places where DSS 
exists, a longitudinal monitoring platform for health status in the community can further 
be utilized to include drug safety follow-up and can generate useful real time 
information.   
4.2.6 Conclusion  
This assessment has provided useful information on the feasibility of monitoring early 
drug exposure in pregnancy. This methodology can be further extended to include a 
close follow-up of pregnant women and their newborns after birth.  Such an extension 
has the potential to reveal detailed information about pregnancy status and subsequent 
offspring developmental safety milestones and could serve as a comprehensive 
pharmacovigilance reporting system.  
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Background. The emergence and rapid spread of resistance to anti-malarial drugs over 
the past two decades has led to most malaria endemic countries to abandon most 
historically used anti-malarial in the past. The increased availability of fixed-dose ACT 
by 2009 has led to nearly 77 out of 81 P. falciparum malaria-endemic countries and 
territories to adopt ACTs for use in their national drug policies.  
Mainland Tanzania replaced sulfadoxine-pyrimethamine with artemether-lumefantrine 
(AL) in 2006. Following this change in Tanzania, a study that monitored the 
performance of AL in the invivo set-up was conducted in 2008. 
Method. The monitoring study was conducted using the WHO invivo assessments 
protocol in the framework of pharmacogenetic/kinetic project. This study took place 
from March to May 2008 at the Kibaoni Health Centre in Ifakara town 
Results.  
There were 13 (9%) and 9 (7%) patients who were lost to follow-up until day 28 and 
day 42 respectively and therefore not included in the final analysis. There was no early 
treatment failures and crude ACPR were 125 (95.4%) at day 28 and 122 (96.7%) at 
day 42.  During the 28 day follow-up (FUP) there were 2 (1.5%) LCF and 4 (3.1%) LPF 
failure rates while during the 42 day FUP there were only 4 LPF (3.3%). The mean 
haemoglobin improvement of 1.1 and 1.6 g/dl from baseline-day 0 to  day 28 and day 
42 follow-up was statically significant in both groups (p<0.001 both). 
Conclusion. The excellent efficacy of AL one year after country-wide policy 
implementation suggests that combination therapies with effective drugs can potentially 




The emergence and rapid spread of resistance to anti-malarial drugs over the past two 
decades has led most malaria endemic countries to abandon the most historically 
widely used anti-malarial chloroquine (WHO 2009). (Hatz, Abdulla et al. 1998; Breman, 
Alilio et al. 2004). This followed an intense search for new safe and efficacious anti-
malarial alternatives by researcher community and pharmaceutical companies (Falade, 
Makanga et al. 2005; Makanga, Premji et al. 2006). During the last decade, several 
options of fixed combinations of anti-malarials have gone through series of clinical trial 
testing their efficacy and safety parameters before market authorization (Makanga, 
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Premji et al. 2006). Few among these new therapies have passed international 
requirements for post marketing large scale up-scaling in to national malaria first line 
policies of several malaria endemic countries.  Despite ACT to be proven efficacious in 
the beginning of last decade, global adoption of new anti-malaria policy was slow with 
little support from WHO.  Thanks to prominent scientists that criticized the n lack of 
policy change at the global level, 2004 became the turning point resulting in many 
endemic countries changing their policy to ACTs (Attaran, Barnes et al. 2004; White, 
Nosten et al. 2004). Despite the Global Fund to support the free availability of ACT in 
most malaria endemic countries, during the early phase wide-ACT implantation it 
wasn’t readily accessible due to various hurdles in health systems in most malaria 
endemic countries.  In the aftermath of ACT availability at scale at the beginning of the 
current decade a cluster sampling surveys in most sub-Saharan African countries 
indicated that less than 15% of children under five with febrile illnesses who sought 
health care were being treated with ACT (WHO 2009).   
The increased availability of fixed-dose ACT by 2009 has led to nearly 77 of 81 P. 
falciparum malaria-endemic countries and territories to adopt ACTs for use in their 
national drug policies (WHO). In 2008, artemether-lumefantrine (AL) fixed-dose 
combination has reached more than 78 million treatment courses (WHO). In the United 
republic of Tanzania, Zanzibar changed its first line anti-malarial treatment from 
ineffective chloroquine to amodiaquine and artesunate since September 2003 whilst in 
Mainland Tanzania AL replaced sulphadoxine-pyrimethamine (SP) with AL in 2006 
(Kabanywanyi, Mwita et al. 2007).  
 
Following the adoption of ACT with AL as the anti-malaria first line policy in late 2006 
and its subsequent implementation in 2007 country wide, a new in vivo study was 
conducted to compare the efficacy of AL one after implementation with that before 
implementation. This study was part of a broader assessment of the pharmacogenetic-
kinetic of AL and took place in a health facility in the Kilombero river valley (Hodel, 
Kabanywanyi et al. 2009).  
 
5.1.3 Methods 
Study site and design. The study was conducted from March to May 2008 at in the 
Kilombero river valley at the Kibaoni Health Centre located six kilometers outside of the 
old Ifakara town. In this part of the country malaria transmission is perennial and peaks 
between May and July, after the long seasonal tropical rainfall. 
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The WHO standardized protocol for the assessment of therapeutic efficacy of anti-
malarial drugs (WHO 2000) was used. The study included sick children who were 6-59 
months old / of age and presented with history of fever in the past 24 hours or axillary 
temperature of ≥ 37.5°C, and mono-infection of P. falciparum count of 50-5,000/200 
white blood cells (WBC) assumed to be 2,000-200,000 parasites/µl.  Patients were 
excluded from the study if they presented with repeated convulsion, inability to take 
anything orally, severe anaemia i.e. Hb≤5gm/dl, difficulty in breathing or patients with 
signs consistent with renal failure and patient’s parent’s/guardian’s unwillingness to 
participate. 
 
Intervention. The patients were allocated to a standard dose of AL [Coartem®, 
Novartis], a fixed combination of 20 mg of artemether and 120 mg of lumefantrine) that 
was given to children according to bodyweight as follows: One tablet (i.e. 20 mg 
artemether /120 mg lumefantrine) to those weighing 5-14kg and two tablets (i.e. 40 mg 
/ 240 mg) to children with 15-24 kg. The full course of treatment for all study patients 
consisted of 6-doses that was given at 0, 8 and 16 hours; the remaining doses were 
given at 12-hourly intervals for a total of three days. All morning treatments were 
supervised by study nurse and patients were observed for 30 minutes following the 
drug intake. All patients who vomited within 30 minutes intervals were re-administered 
another full dose of the same medicine.  
 
Patients were followed for 28 days to assess clinical and parasitological responses and 
those that did not turn up for scheduled dose were visited at home by the study nurse 
on the same day. A patient was considered lost to follow-up if at the moment of 
scheduled visit he or she did not turn up and could not be found at home after three 
home visit attempts within one week of follow-up. An intention-to-treat analysis was 
planned for a follow-up extension to include day 42 end points. All patients who were 
available for this extension were followed up to day 42. Treatment outcomes were 
classified as early treatment failure (ETF), late clinical failure (LCF), late parasitological 
failure (LPF) and adequate clinical and parasitological responders (ACPR) using the 
guidelines (WHO 2003).  
 
Clinical and laboratory procedures. Patient follow-up was scheduled on days 1, 2, 
3,7,14, and 28 or day 42. On each visit, (including day 0 under which patient were 
enrolled) clinical, parasitological and haematological examinations were performed. 
Haemoglobin level (Hb) was assessed using HemoCue® (Angelholm, Sweden) and Hb 
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of ≤5 g/dl was considered as severe anaemia. Parasitological examinations involved 
assessment by rapid diagnostic tests with Parahit© (Span Diagnostics Limited, India) 
and microscopic assessment by thick and thin blood smears from a research 
microscopist of the Ifakara Health Institute (IHI). Parasitaemia was expressed as count 
per 200 WBC of blood assuming a normal leucocytes level of 8,000/µl.  
 
Analysis. Data generated in patient’s case record forms were entered into FoxPro® 
database software version 7 (Microsoft Corporation, Redmond USA 2001) at IHI. Data 
analysis was performed using STATA® statistical analysis software package version 
11 (Stata corporation, Collage Station TX, USA, 2007). Descriptive analysis was done 
and differences in proportions of treatment outcome were compared using Chi square 
test for proportions. Student’s t-test was applied for continuous variables. Data on 
patients that were excluded for different reasons and those that were lost to follow-up 
were not considered in the final analysis.  
5.1.4 Results 
 
Study profile and patient’s records.  A total of 389 malaria confirmed patients who 
attended the outpatient department of the Kibaoni health centre between March-May 
2008 were screened for eligibility into the study. A total of 131 and 122 children were 
eligible for invivo efficacy study and hence included in the final analysis for days 28 and 
42 endpoints respectively. There were 13(9%) patients who were lost to follow-up 
before day 28 and therefore not included in the final analysis. Similarly there were an 
additional 9 (7%) patients who were lost to follow-up during the day 42 extension and 
therefore not included in the final analysis. 
 
Treatment outcome. There was no early treatment failure in all patients that met 
inclusion criteria and could be followed up until day 28 at least. Crude ACPR were 125 
(95.4%) and 122 (96.7%) for day 28 and day 42, respectively.  During the day 28 
follow-up there were 2 (1.5%) LCF and 4 (3.1%) LPF failure rates while in day 42 there 
were only 4 (3.3%). 
For the 6 failures samples after day 28 and the 4 after day 42 discrimination analysis of 
recrudescence versus re-infection using PCR could not be performed. Indeed, the filter 
papers were misplaced during the renovation of the laboratory unit of the Ifakara Health 
Institute in Ifakara. 
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The mean haemoglobin improved moderately from 10.3 g/dl on day 0 to 11.5 g/dl on 
day 28 and to 12.0 g/dl on day 42 follow-up. The mean haemoglobin recovery after day 
28 was statically significant in both groups (p<0.001 both).  
 
5.1.5 Discussion 
One year after its implementation as first line anti-malarial policy in Tanzania, the level 
of efficacy of AL was still high and consistent with what had been observed three years 
prior to the policy change back in 2004. As a matter of fact, the day 28 ACPR estimate 
of 95% that has been recorded in this paper was even higher than that recorded before 
implementation at 87% (Kabanywanyi, Mwita et al. 2007).  This finding is likely to be 
due to chance. Other factors may have played a role.  For example, at present AL is 
used countrywide and is distributed free of charge through public health care facilities 
which implies that any malaria case seen at most health facilities is readily promptly 
treated (Alba, Dillip et al. ; Alba, Hetzel et al.) with anti-malaria. This results into cutting 
down the potential community biomass of asexual parasitaemia that could resulted in 
to sexual form of parasites reservoir that account for transmission intensity.  It can be 
argued that, the higher coverage of insecticide treated net (ITN) in the area has 
contributed to the extended protection against malaria 42 days after AL treatment. It is 
acknowledged that the implementation of complementary strategies leads to better 
outcomes. 
 
This study did not evaluate the nature of parasites found in 9% of all slides of patients 
that were considered either LCF or LPF. Failure to analyze these samples is not a 
major issue considering the low number of clinical and parasitological failures. Our 
estimate of an efficacy of 95% is quite conservative since we assume that all parasite 
recurrences are recrudescence. The efficacy could have been even higher, should 
molecular analyses been available. Indeed, in the same study in 2004 (Kabanywanyi, 
Mwita et al. 2007), it was shown that in areas with intense perennial malarial 
transmission the majority of patients that were classified as failure rates after blood 
smear analysis, were then found to be new infections by PCR analysis and 
subsequently classified as ACPR.  
 
Conclusion. The current crude clinical efficacy rates of AL one year after country-wide 
policy implementation suggest that AL is still highly efficacious to treat malaria. These 
findings provide substantial evidence that combination therapies with effective drugs 
can potentially be used over a long period of time.   
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To identify and implement strategies that help meet safety monitoring requirements in 
the context of an observational study for artemether-lumefantrine (AL) administered as 
first-line treatment for uncomplicated malaria in rural Tanzania.  
 
Methods 
Pharmacovigilance procedures were developed through collaboration between the 
investigating bodies, the relevant regulatory authority and the manufacturer of AL. 
Training and refresher sessions on the pharmacovigilance system were provided for 
healthcare workers from local health facilities and field recorders of the Ifakara Health 
Demographic Surveillance System (IHDSS). Three distinct channels for identification of 
adverse events (AEs) and serious adverse events (SAEs) were identified and 
implemented. Passive reporting took place through IHDSS and health care facilities, 
starting in October 2007. The third channel was through solicited reporting that was 
included in the context of a survey on AL as part of the ALIVE (Artemether-
Lumefantrine In Vulnerable patients: Exploring health impact) study (conducted only in 
March-April 2008).  
 
Results 
Training was provided for 40 healthcare providers (with refresher training 18 months 
later) and for six field recorders. During the period 1st September 2007 to 31st March 
2010, 67 AEs were reported including 52 under AL, five under sulphadoxine-
pyrimethamine, one under metakelfin, two after antibiotics; the remaining seven were 
due to anti-pyretic or anti-parasite medications. Twenty patients experienced SAEs; in 
16 cases, a relation to AL was suspected. Six of the 20 cases were reported within 24 
hours of occurrence.  
 
Discussion 
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Safety monitoring and reporting is possible even in settings with weak health 
infrastructure. Reporting can be enhanced by regular and appropriate training of 




Experience gained in this setting could help to improve spontaneous reporting of AEs 
and SAEs to health authorities or marketing authorization holders. 
 
5.2.2 Background 
Spontaneous reporting of suspected adverse drug reactions (ADRs) utilizing post-
marketing surveillance or pharmacovigilance techniques during drug therapy is less 
applicable in many sub-Saharan African countries (Edwards 1998). Pharmacovigilance 
is the science and activities relating to the detection, assessment, understanding and 
prevention of adverse effects or any other drug-related problem (WHO). 
Pharmacovigilance plays a key role in ensuring that patients receive safe drugs. The 
knowledge of a drug’s adverse effects can be increased by various means, including 
spontaneous reporting, intensive monitoring and database studies (Harmark and van 
Grootheest 2008). Post-marketing surveillance - which is often used synonymously for 
pharmacovigilance (Cobert and Biron 2002) and will be used throughout this article - is 
an important component of safety monitoring for drugs after they have been licensed 
for use. Detailed data on adverse events (AEs) are collected during the controlled 
clinical trials that are required for licensing, but however rigorous this process, the 
information collected cannot be regarded as entirely comprehensive due to the 
relatively restricted number of patients involved (Edwards 1998) and the exclusion 
criteria that are frequently applied, for example to omit pregnant women, young 
children, or elderly patients (Gough 2005). Accordingly, post-marketing surveillance, 
especially in the context of observational studies, can be a valuable source of 
additional safety data within a large patient population in a real-world setting.  
The main factors limiting the implementation of pharmacovigilance in resource-limited 
settings include limited access to healthcare facilities, availability of most prescription 
drugs from the informal market, poor labeling of medications, high levels of illiteracy, 
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poor record-keeping, a shortage of qualified healthcare professionals and a lack of 
awareness among healthcare workers of the need to identify and report suspected 
ADRs that occur during drug therapy. Post-marketing surveillance, including monitoring 
of anti-malarial drugs, is currently not undertaken in most sub-Saharan countries. A few 
countries in the region, including Tanzania, have managed to introduce a system of 
yellow cards, but this reporting process is still inefficient. Therefore, the benefits of 
pharmaco-epidemiological studies with planned, protocol-mandated collection of safety 
data may be particularly relevant in this region. However, careful attention must be paid 
to strategies that help to achieve effective safety monitoring during such studies. 
Failure to properly assess the safety of a widely used drug such as a first-line anti-
malarial treatment could result in public misperception and lead to problems with 
acceptability. This was seen in recent years with sulphadoxine-pyrimethamine (SP) 
(Mubyazi, Bloch et al. 2005). Concerns about SP-related serious adverse skin 
reactions (e.g. Stevens-Johnson syndrome) led to unnecessary delays in the process 
of policy change in several African countries (Mubyazi and Gonzalez-Block 2005). At 
the time, it was difficult for Ministries of Health to provide evidence-based information to 
the media and the public, and as a result public suspicion lingered for a long time. 
Since then, following recommendations from the WHO that artemisinin-based 
combination therapy (ACT) be used as first-line treatment of uncomplicated malaria 
(WHO), artemether-lumefantrine (AL, Coartem®, Novartis Pharma AG, Basel, 
Switzerland) has been widely adopted throughout sub-Saharan Africa as first-line 
treatment for uncomplicated Plasmodium falciparum malaria. The efficacy and safety of 
AL have been extensively documented in clinical trials (Falade, Makanga et al. 2005; 
Koram, Abuaku et al. 2005; Martensson, Stromberg et al. 2005; Mutabingwa, Anthony 
et al. 2005; Dorsey, Staedke et al. 2007; Zongo, Dorsey et al. 2007), but safety data for 
AL are currently limited when deployed on a large scale outside controlled clinical trials.    
In November 2006, Tanzania adopted AL as first-line anti-malarial therapy as part of its 
national policy. Following this decision, the ALIVE (Artemether-Lumefantrine In 
Vulnerable patients: Exploring health impact) study was initiated to evaluate the impact 
of implementing AL as first-line malaria treatment in a rural, malaria-endemic region of 
the country. ALIVE is an observational study undertaken by the Ifakara Health Institute 
(IHI) and the Swiss Tropical and Public Health Institute, and sponsored by Novartis 
Pharma AG and the Novartis Foundation for Sustainable Development. As for any 
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study of this type, specific requirements for safety monitoring were specified in the 
protocol, but the challenges in meeting these requirements were recognized.  
This paper describes how the pharmacovigilance requirements of the ALIVE study 
were being addressed through innovative initiatives that included dedicated training of 
relevant healthcare workers and community longitudinal demographic surveillances 
recorders. The use of short message service (SMS) text alerts was also encouraged. 
This may provide a potential model to ensure compliance with safety reporting 
requirements in other observational studies or more general post-marketing 
surveillance programmes.  
5.2.3 Methods 
The ALIVE study 
ALIVE is a prospective, observational, community-based, longitudinal, demographic 
surveillance study in adults and children, undertaken to assess the impact of AL on 
malaria morbidity and mortality in a rural, malaria-endemic area of Tanzania when used 
as first-line treatment for uncomplicated malaria.  Since first-line use of AL was adopted 
in Tanzania as national treatment policy in late 2006, it has been distributed to health 
facilities for use twice daily for three days to all patients’ ≥3 months of age with a 
clinical diagnosis of uncomplicated malaria. The first dose is administered under 
supervision at the health facility.  
The primary objective of the study is to assess the effect of AL on all-cause mortality in 
infants and children aged ≥3 months (and >5kg) and <5 years old compared to 
historical data using SP. Secondary objectives include the assessment of overall and 
malaria-related health facility attendance rate in children and in adults. This study also 
provided a framework for assessment of patient satisfaction, adherence to the AL 
regimen in both children and adults using a structured questionnaire, and safety 
monitoring of AL (Kabanywanyi, Lengeler et al.). 
The study is taking place over a five-year period (2007-2011) in two rural districts of 
Tanzania (Ulanga and Kilombero). The ALIVE study population comprises the 
population of the Ifakara Health Demographic Surveillance System (IHDSS) in the 
Ulanga and Kilombero Districts, which numbered approximately 82,000 at the start of 
the study.  The study area is characterized by monsoon tropical rains that fall from 
December to May, leading to an average annual rainfall of 1,200 mm. Malaria 
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transmission ranges from intense to moderate and transmission is perennial, peaking 
after the period of long rains with little seasonal variation (Smith, Charlwood et al. 
1993). Across the study area there are 25 villages and 25 health facilities that include 
health posts, dispensaries, health centres and hospitals, with varying quality of care. 
The ALIVE study is conducted in compliance with the Declaration of Helsinki following 
approval by the institutional review board of IHI and the Tanzanian National Institute for 
Medical Research (NIMR). 
Ifakara Health Demographic Surveillance System  
The IHI runs a well-established demographic surveillance system covering parts of the 
Ulanga and Kilombero districts in the ALIVE study, whereby standardized information 
on pregnancies, births, deaths and migrations are collected every four months by 
trained field recorders who visit each of the approximately 19,000 households in the 
surveillance areas of the two districts (Schellenberg, Abdulla et al. 2001). A complete 
household survey is performed annually to update the IHDSS database with 
socioeconomic and other key indicators. The IHDSS is being used to collect selected 
outcomes data in the context of the ALIVE study. The IHDSS unit is part of the Indepth-
Network, a global network of 37 field sites in Africa and Asia focused on health and 
population research . 
Pharmacovigilance monitoring 
In the context of this study, an AE is defined as ‘unfavorable and unintended sign 
including an abnormal laboratory finding, symptom or disease associated with the use 
of a medical treatment or procedure, regardless of whether it is considered related to 
the medical treatment or procedure, that occurs during the course of the study’. A 
serious adverse event (SAE) is defined as ‘an undesirable sign, symptom or medical 
condition which is fatal or life-threatening, requires or prolongs hospitalization, results 
in persistent or significant disability/incapacity, constitutes a congenital abnormality or a 
birth defect, is medically significant, or may jeopardize the subject and may require 
medical or surgical intervention to prevent one of the outcomes listed previously’. A 
suspected causality assessment is defined as follows: ‘The temporal relationship of the 
clinical event to trial drug administration makes a causal relationship possible, and 
other drugs, therapeutic interventions or underlying conditions do not provide a 
sufficient explanation for the observed event’.  
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The protocol included three channels through which AEs and/or SAEs can be identified 
and reported (Figure 1.5), to ensure that reporting is compliant with the regulations of 
the Tanzanian Food and Drugs Authority (TFDA) and with standard operating 
procedures of Novartis, the manufacturer of AL and the study sponsor. Of these, the 
first two channels (IHDSS and health facilities) employ passive pharmacovigilance 
while the third (patient satisfaction/adherence survey) actively solicits information on 
AEs and SAEs. Standard reporting forms from the TFDA were used to collect data on 
AEs. Standard Novartis SAE forms were, in addition, used to report SAEs.  
Safety data from patients of all ages were reported. 
1. IHDSS (Level I). Field reporters in the IHDSS (who are permanent residents in the 
area) have been instructed that for any AL-associated AE (regardless of seriousness) 
spontaneously brought to their attention, they should complete a TFDA form, and 
recommend to the reporter/patient that the event be reported to the health facility. The 
TFDA form is delivered to the local health facility, where additional details are added if 
possible. In the event of an SAE, a Novartis SAE form is additionally completed, and 
the SAE is assessed for causality by the physician and forwarded to Novartis. 
Additionally, in the event of an SAE being identified by IHDSS reports, IHDSS 
interviewers are trained to advise the patient to attend the local health facility 
immediately.  
2. Health facilities (Level II). Health professionals working in health facilities (i.e. 
medical officers, pharmacists, clinical/maternal and child health nurses, or laboratory 
staff) have also been instructed to complete a TFDA form for any spontaneously 
reported AL-associated AE, regardless of seriousness. In the event of an SAE, a 
Novartis SAE form is additionally completed. Assessment of causality by the treating 
physician is undertaken. If AL is administered during pregnancy, a specific Novartis 
pregnancy form is completed.  
3. Patient satisfaction/adherence survey (Level III). During the patient 
satisfaction/adherence survey that involved 552 malaria patients and was conducted 
between March-April 2008, information was actively solicited on AEs and SAEs, and 
recorded on the TFDA form (AEs) and the Novartis SAE form (Kabanywanyi, Lengeler 
et al.). If an SAE is suspected after assessment by a treating physician, the form is 
submitted to Novartis.  
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The TFDA forms are collected monthly from health facilities and transmitted to the 
TFDA safety desk in Dar es Salaam by postal mailing.  
From Ifakara, all SAE forms are transmitted to the local East African Novartis safety 
office, by fax or email. All data are entered to a specific ALIVE safety database held at 
the IHI. The ALIVE safety coordinator also actively follows up the patients for 
verification and assessment and, if necessary, the safety coordinator refers the patient 
to a health facility for further assessment and management. In the event of incomplete 
information from the relevant healthcare providers, the ALIVE coordinator may visit the 
patient and complete all necessary forms on site. All TFDA and Novartis SAE forms are 
also forwarded to the TFDA (Figures 1.5 and 2.5).  
The TFDA form requires standard reporting information (e.g. patient demographics, 
description of the event, suspected and concomitant drug(s), management and 
outcome of the event etc). The Novartis SAE form, which was field-tested by IHDSS 
and was found to be consistent with the TFDA report form, requires information on the 
diagnosis and description of the event, how the event met criteria for classification as a 
SAE, treatment doses at or before onset of the SAE, therapy dates, past medical 
history, relevant concomitant drugs, relevant laboratory values, investigator’s causality 
assessment (i.e. suspected [possibly or probably related to study drug] or not 
suspected) and outcome. If a causality assessment is missing when an SAE is 
reported either at a health facility or during the patient satisfaction/adherence survey, 
the SAE form is sent to Novartis for provisional reporting. 
SMS reporting 
In order to ensure timely reporting of AEs and SAEs, IHDSS field recorders or health 
facility staff were encouraged to send a mobile telephone SMS text alert to the ALIVE 
safety coordinator immediately when an AE or SAE is identified, prior to submitting the 
physical reporting form. The SMS includes a summary of patient demographics, date 
and type of event. Using this information, the safety coordinator then uses SMS texting 
to alert the local East African Novartis safety office and as necessary sends a fax or 
scanned copy of the initial report by email. Reminders to IHDSS field reporters and 
staff at health facilities that completed forms are required within the proscribed time 
frame (i.e. initial report within 24 hours of event and follow-up report not later than 15 
days after the initial report) are also sent through SMS alerts.  
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Training for healthcare workers 
In October 2007, a one-day training session was provided for healthcare providers from 
health facilities located in the two districts in which the ALIVE study was undertaken. 
Participants were divided in to two groups, each trained separately once during each of 
the two consecutive training days. Each session comprised at least 35 persons, from 
both of the districts that host IHDSS (Kilombero and Ulanga). This training was 
conducted jointly by facilitators from the investigating bodies (IHI and the Swiss 
Tropical and Public Health Institute), the regulatory authority (TFDA) and the drug 
manufacturer (Novartis Pharma AG). Trainees were designated as focal persons for 
their health facilities after training.  During the training session, delegates were 
instructed on how to identify AEs and SAEs, procedures for completing the relevant 
forms, and the reporting channels (Table 3.5). All reporting forms were presented and 
delegates were shown how to complete each one in a step-by-step process. Plenary 
presentations were followed by small-group breakout sessions in which case studies 
provided an insight into the identification and handling of AEs and SAEs and how to 
report them in a timely manner in compliance with the requirements of TFDA and 
Novartis. Delegates received training materials, handouts and copies of all relevant 
reporting forms.  
Eighteen months later (April 2009) another very similar training session was 
undertaken by experts from Novartis Pharma AG, Swiss Tropical and Public Health 
Institute, IHI and TFDA. This training included more details and emphasis on expedited 
reporting and causality assessments.  
A similar package of training materials was also provided to IHDSS field recorders 
individually in the field by the ALIVE safety coordinator. In addition, a retraining session 
was provided for IHDSS field recorders, again undertaken by IHI with materials 
developed jointly by the Swiss Tropical and Public Health Institute, the TFDA and 
Novartis. The session covered the definition of safety terms (AEs, ADRs and SAEs), 
explained the reporting forms, and described the reporting procedures. 
5.2.4 Results 
The first training session, in October 2007 was attended by 40 healthcare providers 
from health facilities in the study districts. The second training session was attended by 
35 healthcare providers, of whom more than half had not attended the first training 
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course because they had recently been relocated from facilities outside the ALIVE 
study area or returned from college. Six IHDSS field recorders attended the IHDSS 
training session and all IHDSS field recorders received reporting materials.  
Pharmacovigilance activity from 1st September 2007 to 31st March 2010 is described in 
the following sections. Within this period, 67 AEs were reported across the total patient 
population, of which seven were identified through Level I (passive surveillance), 59 
through Level II (passive surveillance) and the remainder through Level III (active 
surveillance). Among the 59 AEs that were reported through Level II, nearly 24% were 
exposure to AL during pregnancy. Eleven exposures occurred during the second 
trimester and the remaining three occurred in the third trimester. One of the three AEs 
that took place in the third trimester was a stillbirth, which occurred four weeks after AL 
exposure during the 34th week of pregnancy with no suspected relationship with AL.  
The other exposures were not associated with any adverse pregnancy outcome. The 
reporting rate peaked shortly after the first training course, subsequently declining until 
after the second training course in April 2009 (Figure 3.5).  
Of the 67 AEs reported, 52 occurred after AL therapy, five after SP, one after 
metakelfin, and another one after amodiaquine and paracetamol. Of the other AEs, one 
occurred after penicillin injection, two after paracetamol, four after ivermectin and one 
after administration of amoxicillin. During the same period (1st September 2007 to 31st 
March 2010), a total of 181,609 patients with suspected malaria reported to health 
facilities in the ALIVE study area and received AL as first-line treatment for malaria. 
The reporting rate of AL-associated AEs was therefore 28.6 per 100,000 AL-exposed 
patients. The AEs that were recorded after AL included vomiting (5 cases), itching 
and/or rash (21 cases); difficulty breathing, convulsion and headache occurred in 12 
cases. The other 14 AEs recorded after AL administration, which occurred alone or in 
combination, were high fever (2), dyspnoea (2), fatigue (3), dizziness (2), paraplegia (1) 
and a swollen eyelid (1). Others were insomnia (1), stiffness of joints and neck (1) and 
dysuria (1). In all cases occurrences were reversible and regressed with malaria 
symptoms. The five AEs that occurred after SP were mild erythematic skin lesions that 
did not progress to Stevens-Johnson syndrome. The AEs seen following treatment with 
penicillin and amoxicillin were both rashes.  
A total of 20 patients were reported who experienced SAEs during September 2007 to 
March 2010 (Table 4.5). In 16 cases, a relation to AL was suspected. All but two 
patients recovered; in the two cases where the patient died and the one in which a 
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stillbirth occurred, the SAE was not classified as having a suspected relation to AL.  Of 
the 20 patients with SAEs, 6 cases were notified to the ALIVE safety database within 
24 hours of occurrence. Twelve of these cases were detected at the health facilities 
and seven at home through IHDSS surveys (passive surveillance). Only one case was 
detected at home during the patient satisfaction/adherence survey (active surveillance) 
by a research field interviewer and was thus reported directly to the safety coordinator 
in Ifakara.  Two patients died. One was a 4-year-old child who died in hospital on the 
third day after admission. The patient was diagnosed with malaria at a secondary 
health care facility and given two tablets of AL, then referred to the tertiary health care 
facility where severe malaria was diagnosed on the day of referral, together with 
symptoms of convulsion and cough. AL was stopped and the patient put on quinine 
injection. Two days later, the patient died in the hospital, with the verbal autopsy giving 
the cause of death as difficulty in breathing. The second death occurred in an infant of 
five months, who was initially treated with AL and amoxicillin at a secondary health 
care facility one day before death. On the next day the infant’s condition deteriorated 
and AL discontinued, and the infant was then treated at the nearby primary health care 
facility as a case of severe malaria and pneumonia using quinine and penicillin 
injection. The patient was not referred to hospital on time and as a result died at home 
due to severe respiratory distress. 
 
5.2.5 Discussion 
Observational studies such as ALIVE offer the opportunity to obtain safety data on 
marketed drugs in settings that extend beyond the relatively small and selected 
populations that are assessed in randomized, controlled clinical trials. Undertaking a 
prospective observational study, however, requires careful consideration of how to 
meet the protocol-specified safety monitoring requirements of the relevant health 
authorities and the manufacturer. Particular challenges are faced in establishing 
pharmacovigilance monitoring in many rural areas of sub-Saharan Africa, where 
existing health services and patient access are often limited and often coupled with low 
awareness and motivation of healthcare staff about the need to report potential safety 
problems that occur during drug treatment.  
The current paper describes how a training programme for healthcare personnel, 
accompanied by provision of training and reporting materials and the use of SMS text 
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alerts, was adopted to support the safety monitoring for a large-scale prospective 
observational study of the use of AL for uncomplicated P. falciparum malaria in a rural 
area of Tanzania. The benefits of training were demonstrated by the increased AE 
reporting rate observed after both initial and follow-up training sessions, and by the 
appropriate nature of the events reported and adequacy of data provided. The decline 
in reporting during the 18-month interval between the initial and follow-up training 
highlights the critical nature of repeated training and reminders. The upsurge in AE 
reporting and subsequent downturn eight months later is a significant cause for 
concern, especially for a programme that has to be incorporated into the routine health 
service delivery system. In particular, the type of training session conducted in this 
study may not be sustainable within the standard health service given the inherent 
costs and time burden for the already overstretched system. In the ALIVE study, 
however, this approach was adopted because there was no efficient and cheaper 
comparable alternative. The view of the authors is that pharmacovigilance reporting 
must be included in the curricula of medical schools and be part of the job description 
of health care workers. Where possible, it should be included in the health information 
management system in the set up of developing countries to maximize capture of AEs. 
This work provides a solid basis for a recently planned project to establish 
pharmacovigilance reporting in eight sites in Burkina Faso, Ghana, Mozambique and 
Tanzania: the INDEPTH Phase IV Safety and Effectiveness Studies Platform (INESS) . 
For each AE reported, minimum reporting requirements were met, i.e. an identifiable 
reporter, an identifiable patient, a suspected product, and an AE. SAEs were reported 
in 20 patients, of whom five were given intravenous quinine after referral to tertiary 
health facilities and subsequently recovered, suggesting a missed diagnosis of 
complicated malaria  for which AL was not the appropriate treatment (Bronzan, 
McMorrow et al. 2008). Rash, as reported here in 21 cases, is a recognized and 
frequent AE associated with artemesinin-based combination therapy (Lefevre, 
Looareesuwan et al. 2001; Falade, Makanga et al. 2005; Makanga, Premji et al. 2006; 
Ibrahium, Kheir et al. 2007). There were 14 cases of AL treatment reported in pregnant 
women during the period described. For the single case of stillbirth that occurred during 
AL exposure, medical records were sparse which made the cause of stillbirth difficult to 
establish. The mother may have been HIV-positive.  In addition, she was given quinine 
at week 32 of pregnancy, followed four days later by vaginal bleeding and then 
stillbirth, suggesting that quinine may have played a causative role. 
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A markedly lower reporting rate is routinely observed in observational post-marketing 
studies that use passive pharmacovigilance monitoring (whereby AEs are only reported 
spontaneously by patients or carers to health professionals) compared to clinical trials 
in which data on AEs are collected actively, even in countries with well-established 
spontaneous reporting systems (Gough 2005; Hazell and Shakir 2006). In some sub-
Saharan African countries, the challenge of capturing safety data may be even more 
profound: in a recent observational study of first-line AL use in rural Ethiopia, not a 
single AE was reported spontaneously over a two-year period despite over 200,000 
individuals presenting with suspected malaria (Lemma, Byass et al.). Reporting rates of 
AEs in the ALIVE study – which mainly relied on passive pharmacovigilance – were 
higher than in the Ethiopian study; however, they were still low taking into account that 
over 180,000 AL treatments were administered during the observation period. This may 
be partly explained by the good overall safety profile of AL, with most of the AEs 
observed in clinical trials being related to malaria itself rather than to AL exposure 
(Makanga, Premji et al. 2006; Abdulla, Sagara et al. 2008). Most of the AEs occurring 
after AL exposure in the current study are similar in nature to those that were observed 
in the pre-registration clinical trials of the drug (Makanga, Premji et al. 2006; Mueller, 
van Vugt et al. 2006). 
Most of the reports of AEs made under the ALIVE pharmacovigilance programme 
reported in this paper were captured through the passive surveillance route, but it 
should be borne in mind that passive pharmacovigilance systems have various 
limitations. Passive pharmacovigilance can be particularly challenging in poorly 
educated, remote communities some distance from the nearest health facility and with 
a low number of trained healthcare workers. These factors are likely to have been an 
important cause contributing to low reporting rates in this study as well. Other passive 
monitoring initiatives, such as the promotion of ‘yellow cards’ in a rural area of 
Mozambique (Sevene, Mariano et al. 2008) and a malaria pharmacovigilance 
programme in South Africa (Mehta, Durrheim et al. 2007) have also shown low 
reporting rates (of ADRs), underscoring the challenge of effective safety data collection 
during anti-malarial therapy in Africa outside the context of clinical trials.  
The use of active surveillance, with prospective follow-up of the treated population, is 
ideal but unrealistic on a large scale due to cost and manpower requirements. In this 
study, however, active surveillance was applied only during a survey that investigated 
the feasibility and acceptability of AL during March-April 2008. The depth of information 
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that was obtained during the survey may not be representative of standard 
pharmacovigilance reporting as considered in this article, due to the short duration of 
the survey.  Notably, the aim of the ALIVE feasibility study was primarily to assess the 
adherence to and acceptability of AL, and results showed that patients believed AL to 
be a good drug (Kabanywanyi, Lengeler et al.). This could have biased their judgment 
such that they did not report minor AEs that might have occurred because this 
conflicted with their belief that the drug was excellent. Using passive reporting it has 
been suggested that reporting rates could be improved by providing non-financial 
incentives to community members and healthcare workers and ensuring confidentiality 
(Bukirwa, Nayiga et al. 2008). It has also been proposed that the lack of local expertise 
in pharmacovigilance could be tackled through developing exchange programmes with 
the major drug regulatory agencies and sharing of best practice, with the long-term 
goal that each country should establish its own national pharmacovigilance system that 
would contribute to a global database such as that held by the Uppsala Monitoring 
Centre (Pirmohamed, Atuah et al. 2007).  
The pharmacovigilance monitoring established for this study had the advantage of 
being a joint initiative between the investigators, the relevant drug regulatory authority 
and the sponsor (here, as in many instances, the drug manufacturer) – an approach 
which has recently been advocated (Pirmohamed, Atuah et al. 2007; Bukirwa, Nayiga 
et al. 2008). This resulted in a valuable combination of local knowledge, utilization of an 
existing healthcare and technical infrastructure, regulatory skills, funding, and 
experience of safety monitoring and data management. Additionally, training and the 
provision of materials spanned all levels of healthcare personnel although the decline 
in AE reporting during the 18-month delay between initial training and follow-up training 
may indicate that more frequent repetition of training, with regular reminders, could 
have increased the number of events reported. Prompt training of new healthcare staff 
would also be beneficial. Lastly, use of SMS texts to notify the ALIVE safety database 
coordinator at the time an AE was identified ensured prompt data capture and 
guaranteed that the event would not be lost during its progress through the subsequent 
reporting channels.  
In the ALIVE pharmacovigilance system reported here, it was observed that most AEs 
resolved in parallel with improvement in the treated clinical malaria. However, the 
relatively short half-life of artemether indicates that if an AE were related to the drug, 
drug clearance would have coincided with clearance of parasites (and host-response 
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inflammatory markers) (Ezzet, Mull et al. 1998; Djimde and Lefevre 2009). 
Lumefantrine, in contrast, has an extended half-life of approximately 33 hours (White, 
van Vugt et al. 1999). Because this study included neither measurement of artemether 
or lumefantrine plasma concentration nor ascertainment of parasitaemia at recovery, it 
is likely that these AEs were related to malaria but the contribution of treatment cannot 
be excluded.  
In conclusion, this article presents a practical model for pharmacovigilance monitoring 
during a prospective observational study that is applicable for rural community settings 
in sub-Saharan Africa or other developing regions. Training of healthcare workers at all 
levels to support protocol-mandated safety monitoring requirements was 
straightforward to undertake and showed a positive impact on the identification and 
safety reporting, but more frequent refresher courses and reminders are required to 
optimize and sustain reporting levels over time. Use of SMS texts is a pragmatic 
solution to communication challenges and helps to avoid lost or delayed reports. 
Finally, a collaborative approach involving all major participants – investigators, 
sponsor and regulatory authorities – from the outset offers a valuable template for 
future studies and facilitates sensitization of healthcare workers to the need for safety 
reporting. It is the authors’ view that these strategies could support the achievement of 
safety monitoring requirements during an observational study. Moreover, they could 
contribute to improvements in ongoing spontaneous reporting of AEs to health 
authorities, marketing authorization holders and the WHO Collaborating Centre for 
International Drug Monitoring (the Uppsala Monitoring Centre) (WHO) in regions with 
limited experience of pharmacovigilance monitoring and in which local resources are 
restricted.  
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Figure 1.5: Reporting channels for adverse events (AE). 
 
Figure legend: IHDSS, Ifakara Health Demographic Surveillance System; TFDA, Tanzanian Food and 
Drugs Authority; HH, Household;  HF, Health Facility;  SAS, Satisfaction/Adherence Survey   
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Figure 2.5: Reporting channels for serious adverse events (SAE).  
 
Figure legend: IHDSS, Ifakara Health Demographic Surveillance System; TFDA, Tanzanian Food and 
Drugs Authority; HH, Household; HF, Health Facility; SAS, Satisfaction/Adherence Survey   
 
 61 | P a g e  
 
Figure 3.5: Number of adverse events (AEs) reported per month during 1st September 
2007 to 31st March 2010.  
 
Figure legend: From 1st September 2007 to 31st March 2010 indicated on the left-hand y-axis. The right-
hand y-axis indicates the percentage of AL tablets prescribed per month, with the total number of AL 
tablets during 1st September 2007 to 31st March 2010 as the denominator. 
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Table 3.5: Content of training programme for healthcare workers at health facilities 
 
Table legend: ADR = adverse drug reaction; AE = adverse event; AL = artemether-lumefantrine; 
ALIVE=Artemether-Lumefantrine In Vulnerable patients: Exploring health impact; SAE = serious adverse 
event; TFDA = Tanzanian Food and Drugs Authority. ADRs were defined as ‘all noxious and unintended 
responses to a medicinal product related to any dose. The responses to a medicinal product means that a 
causal relationship between a medicinal product and an adverse event is at least a reasonable possibility 












Study drug (AL) Indications and dosage 
Contraindications 
Drug interactions 
Use in pregnancy/lactation 
Common ADRs (frequency >10%) 
Special precautions 
Study objectives Primary and secondary objectives of the observational study (ALIVE) 
ADRs, AEs & SAEs Minimum reporting requirements 
Definitions of ADRs, AEs & SAEs (including congenital abnormalities & birth defects) 
Detection and recognition of ADRs, AEs & SAEs 
Reporting of AEs & SAEs Data collection requirements 
TFDA reporting form 
Novartis SAE reporting form  
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Table 4.5: Patient characteristics, type, timing and outcomes of serious adverse events 
(SAEs) reported during 1st September 2007 to 31st March 2010.  
 
Sex Age  
(years) 
SAEa Interval between  
event and 
recording 
Outcome Level of reporting 
Female 37 Severe headache & 
vomiting 
1 days Recovered II 
Female 12 Dyspnoea & vomiting 1 day Recovered II 
Male 2 Twitching 1 days Recovered II 
Female 4 Severe vomiting 4 days Recovered II 
Female 2 Generalized itching/rashb >60 days a Recovered II 
Female 1 Respiratory distress 3 days Died;  





Female 4 Convulsion 9 days Died;  





Female 46 Dyspnoea 1 day Recovered II 
Male 38 Generalized rashb 7 days Recovered II 
Female 47 Generalized rashb 1 day Recovered II 
Male 13 Dyspnoea & swollen 
eyelids 
1 day Recovered II 
Male 7 months Skin rashes 20 days Recovered I 
Female 17 Paraplegia >60 days Recovered I 
Female 5 Joint stiffness >60 days Recovered I 
Male 10 Dizziness & headache 30 days Recovered I 
Female 32 Skin rashes & amnesia >60 days Recovered I 
Female 11 Skin rashes 60 days Recovered I 
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Male 7 Skin rashes 60 days Recovered I 
Female 47 Skin Rashes 10  days Recovered II 
Female 34 weeks 
(gestational 
age) 
Stillbirth >60 days Stillbirth;  






All events were recorded following AL treatment and were classified as SAEs by presenting with any or 
all of the following: (a) fatal or life-threatening (b) prolonging hospitalization (c) resulting in persistent or 
significant disability/incapacity (d) may jeopardize the subject or (e) may require medical or surgical 
intervention to prevent one of the previous outcomes. 
a
 Report was initially misplaced at the health facility and not made available to safety coordinator on time 
b
 Skin depigmentation for an extended period, which was considered to constitute significant incapacity  
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PART VI: IMPACT OF ANTI-MALARIAL FIRST LINE POLICY ON MALARIA 
TRANSMISSION AND UNDERFIVE MORTALITY IN TWO RURAL DISTRICTS OF 
TANZANIA- 
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CHAPTER 6: Impact of artemther-lumefantrine as first line policy on malaria 
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Introduction. Wide use of artemisinin-based combination therapy (ACT) in addition to 
other vector control measures is recommended in the fight against malaria. To date, 
there is scanty evidence on the contribution of ACT to reduce malaria transmission and 
overall U5 mortality in most endemic settings. Little has been documented on the effect 
of artemether-lumefantrine (AL) on malaria prevalence and there is no direct evidence 
that ACTs reduce mortality in Africa.  
As part of the ALIVE [Artemether-Lumefantrine In Vulnerable patients: Exploring health 
Impact] project, we assessed the impact of the introduction of AL as first line treatment 
for uncomplicated malaria on parasite prevalence, anaemia and under five mortality in 
rural Tanzania. 
Methods. Parasite and anaemia prevalence were obtained by repeated cross-sectional 
surveys conducted in two rural districts (Kilombero and Ulanga) in Tanzania during the 
period when the national first line anti-malarial therapy was sulfadoxine-pyrimethamine 
(SP) (2005 & 2006), and when it was AL (2008, 2009 and 2010). Mortality rates were 
obtained using a Demographic Surveillance System (DSS) that covers a dynamic 
expanding population of about 90,000 in both districts. Changes in mortality rates of 
children under five years were compared between both anti-malarial first line policy 
periods. The contributions of key interventions to control malaria introduced in the 
region were adjusted using Poisson regression model.  
Results. A total of 26,396 persons were assessed during annual surveys in 2004, 
2005, 2006, 2008 and 2009. On average the under five children that participated in the 
survey were always nearly 22% of the total population. Asymptomatic parasite 
prevalence in the whole population was 25% in 2004, 11.4%in 2005, 13.6% in 2006, 
11.0% in 2008, and 4.6% in 2009. The coverage of any net was kept at above 91% 
throughout the period. The mean U5 child mortality over the period was 21.9 (95%; 
20.9 to 22.9).  Under five mortality rate per 1000 person-years decreased by 33% from 
baseline in 2005 compared to 2009. ITNs were associated with reduction in community 
parasitaemia. For every 10% increases in ITNs coverage, there was nearly a 48% 
reduction in the annual community parasitaemia [IRR=0.52; 95% CI=0.38 to 0.73]. ACT 
was responsible for 11% annual decrease in under five mortality when adjusted for 
other key factors IRR= 0.89; 95% CI=0.79 to 1.0).  Food security was the only other 
main contributor of malaria decrease over the studied period. One unit (tone of rice/ha) 
annual increase in food security, notably the rice yields, was responsible for nearly 
36% reduction in annual under five child mortality (IRR=0.64; 95% CI=0.54 to 0.75). 
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Discussion. After 3 years of ACT implementation wit AL in Tanzania, there was a 
considerable decline in child mortality and parasite prevalence but no change in 
anaemia prevalence. ACT contributed to this change but to a lesser extent than ITNs 
and contextual factors such as food security. High coverage of ITNs has shown an 
impact on community parasitaemia.  
 
Conclusion. Timely change of anti-malarial first line policy with efficacious ACT in 
areas with high coverage of malaria vector control programmes is an impetus to key 
malaria elimination milestone. In the period when malaria elimination/eradication will be 
attained, food security in rural community will be key to sustain a healthy malaria free 




Deployment of highly efficacious anti-malaria drugs such as artemisinin-based 
combination therapy (ACT) and other malaria control measures have the potential to 
reduce malaria transmission and the overall U5 mortality.  In addition to their potential 
to cure asexual P. falciparum parasite, ACTs have also unique advantage of reducing 
malaria transmission by suppressing sexual parasites carriage rates (Barnes, Durrheim 
et al. 2005). Evidence from South-East Asia indicated that ACTs reduce malaria 
transmission by curbing the number of gametocytes in the person with the disease. On 
the north-western border of Thailand for instance, there was a 47 per cent reduction in 
the incidence of P. falciparum infections one year after the use of ACTs containing 
artesunate and mefloquine. There was a further improvement of a six fold reduction in 
malaria transmission(Barnes and Abdulla 2005).  
In sub-Saharan Africa previous efforts to control malaria have proved less successful 
mostly due to long use of poorly efficacious drugs which P.falciparum has manifested 
drug resistance. In most part of malaria endemic regions chloroquine (CQ) was found 
poorly effective for several decades but it was still being prescribed until most recently. 
In Tanzania for instance P.falciparum was already resistant to chloroquine in more than 
60% of all P. falciparum positive patients in the late 80ies (Hatz, Abdulla et al. 
1998)and was replaced by sulfadoxine-pyrimethamine (SP) only in 2001 after 
demonstrating consistent high failure rates (Mutabingwa, Maxwell et al. 2001; Mugittu, 
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Abdulla et al. 2005). Elsewhere in sub-Saharan Africa in Zambia for instance, during 
the same period it was recorded that the day 28 chloroquine failure rates were already 
at 40% (Barat, Himonga et al. 1998).   SP is anti-folate sulfa based anti-malaria drug 
that was adopted as an interim first line policy by many malaria endemic countries as 
there was no cheap immediate alternative to CQ.   
The emergence and rapid spread of resistance to most ant malarial drugs including SP 
over the past few years has led to the intensification of search for new efficacious anti-
malarial alternatives (Mugittu, Ndejembi et al. 2004). These efforts went parallel with 
global initiatives to combat malaria illness. In the 90s the World Health Organization 
(WHO) launched a Roll Back malaria campaign that advocated the use of more 
efficacious anti-malaria as one of the intervention tool. Despite the urgency call from 
this initiative there were few countries in malaria endemic region that were willing to 
adopt new anti-malaria policy with the use highly efficacious combination therapies 
such as ACTs due to overwhelming high cost imposed by ACT (Mutabingwa 2005). 
Until after 2004 nearly all malaria endemic countries were still using either SP or CQ in 
their first line Anti-malarial policies. The year 2004 became the turning point resulting in 
many endemic countries changing their policy to ACT thanks to the advocacy by 
prominent scientists and to the launch of initiatives such as the Global Fund for AIDS 
Tuberculosis and Malaria, ACT became available as fixed-dose at cheap price.  
Beginning of current decade many global health partners such as Global Malaria 
Initiatives (GMP), Medicine for Malaria Venture (MMV) and others have joined forces to 
new initiatives on fight against malaria illness. Thanks to increasing commitments and 
funding from global health partners and further availability of new fixed-dose ACT by 
2009, nearly 77 of 81 P. falciparum malaria-endemic countries and territories had 
adopted ACTs for use in their national drug policies (WHO 2009). At present for 
instance WHO is monitoring the global supply of and demand for the ACT fixed-dose 
and to date artemether-lumefantrine (AL) fixed-dose combination as part of the 
requirements of the Memorandum of Understanding signed with the manufacturer, 
Novartis Pharma AG, Basel Switzerland, in 2001, to make Coartem® available at cost 
price for distribution in the public sector of malaria-endemic developing countries. It is 
through these initiatives that AL has reached more than 78 million treatment courses in 
2008 (WHO 2009). These initiatives and the recently new others like Affordable 
Medicines Facilities for Malaria (AMFm) will be key especially in the malaria elimination 
phase. 
The other mainstay tool to fight against malaria is insecticide treated mosquito bed nets 
(ITN). This tool has not only shown a directly effect on the individuals using ITN but 
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also on the community at large when high coverage is achieved in that community 
(Binka, Hodgson et al. 2002; Binka and Akweongo 2006). By the year 2008 nearly 31% 
of African household was estimated to own at least one ITN or one long lasting 
insecticidal treated Mosquito net (LLITN). More children aged less than 5 years were 
also sleeping under ITN on average of 24% in 2008 as compared to 17% in the 
previous 2 years.  In several countries in the African region where high coverage of 
ITNs has been achieved, Tanzania included, a fall of malaria cases and deaths by 
more than 50% have been reported. In some malaria endemic countries and territories 
such as Zambia, South Africa and Zanzibar a territory in United republic of Tanzania 
the uptake of indoor residual spraying (IRS) of mosquito insecticides has gained 
significant coverage as compared to other nations. Such developments are 
encouraged and may suggest that overall attainment of initiatives such as Millennium 
Development Goals 4 & 6 (MDG) to reduce child mortality by two third ahead of the 
target time i.e., 2015 and combat malaria and other infectious diseases are possible 
(Barnes, Chanda et al. 2009; WHO 2009). 
Deployment of combined strategies such as ACT with vector control measures such as 
ITN and IRS is an important strategy to reduce malaria transmission and overall under 
five mortality (WHO 2009). To date most malaria endemic countries have realised the 
need to implement a combination of all available strategies to combat malaria as 
recommended by global health authorities. As part of the ALIVE [Artemether-
Lumefantrine In Vulnerable patients: Exploring health Impact] project, we assessed the 
impact of the introduction of AL as first line treatment for uncomplicated malaria on 
parasite prevalence, anaemia and under five mortality in a malaria endemic region in 
rural Tanzania where ITN coverage was already high before implementation of ACT. 
This paper presents dynamic changes in uptake of several interventions aimed to 
address the burden of malaria  and trends in achievements recorded over time in 
reduction of  malaria transmission and overall under five mortality in the years before 
(SP era) and after ACT implementation (AL era).   
  
6.1.3 Methodology 
The study site for the impact assessment of the introduction of ACT in Tanzania is a 
rural area in South-Eastern Tanzania in the Kilombero river valley where two rural 
administrative districts lie side by side. Malaria transmission is intense and perennial in 
both districts. There are two main rainy seasons, October-December the short rainy 
season and February May the long rainy season. The area is inhabited by a mix of 
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mainly indigenous subsistent farmers and few recently immigrated pastoralists 
communities from the North of the country. Farming is set at a more distance from 
family homestead in the race farming fields of the Kilombero river bank plains 
traditionally know as Shamba. These satellite farming fields are characteristic to 
malaria transmission as majority of individuals normally live in semi constructed huts 
during farming activities periods that includes; cultivation, weeding and harvesting 
periods at the peak of malaria transmission. This area is characterized by malaria and 
waterborne diseases such as cholera and diarrhea. This area was chosen for it its 
potential of hosting a longitudinal population based demographic surveillance system 
(DSS) that monitors vital demographic parameters such as in and out-migration, 
pregnancies and deliveries, births and deaths and special household surveys that 
record malariariometric indicators and morbidity. This system was launched in 1996 
and operates in two districts Kilombero and Ulanga and covers nearly 18000 
households and a population of about 95000 individuals (Schellenberg, Abdulla et al. 
1999; Armstrong Schellenberg, Bryce et al. 2004). This area was chosen also due to its 
potential to host key efficacious anti-malarial interventions and implementation 
programmes that ranged from health system support to social marketing of key malaria 
interventions for nearly 14 years back.  At the beginning of ALIVE in 2007 there was no 
action plan in the region to implement other vector control strategy such as IRS and 
others alike. 
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Figure 4.6: Maps of Tanzania depicting malaria risk: (a) before and (b) after the 
introduction of ACT. ALIVE study area is circled in a marked selection on both maps. (a) 
Before ACT introduction 




 (b) After ACT introduction 




Indeed several malaria intervention programmes have been implemented in the region 
starting of late 1990s. These programmes include; the integrated management of child 
illness (IMCI) that introduced a set of guidelines for management of sick children seen 
at primary health care facilities beginning of  2002 (Armstrong Schellenberg, Bryce et 
al. 2004). In 1997 to 1999 a project that socially-marketed subsidized Insecticide 
Treated Mosquito bed-nets in K/U Districts (KINET) was implemented (Schellenberg, 
Abdulla et al. 1999). The ITN model has been up-scaled nationwide in the programme 
named after-TNVS (Tanzania National Voucher Scheme). Another intervention that has 
been implemented in the region which anchors its activities to the IHDSS is ACCES 
programme. A schematic diagram in included in (figure 5.6) below that shows 
timeframe of these interventions.  
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Figure 5.6: Schematic representation of malaria interventions in Ifakara region and 





Study design  
The ALIVE project was initiated to evaluate the impact of implementing AL as first-line 
malaria treatment in a rural, malaria-endemic region of the country.  ALIVE is a 
prospective, observational, community-based, longitudinal, demographic surveillance 
study in adults and children, undertaken to assess the impact of AL on malaria 
morbidity, transmission and mortality in a rural, malaria-endemic area of Tanzania 
when used as first-line treatment for uncomplicated malaria. The primary objective of 
the study was to assess the effect of AL introduction on all-cause mortality in children 
aged <5 years old compared to historical data when SP was used. Secondary 
objectives include the assessment of overall and malaria-related health facility 
attendance rate in children and in adults. This study also provided a framework for 
assessment of patient satisfaction, adherence to the AL regimen in both children and 
adults using a structured questionnaire with AL safety monitoring indicators. This study 
relied on a before and after design covering a period of three years during SP use 
(2004-6) and three years of AL use (2008-2010) as first line national policy. The 
present paper presents results on data collected up until end of 2009. 
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Ascertainment of mortality  
 
The Ifakara health demographic surveillance system (IHDSS) operates all year around 
whereas field based recorders operate at a house level by registering all vital 
demographic parameters; death, births, migration and pregnancy. Special questions 
are introduced that interviewers administer routinely as per research need quarterly in 
planned surveys to a sample of household in each round.  Alongside field based 
IHDSS interviewers the system has identified in each hamlet a reporter who is a 
member of that particular hamlet to initially make an enquiry about each death that took 
place in the hamlet to the field based reporters. Hamlet reporters are vital to maximize 
the capture of all events and therefore a modest payment is made on monthly bases 
for every event reported. Based on this initial report, a list of deceased individual that 
contains name, date of birth, sex and date of death is populated in the Ifakara database 
and a printout is made available monthly to field based reporters to facilitate a full 
verbal autopsy interview with bereaved family members. 
Verbal autopsy interviews are scheduled at least 40 days later after the death and this 
period is considered minimum for the traditional mourning period. Most preferred 
respondents are family member who taken care the deceased during terminal period. 
Verbal autopsy is adopted as the simplest cause of death ascertainment in the 
INDEPTH network (INDEPTH 2010) where vital registration system is not in place. This 
process involved IHI DSS interviewers who interviewed close relatives of the deceased 
using a structured questionnaire that was adopted from.  In the questionnaire account 
of sequelaes and events that led to deaths were recorded. All causes of deaths were 
collated to a large database where the final diagnosis of the cause is arrived after three 
physicians’ panel that review the codes of disease adopted from the international 
classification of Disease and related health problems. For each death, at least two 
clinicians independently assigned a primary or underlying morbidity that resulted to 
death. In case of discordant results a third physician was asked to code the cause of 
death independently. In the event that there is discordant from three physicians the 
cause was then assigned an undetermined cause. These codes are then compared 
using a custom written programme in FoxPro [Visual Studio FoxPro Inc, Microsoft 




An annual cross-sectional survey to measure parasite prevalence in the whole 
population and anaemia (haemoglobin<5 g/dl) in children under five years was 
conducted among all consenting members of a random sample of 2000 households in 
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2008, 2009 and 2010, approximately 18 months, 30 and 42 months after countrywide 
AL introduction. These surveys always were being conducted at the same time point 
every year during May-September at the end of long seasonal rainfalls that correspond 
to a peak of malaria transmission. A questionnaire with information on fever in the past 
two weeks and health care seeking attempts, ITN ownership and use IPTp in 
pregnancy was applied. A drop of blood from a finger prick was collected on Hemacue 
cuvettes and examined for anaemia only in children less than 5 years old using 
Hemacue® machine (Angelhom Sweden). Thick blood smear on a glass slide was 
investigated for the presence of parasite by specialized microscopist from IHI and rapid 
diagnostic test for malaria (RDT) was used to confirm malaria infection that was 
diagnosed by microscope on blood slide from all household members. When the RDT 
was positive, a treatment of AL was offered on the spot.  Results from these three 
surveys were compared with those obtained during the SP era 2004, 2005 and 2006 
when SP was used as nation first line anti-malarial.  
 
Data management and analysis 
Data management was made on a tailor-made Visual FoxPro 7 (Microsoft Corporation, 
Redmond USA 2001) at Ifakara Health Institute (IHI). Data analysis was performed 
using Intercooler STATA® statistical analysis software package Stata (Stata 
corporation intercooled version 11, Collage Station TX, USA, 2007) 
Descriptive analysis was done to quantify reported fever in the past two weeks, 
prevalence of community parasitaemia anaemia in children and ownership of ITN. 
Under five (infant and <5 years) mortality was calculated as rates per 1000 person-
years of exposure. The effect of first line anti-malaria drug policy on malaria 
parasitaemia and under-five children mortality was assessed separately by Poisson 
models. Key factors such as ITN ownership, mean annual rainfall, agricultural yields 
were independent variables that were used in univariate analysis to explore the 
association with mortality and parasitaemia. For the year 2007 in which no survey was 
conducted estimates from preceding year was inferred to represent values for 2007. 
For multivariate Poisson model, we fitted two models: one with parasitaemia as 
dependent (intermediate predictor of mortality), the second with mortality rate as 
dependent parameter. All factors were included into the models using a backward 
stepwise removal for predictors that exceeded 15% point of significance. We 
considered food yields as a proxy of food security to represent malnutrition in place of 
food shortage. Anti-malarial policy was dichotomized as 0 values to present a period 
with SP as first line in 2004-2006 and 1 represented first line as AL in 2007 to 2010.  




A total of 26,396 persons were assessed during annual surveys in 2004, 2005, 2006, 
2008 and 2009. On average the under five children that participated in the survey were 
always nearly 22% of the total population. Asymptomatic parasite prevalence in the 
whole population was 25% (95% CI; 22.3 to 27.7) in 2004, 11.4% (CI; 8.4 to 13.7) in 
2005, 13.6% (CI; 11.1 to 16.3) in 2006, 11.0% (CI; 8.4 to 14.1) in 2008, and 4.6% (CI; 
2.7 to 7.5) in 2009. The coverage of any net was kept at above 91% throughout the 
period. Details of six years surveys are presented on table 5.6. The mean U5 child 
mortality rate per 1000 person-years over the period was 21.9 (95%; 20.9 to 22.9). 
Table 6.6 and figure 6.6 presents mortality profile going back to 1997.  
 
After 3 years of AL implementation, there was a considerable decline in parasite 
prevalence but no change in anaemia prevalence. Figure 7.6 represents prevalence of 
anaemia in children less than five years during the evaluation period. On average 
gametocyte carriage rate has remained < 1% throughout the period. Mortality in 
children <5 years decreased with maintenance of a downturn trend that was sustained 
from preceding periods. In the Poisson univariate analysis, malaria interventions that 
were found to be independently associated with community parasitaemia hence under 
five child mortality was coverage of ITNs and use of ACT. Food security and rainfall 
were the only contextual (non-intervention) factor that showed a strong relationship 
with decrease in parasite prevalence as well as a downturn in under five child mortality.  
In a multivariate analysis of all interventions with community parasitaemia, ITNs was 
the only intervention that was associated with parasitaemia.  For every 10% increases 
in ITNs coverage, there was nearly a 48% reduction in the annual community 
parasitaemia [IRR=0.52; 95% CI=0.38 to 0.73]. Table 7.6 shows results from the 
univariate and multivariate Poisson model on parasitaemia and table 8.6 on U5 child 
mortality. In the multivariate analysis between U5 child mortality and all other factors 
rice yields and ACT were the only factors that were associated with decrease in 
mortality. ACT was responsible for nearly 11% annual decreases in under five mortality 
when adjusted for contextual factors [IRR= 0.89; 95% CI=0.79 to 1.0]. A unit annual 
increase in food security; notably the rice yields was also responsible for nearly 36% 
reduction in annual under five child mortality [IRR=0.64; 95% CI=0.54 to 0.75. 
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Table 5.6: Characteristics of surveyed individuals and contextual factors in the ALIVE 




Table 6.6: Under five mortality case, rates and computed persons years (pyr) 
 
 
Year Deaths pyrs Annual rate 
1997 284 8.95149 31.72655 
1998 249 8.87911 28.04333 
1999 246 8.67338 28.36264 
2000 298 10.07777 29.57003 
2001 284 11.26623 25.20807 
2002 345 11.96768 28.82764 
2003 392 12.16668 32.21913 
2004 307 12.59317 24.37829 
2005 346 12.82348 26.98177 
2006 318 13.73179 23.15794 
2007 325 14.65734 22.17319 
2008 299 15.79292 18.93254 
2009 297 16.6297 17.8597 
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Table 7.6: Effect of malaria control interventions and other key factors on malaria 
prevalence as determined from Poisson regression model between years (2004-2009) 
 
 
Table 8.6: Effect of malaria control interventions and other key factors on annual under 








Attributes Univariate model  
 
IRR (95% CI) 
p-value Multivariate model 
IRR (95% CI) 
p-value 
1st Line anti-malaria policy 
   SP (2004-2006) 
   ALu (2007-2009) 
 
1 










ITN ownership (10% rise in coverage) 0.52 (0.38; 0.73) <0.001 0.52 (0.38; 0.73)         <0.000 
Contextual factors 
Rice yields (tone/ha) 
Rainfall (total annual rainfall in mm) 
 
0.27 (0.11; 0.71) 
0.98 (0.91; 1.05) 
 
<0.001 





Attributes Univariate model  
 
IRR (95% CI) 
p-value Multivariate model 
IRR (95% CI) 
p-value 
1st Line anti-malaria policy 
   SP (2004-2006) 
   ALu (2007-2009) 
 
1 










ITN ownership (10% rise in coverage) 0.84 (0.79; 0.89) <0.001   
Contextual factor 
Rice yields (tone/ha) 
Rainfall (total annual rainfall in mm) 
 
0.64 (0.54; 0.75) 
0.98 (0.96; 0.99) 
 
<0.001 
  0.001 
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Figure 7.6: Prevalence of anaemia in children under five years during evaluation period. 
 





Two years after the implementation of anti-malarial first line policy in Tanzania in the 
Kilombero river Valley the ALIVE project has documented a sharp downturn of malaria 
parasitaemia from 11% (698/5223) in 2006 to 4.6%(341/7401) in the community among 
asymptomatic individuals. There is also a consistent reduction in all-cause U5 child 
mortality from annual 23.2 cases/1000py in 2006 to nearly 17.9 cases/1000py in 2009. 
Both reductions in malaria transmission and mortality that were observed under ALIVE 
can be attributed In part to ACT. On one hand the mortality changes documented have 
to be seen as a trend in the downturn that goes back to mid 1990 which can be 
extrapolated to a secular trend in the framework of several other interventions that 
were put in place since mid last decade. On the other hand the sharp downturn in 
malaria parasite prevalence in asymptomatic individuals in the DSS community as 
documented in 2009 when compared to the pre-ACT era is strong evidence that the 
introduction of AL has had an impact on malaria transmission in Tanzania, whereas 
ITNs coverage has remained high over the whole observation periods (pre- and post-
AL era).  
   
The introduction of AL as the first line treatment of malaria in Tanzania and in the 
Kilombero river valley in particular was privileged to coincide with a number of 
achievements on the ground. First AL was introduced in Kilombero at the time when 
SP had already attained good accessibility coverage in both private and public outlets 
(Hetzel, Msechu et al. 2006). Second AL was introduced in the region at a time 
Tanzania was up-scaling ITN with bundled or LLITN programme countrywide through- 
NATNET Scheme. It can therefore be argued that despite the significant failure rate of 
SP in the general community at the time policy transition was being implemented with 
AL as first line, much of AL good performance have been backed-up by the former 
interim SP policy. This is due to the fact that SP was readily accessible in two years 
preceding AL introduction through strategies implemented by the ACCESS project that 
resulted in to increased channels of anti-malarial availability in the region (Alba, Hetzel 
et al.).  This could mean that most malaria fevers at the moment of ascertainment were 
being treated with anti-malarials on time and resulted in a reduction of the overall 
community malaria transmission [Alba et al, fever paper]. Several other factors may 
have played a role in the transmission and mortality downturn that was recorded. It is 
imperative to note here that the improvement in health care seeking behavior and gain 
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in food yields in particular were contributing factors behind this surge (Alba, Dillip et al. 
; Alba, Hetzel et al.). Food security is key to sustain gains in child mortality obtained 
with implementation of effective malaria control interventions.  
 
Introduction of ACT did not seem to have impacted on malaria transmission in the 
multivariate Poisson analysis as it did in the Poisson model on mortality. This is not 
readily explained since it would be expected that the reduction of overall mortality that 
is due to the reduction of malaria, thanks to ACT introduction, would parallel affect 
malaria transmission. In fact, it is more likely, from our observations, that the effect of 
ACT on mortality is due to the direct benefit of ACT on level of cure, namely on the 




Our findings are prone to various limitations as follows. First, the before after design; 
has sliced three years before and three years after ACT introduction. The timeframe 
might be too short to have sufficient confidence that the observed downturn in U5 
mortality is due to the change in ACT policy. The same applies to the absence effect of 
ACT on malaria transmission, although the modest reduction was seen in mortality 
during the same period of ACT introduction. Also, many other factors than those 
analyzed may have influenced mortality and were not taken into account (vitamin A 
distribution, IPTp, IMCI etc.). Third, there have been some hurdles in ACT distribution 
in the region, and as it is now the delivery system is still imprecise to account for good 
coverage of ACT accessibility by rural community in need of it.   
 
Despite these limitations our findings are still valid and consistent with similar 
assessments that were conducted elsewhere. Similar studies elsewhere in Sub-
Saharan Africa,  Kwa Zulu Natal province in South Africa for instance in 2003 showed 
that malaria-related deaths decreased by 97% over two years after a combined 
strategy of implementation of ACT and other intervention such as ITN and IRS (Barnes, 
Chanda et al. 2009). Our findings on the effect of ITNs on malaria transmission are 
consistent with results from the Cochrane review synthesized evidence from 
randomized trials on bed-net in Sub-Saharan Africa that showed a 17% protective 
efficacy of ITN in area where coverage is near to 60% (Lengeler 2000).  
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Conclusion Three years after ACT implementation wit AL in Tanzania, there was a 
considerable decline in U5 child mortality, and ACT introduction has contributed to this 
decline. Malaria parasite prevalence declined to more than 65% over the entire period 
but no change in anaemia prevalence was observed. Key malaria interventions such as 
ITN and contextual factors such as food security have contributed greatly to these 
changes. Timely change of anti-malarial first line policy with efficacious ACT in an area 
of Ifakara DSS with high coverage of malaria vector control programmes has 
demonstrated key findings to malaria elimination milestone. In the future malaria 
elimination/eradication period, food security in rural community will to be key to sustain 
healthy malaria free U5 children who initially were vulnerable to fatal malaria. 
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PART VII: DESCRIPTION TO PROGRAMMATIC ISSUES OF PROPER USE OF AL 
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Background: Controlled clinical trials have shown that a six-dose regimen of 
artemether-lumefantrine (AL) therapy for uncomplicated Plasmodium falciparum 
malaria results in cure rates >95% with good tolerability.  
Materials and methods: A prospective study was carried out to document the 
adherence to and acceptability of AL administration. This was undertaken in the 
context of the ALIVE study, a prospective, community-based, observational study in a 
rural, malaria-endemic area of Tanzania. Following microscopic confirmation of P. 
falciparum infection, the first AL dose was taken under supervision, with the 
subsequent five doses taken unsupervised at home. Patients were randomized to 
receive a home-based assessment close to the scheduled time for one of the 
unsupervised doses, but were blinded to which follow-up visit they had been allocated. 
A structured questionnaire was administered by trained staff and AL consumption was 
confirmed by inspection of blister packs.  
Results: A total of 552 patients were recruited of whom 352 (63.8%) were <13 years 
old. The randomization process allocated 112, 109, 110, 100 and 111 patients to a 
follow-up visit after doses 2, 3, 4, 5 and 6, respectively. For dose 2, 92.0% of patients 
(103/112) correctly took AL at 8±1 hours after dose 1. The remaining doses were taken 
within 4 hours of the correct time in 87-95% of cases. Nine patients (1.7%) missed one 
dose. Blister packs were available for inspection in 548 of cases (99.3%) and 
confirmed patient-reported data that the previous dose had been administered. Nearly 
all patients took AL with water (549/552 [99.5%]). Two patients (0.4%) took the drug 
with food. The dosing pictogram and clustering of tablets within the blister packs was 
considered helpful by 91.8% and 100.0% of patients, respectively. Overall, 87.1% of 
patients (481/552) found AL easier to take/administer than sulphadoxine-
pyrimethamine (SP) and 87.7% (484/552) believed that AL was more effective than SP.  
Discussion: Factors contributing to adherence were likely to be helpful packaging, 
pictorial dosing instructions and patients’ conviction that AL is effective. 
Conclusion: Adherence to the dosing regimen and timing of AL administration was 
very good.  
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7.1.2 Background 
Malaria is the leading cause of outpatient and inpatient admissions in most sub-
Saharan African countries, including Tanzania, and continues to exert a high burden in 
terms of mortality [1-3], morbidity [1, 4] and health expenditure [5, 6].  The use of anti-
malarial drugs for chemotherapy and chemoprophylaxis is a critical component in the 
fight against malaria, but Plasmodium falciparum resistance to conventional anti-
malarials, such CQ and sulphadoxine-pyrimethamine (SP), is high [1, 7-10].  It is for 
this reason that the World Health Organization (WHO) has been recommending 
artemisinin-based combination therapy (ACT) as first-line therapy to replace failing anti-
malarial drugs [11]. 
The ACT artemether-lumefantrine (AL, Coartem®), combines the short-acting 
artemisinin derivative artemether with long-acting lumefantrine. Giving the second dose 
of AL eight hours after the first dose quickly achieves and maintains the blood 
concentration of artemether above the minimum effective concentration [12] to help 
ensure that malaria parasites are exposed to high levels during the middle third of their 
life cycle, when they are most susceptible to anti-malarial agents [13]. AL has 
demonstrated a high level of efficacy and a good tolerability profile [14-18]. As a result, 
the national treatment policy of Tanzania was revised in November 2006 to adopt AL 
as first-line treatment for uncomplicated malaria.  
AL is administered as a six-dose regimen over a period of three days [19]. Controlled 
trials using this regimen have demonstrated cure rates of over 95% [20-23], consistent 
with recommendations from WHO that cure rates for uncomplicated P. falciparum 
malaria should be at least 90% and preferably exceed 95% [11]. Evidence regarding 
the adherence to the AL dosing regimen and feasibility of its use in programmatic 
conditions remains limited [24-29]. Nevertheless, proper evaluation of adherence and 
acceptance outside the context of controlled clinical studies is important as AL is widely 
deployed throughout malaria endemic sub-Saharan countries.   
Following the inclusion of AL within the national Tanzanian treatment policy, the ALIVE 
(‘artemether-lumefantrine in vulnerable patients: exploring health impact’) study was 
undertaken in a rural, malaria-endemic area of the country with the aim of evaluating 
the impact of introducing AL as first-line malaria treatment on malaria-related morbidity 
and mortality. As part of ALIVE, a prospective study was conducted under routine 
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conditions to document the adherence to and acceptability of AL drug administration in 
this setting. 
7.1.3 Methods 
The ALIVE study 
ALIVE is a prospective, observational, community-based, longitudinal, demographic 
surveillance study taking place in two rural districts of Tanzania (Ulanga and 
Kilombero). The primary objective is to assess the effect of AL on all-cause mortality in 
infants and children aged ≥3 months (and >5kg) and <5 years old, using historical data 
based on the former first-line treatment with SP as comparator.  Secondary objectives 
include assessment of adherence to the AL regimen, knowledge of correct AL intake 
and patient satisfaction 
The conduct of the ALIVE study complies with the Declaration of Helsinki. The study 
protocol was approved by the institutional review board of the Ifakara Health Institute 
(IHI), which implements the ALIVE study, and the Tanzanian National Institute for 
Medical Research (NIMR). 
Administration of AL 
As per the instructions from the manufacturer (Novartis Pharma AG, Basel, 
Switzerland), AL is dosed according to body weight: 5 to <15kg, 1 tablet per dose; 15 
to <25kg, two tablets per dose; 25 to <35kg, three tablets per dose; ≥35kg, four tablets 
per dose. The first two doses of AL are to be given eight hours apart on day 1.  On 
days 2 and 3, AL is to be given twice daily, 12 hours apart; with the morning dose being 
administered 24 hours after the first dose was taken. 
In this study, the first dose of AL was taken under supervision at the health facility, with 
the subsequent five doses taken unsupervised at home. Dosing and time of 
taking/administering the drugs was explained and the time was clearly marked on the 
AL blister packs by the dispensing healthcare provider. Patients or caregivers were 
advised to ensure AL was not taken/given on an empty stomach.  
 
Assessment of adherence and acceptability  
Assessment of adherence to and acceptability of AL was conducted within the context 
of the ALIVE study and was undertaken at the Mlimba Health Center in the Kilombero 
 89 | P a g e  
 
District during the period March to April 2008, i.e. approximately one year after the new 
treatment policy was introduced in Tanzania (January 2007).  Patients living in villages 
no further than six kilometers from the Mlimba Health Center were eligible to take part 
in the assessment if they had no clinical signs of complicated malaria and P. falciparum 
infection was confirmed by blood smear. Informed consent was obtained from all 
patients.  
A computer-generated randomization list was used to allocate eligible patients to a 
home visit for one of the five doses of AL to be taken after the initial, supervised dose. 
It was planned that all patients be visited at home at a time close to the scheduled time 
of AL administration. In the event those patients were due to be visited late in the 
evening or at night following an evening dose, visits were scheduled for the following 
morning. Patients or caregivers were informed that there would be a follow-up visit but 
were blinded as to which of the five possible follow-up visits they had been allocated.  
Each visit was undertaken by one of two IHI field workers or three local field assistants, 
after appropriate training based on standard AL training materials provided by the drug 
manufacturer (Novartis) which had been field tested by researchers from IHI in Ifakara.  
For patients younger than 13 years, the patient’s caregiver was interviewed instead of 
the patient.  
Questionnaire 
A structured questionnaire (see Additional file 1) was developed by researchers from 
IHI and the Swiss Tropical Institute and Novartis, after which it was field tested by 
researchers from IHI in Ifakara, and then administered to the patient or caregiver at 
each visit. This included questions on the number of doses to be administered, the 
number of tablets per dose, the exact time at which the last dose was given, reason for 
any missed doses, appropriate action if a dose was vomited, consumption of 
concomitant food or drink at the time of AL dosing, and how patients/caregivers 
remembered that AL doses should be taken. Additional questions included whether the 
instructions/drawing on the AL pack were considered useful, how patients/caregivers 
perceived the clustered doses in the blister packs, how easy it was for them to 
take/administer AL, how effective they judged AL as compared to SP (the previous 
first-line therapy for uncomplicated malaria in Tanzania), and their preference for AL 
over other treatments (antibiotics, analgesics/antipyretics, quinine injection, herbs from 
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traditional healer or remedy from witchdoctor). Consumption of the dose was confirmed 
by inspection of the AL blister packs.  
7.1.4 Results  
Patient population  
A total of 552 patients met the eligibility criteria and were recruited for the study (Table 
9.7). The majority of patients (352/552 [63.8%]) were aged less than 13 years. All 
included patients had come to the medical facility to seek medical attention for fever.  
Almost all patients (544/552, 98.6%) were reported to be unwell or moderately unwell 
at the time of presentation to the health facility.   
The randomization process allocated 112, 109, 110, 100 and 111 patients to a follow-
up visit after doses 2, 3, 4, 5 and 6, respectively.   
Adherence to AL 
AL was dispensed at the Mlimba Health Center in all cases. When asked, 100% of 
patients/caregivers reported that they had received an explanation of how to use AL. 
Results of the questionnaire confirmed that all patients/caregivers understood the 
number of doses required, and the number of tablets that should be taken or 
administered per dose (Table 10.7). All but one patient responded that five doses in 
total were to be taken, an answer that was correct when referring only to the doses for 
which they were responsible (the first dose was given by the healthcare provider).  AL 
was taken at the correct time in approximately 90% of cases for each dose (Table 
10.7). For dose 2, 92.0% of patients (103/112) took AL at 8±1 hours after dose 1. The 
remaining doses were taken within four hours of the correct time in 87-95% of cases. In 
total, nine out of 522 patients (1.7%) reported missing a single dose of AL. In two out of 
these nine cases, the patient had forgotten to take the final dose. One patient used the 
intended dose to replace a dose vomited previously, and one patient ceased to take 
the drug after vomiting. In the remaining five patients there was no apparent reason for 
missing prescribed doses. AL blister packs were available for examination at the 
randomized visit in 548 cases (99.3%), and the reported number of doses taken 
corresponded with actual pill count at each visit.  No patient missed more than one 
dose, and no patient missed dose 2. In case of a dose being vomited, the majority of 
patients correctly understood that they should return to the health facility for a 
replacement dose (316/552, 57.3%). However, a relatively high proportion of patients 
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(42.7%) incorrectly believed that a replacement dose could be taken from the existing 
blister pack or that no action was required.  
Nearly all patients took AL with water (549/552 [99.5%]). Two patients (0.4%) took the 
drug with food. The most frequently reported factor that positively influenced adherence 
to the timing of AL dosing was the impact of the current illness (Table 10.7).   
Acceptability of AL  
Almost all patients (91.8%) found the dosing pictogram helpful, and all patients 
reported that clustering of tablets within the blister packs was useful (Table 11.7). In 
total, 87.1% of patients (481/552) found AL easier to take/administer than SP and 
484/552 (87.7%) believed that AL was more effective than SP (Table 11.7). 
Approximately 90% of patients (495/552) would not have preferred other medications 
than AL to treat the current illness, although 5.6% (31 patients) would have chosen 
quinine injections. Two patients would have preferred to receive herbs from a 
traditional healer.   
7.1.5 Discussion 
Adherence to the standard AL regimen was very good in this population of patients in a 
rural area of sub-Saharan Africa.  The full six-dose regimen was taken by 98% of 
patients, with the dose being taken at a satisfactory time in ~90% of cases.  These 
results were obtained without any additional training for staff at the dispensing health 
center beyond the standard National Malaria Control Programme training initiative, and 
no special guidance was given to patients other than that which is routinely offered by 
the local healthcare personnel. The proportion of patients taking all five unsupervised 
doses was consistent with other reports for ACT in general [24, 25] and AL in particular 
[26, 27, 28, 29]. This is, however, the first study to provide data related to the timing of 
AL administration, and the first to apply a randomized study design to the assessment 
of AL adherence.  
Although multiple doses of AL are required, there is no need for individual dose 
calculations according to body weight; instead, complete treatment packages are 
available for each body weight group. Thus, AL is simpler to prescribe than SP, the 
previous first-line therapy, which requires weight-adjusted dosing. However, patients 
need to take five doses of AL unsupervised over a three-day period compared to a 
single dose of SP. Our findings, however, indicate that adherence to the AL regimen is 
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very good following standard instructions from the dispensing healthcare provider, as 
confirmed by pill counts at the randomized visits. According to the patient responses to 
the questionnaire, the clustering of tablets for each dose within the AL blister packets is 
likely to have contributed to the correct number of tablets being taken, and the 
pictogram shown on the packaging was considered as a helpful supplement to the 
instructions provided by healthcare workers. The pictogram made the timing of drug 
administration clear in this rural area where few individuals have a clock or wrist watch 
[30]. Care should be taken, however, that dispensing staff explain that the ‘sun’ and 
‘moon’ symbols refer to daytime and night-time, and not sunrise and sunset as believed 
in a few isolated cases among our study population. Finally, the wide-held response 
that AL is effective may also have played a role in supporting adherence to the 
regimen.  
It was notable that responses indicated that AL was virtually never taken with food, 
despite the fact that health providers emphasized that AL works better if not taken on 
an empty stomach.  Based on responses to the question about timing of tablet intake, it 
appears that some patients may have eaten shortly before or after taking the AL dose 
and did not consume additional food at the time of dosing, but specific information was 
not collected. It is encouraging, however, that a recent analysis of data from a large-
scale study of AL in five African countries found that although concomitant food intake 
increased lumefantrine absorption in children with malaria, there was no tendency for 
lower food intake in the few patients in whom treatment failure was recorded [31]. 
Indeed, all 37 patients who were unable to eat food with any dose achieved PCR-
corrected cure at day 28.  Nevertheless, food consumption, or resuming food 
consumption as soon as possible, at the time of AL dosing remains advisable in order 
to maximize effectiveness, in view of the observed association between lumefantrine 
exposure and clinical and parasitological outcomes [23]. This can, of course, be 
challenging since initially patients may be reluctant to eat due to symptoms of nausea 
and vomiting during the acute phase of malaria.   
Fewer than 60% of patients or caregivers understood the need to return to the health 
clinic for a replacement if a dose was vomited. Although the number of patients in 
whom a dose was reported to have been vomited was low (n=2), the findings that more 
than 40% of patients or caretakers did not know what to do if this happens is of 
concern.  
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The current findings provide detailed evidence of the timely intake of AL under 
programmatic conditions. Other analyses of unsupervised adherence have all involved 
home visits after the three-day course was completed [26-29]. Encouragingly, however, 
no study has reported fewer than 90% of patients taking all six doses by the end of the 
three-day treatment period, based on pill counts. In our case, we were able to validate 
oral information about pill administration in over 99% of cases, and found no difference 
between reported consumption and the remaining number of pills. Such validation is 
essential given the known limitations of self-reporting [32]. Our findings concur with 
those described recently by Bell et al, based on a study in Malawi in which children or 
adults with uncomplicated P. falciparum malaria were randomized to receive AL or 
chorproguanil-dapsone [29]. Of the patients randomized to receive AL, 100% reported 
correct pill consumption during oral interviews. However, in a subpopulation of 87 
patients in whom pills were dispensed from an electronic pill container that recorded 
the time of opening, Bell et al found that the rate of adherence was only 92%. Thus, the 
adherence rate obtained using this different measurement approach was the same as 
that observed in our study population (92%), where we assessed adherence by 
randomized, scheduled visits shortly after each dose was due to be taken.  Clinically, 
the high adherence rates observed when AL is self-administered after the first dose 
have been shown to result in excellent efficacy rates irrespective of whether the drug is 
given supervised or unsupervised [23]. 
Certain aspects of the study design merit consideration. The study was undertaken in 
the context of routine use of AL therapy in a rural area of sub-Saharan Africa. The 
healthcare providers who dispensed AL did not receive any special training in addition 
to the standard training provided through the National Malaria Control Program when 
first-line treatment with AL was introduced, approximately one year prior to our 
assessment. Also, the randomization approach helped ensure comparability of groups 
for each AL dose assessed, and minimized the influence of interviews by avoiding 
expected or repeated visits. However, we are aware that responses may be due to the 
phenomenon that patients or caregivers provided answers they thought would be 
expected or desired by the interviewer. Whether or not a pill had been removed from 
the blister pack could be checked through pill counts, but other questions – e.g. those 
in which the acceptability of AL was compared to other treatment options – could not 
be validated. Furthermore, responses for children under 13 years were given by 
parents or caregivers, not by the patient. Therefore, the views expressed in cases of 
children under 13 are those of their parents/guardians and may not necessarily reflect 
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the patient’s perspective. We also recognize that the questions posed could be refined, 
particularly those which resulted in 100% or near-100% responses, such as ‘Was the 
clustering of AL doses useful to remember how to take the drug?’. Moreover, there is a 
need to standardize questionnaires that assess adherence and acceptability to improve 
the quality and subtlety of the information gained and to improve comparability between 
studies.  
In conclusion, adherence to the AL regimen as standard first-line treatment of 
uncomplicated P. falciparum malaria was high among this rural study population. 
Patients adhered closely to the dosing regimen, partly due to effective packaging and 
pictorial dosing instructions and to patients’ conviction that AL is effective. These 
results may be helpful for future training of healthcare providers by National Malaria 
Control Programmes in sub-Saharan Africa before and during implementation of ACT 
therapy as first-line anti-malarial treatment. 
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Table 9.7: Patient characteristics (n=522) 
 
 
a Dose used to replace vomited dose 2 (n=1), dose not taken due to stomach ache (n=1) 
b Dose delayed (n=1), tablets lost (n=1) 
c No reason given (n=1), dose not taken due to excessive vomiting (n=1), admitted to hospital due to 
Attribute N (%) 
Age 
   <13 years 
   ≥13 years 
                                 
352 (63.8)  
200 (36.2)   
Female gender 319 (57.8) 
Level of education of patient/caregiver 
   None  
   Primary school  
   Secondary school 






Occupation of patient/caregiver 
  Employed  
  Self employed  
  Farmer 







  3 months – 3 years 
  3 – 8 years 
  8 – 12 years 






Patient condition on presentation at health facility 
   Very unwell 
   Unwell  
   Moderately unwell  
   Moderately well  
   Well 
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asthma, treated with quinine (n=1) 
d Forgot to take dose (n=1) 
e Refers to morning dose (results were similar for evening dose) 
f Not specified 
Table 10.7: Assessment of adherence to the AL dosing regimen, as evaluated by 
questionnaire (n=522) 
  N (%) 
How many doses in total to be administered for a complete 







6 1 (0.2) 
Number of tablets per dose to be taken?   
    1 tablet 270/270 (100) 
    2 tablets  62/62 (100) 
    3 tablets 40/40 (100) 
    4 tablets 180/180 (100) 
AL dose taken at correct time (i.e. ± 1 hours for dose 2, ±4 
hours for doses 3-6) 
  
   Dose 2   
   Dose 2 103/112 (92.0) 
   Dose 3 103/109 (94.5) 
   Dose 4 100/110 (91.0) 
   Dose 5 96/110 (87.0) 
   Dose 6 99/111 (89.2) 
Number of missed doses   
    Dose 2  0/122 (0) 
    Dose 3a 2/109 (1.8) 
    Dose 4b 2/110 (1.8) 
    Dose 5c 3/100 (3.0) 
    Dose 6d 2/111 (1.8) 
Action to be taken if tablets are vomited   
   Go back to health facility for replacement dose 316 (57.3) 
   Give another dose 209 (37.8) 
   Do nothing 27 (4.9) 
   Don’t know 0 (0) 
With what was AL taken/given?   
   Nothing 0 (0) 
   Water only 549 (99.4) 
   Food 2 (0.4) 
   Beverage 1 (0.2) 
   Other                                                                   0 (0) 
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Timing of tablet intake when administered with food?   
    Before meal 171 (31.0) 
    During meal 2 (0.4) 
    After meal 379 (68.6) 
What acted as a reminder to take tablets?e   
    The dispenser’s instructions 231 (41.8) 
    The pictograms 309 (55.9) 
     Illness 12 (2.2) 




Table 11.7: Acceptability assessments (n=552) 
 
 N (%) 
Were the instructions (drawings) in the AL pack useful? 
    Yes 
    No 





Was the clustering of AL doses useful to remember how to 
take the drug? 
   Helpful 
  Confusing 






How do you or your child feel now?  
   Very unwell  
   Unwell  
   Moderately unwell  
   Moderately well  
   Well 








How do you find AL to administer/take?  
   Easier to take than SP  
   Less easy than SP  
   Same as SP 






Do you find that AL works?  
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    Yes 
    Better than SP             
    Same as SP 
    Don’t know 






Would you or your child prefer to have anything else than  
AL for this particular illness? 
       No  
       Yes  
             No specific choice 
             Antibiotics 
             Analgesics/antipyretics  
             Quinine injection  
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CHAPTER 8: DISCUSSION  
 
This chapter provides discussion of the main findings gathered from different parts of 
the work presented in this thesis as reflected from main objectives (Chapter 2), namely 
anti-malarial policy issues with respect to preparedness to policy adoption and the 
monitoring of its implementation. Subsequently the chapter also provides 
recommendations and considerations for future researches on anti-malarial therapy 
and treatment policy. In-depth discussion is given below under sub-thematic sections 
as outlined in the main thesis. 
 8.1 Enabling environment for health policy changes in the treatment of 
uncomplicated malaria with ACT before and after the introduction of AL as first 
line policy in Tanzania 
 
In 2001 when most malaria endemic countries in sub-Saharan African were at the 
cross-road of adopting ACT, Tanzania implemented SP as an interim first line anti-
malarial policy. At the same time, researchers at the Ifakara Health Institute (Ifakara 
Health Research and Development Centre, by then) and elsewhere in the country were 
already in the process of researching for ACT candidates’ drugs to be used as anti-
malarial new first line policy (Mutabingwa, Nzila et al. 2001; Adjuik, Babiker et al. 2004; 
Kabanywanyi, Mwita et al. 2007; Abdulla, Sagara et al. 2008). The change from 
chloroquine to SP was an interim measure taken by the ministry of health in Tanzania 
to pave the way for a smooth transition to ACT once enough evidence on candidate 
ACT drugs of choice as well as funding mechanism were properly established. The first 
line policy with ACT was adopted in late 2006 and full implementation took place in 
2007. In Tanzania, ACT policy adoption by policy makers and uptake by the public at 
large was fast due to preparedness that was put in place based on experience 
accumulated during implementation of SP policy in the past (Mubyazi and Gonzalez-
Block 2005; Hetzel, Msechu et al. 2006; Kabanywanyi, Mwita et al. 2007). It is 
important to note here that, in 2001 the time when the country was moving from CQ to 
SP things went somehow bitter resulting in several outcries particularly related to safety 
issues of SP. These concerns resulted in poor policy uptake by the public (Mubyazi 
and Gonzalez-Block 2005). Based on the lessons learnt in the past effective measures 
were put in place in order to allow for a smooth transition to ACT policy implementation 
in Tanzania. The gained experience was useful not only to researchers in the field 
whose studies provided evidence for policy change, but also policy-makers. For these 
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reasons research findings should be linked to advocacy in order to affect any required 
translation of results to policy (Mubyazi and Gonzalez-Block 2005). This experience is 
particularly important for researchers in the field who often propose novel interventions 
but face opposition and delay from policy-makers to uptake the gained research 
evidence on time. The outcry from scientific community in 2004 on the need to avail 
and upscale ACT attests to the frustrations and problems associated with delay in 
policy implementation (Duffy and Mutabingwa 2004; White, Nosten et al. 2004).  
 
The call for global action by the research community and the general acceptance by 
African heads of states through the Abuja declaration in 2000 to support global 
initiatives for up-scaling malaria intervention programmes is the best ever recorded 
example worthy of emulation (WHO 2000). The Abuja declaration laid down several 
bench-marks to be attained by the year 2010. Major among the bench marks were: at 
least 60% of those suffering from malaria have prompt access to treatment within 24 
hours of onset of symptoms, at least 60% of those at risk of malaria, particularly 
children under five years of age and pregnant women access preventive tools such as 
ITN, at least 60% of all pregnant women who are at risk of malaria have access to 
chemoprophylaxis or presumptive treatment. The political will shown by most African 
heads of states to commit themselves to the Abuja declaration is one of the major 
steps that have led to a positive region-wide adoption and scaling up of several 
effective malaria interventions like ACT and ITN in the beginning of the decade.  
 
Surprisingly enough in most endemic African countries, ten years after the Abuja 
declaration the desirable target of improvement in most bench-marks is still far to 
reach. It is worth noting here that despite the Abuja political commitment and excelled 
support from donor communities to scale up several malaria interventions, political 
leaders in Africa still believe malaria must always be fought with support from abroad. 
Because the Abuja declaration was a political statement that was neither legally 
binding nor supported by any rigorous enforcement, researchers and the donor 
community have another task; i.e., to advocate a bridge of research knowledge-to-
policy by helping build capacity of most health system in Africa. It is expected that most 
of the remaining gaps to addressing benchmarks of the Abuja declaration could be 
realized through implementing the MDGs that re-addresses untouched issues in the 
Abuja declaration (UN 2010). It must be emphasized that that political will alone is not 
enough but has to be followed by appropriate mechanisms to put the will of the 
politicians in a real life meticulous process. Because ten years after the Abuja 
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declaration hundreds of thousands of young African children are still dying due to 
malaria and there is equally similar a number of avoidable still birth babies that are 
occurring in many parts of malaria endemicity (WHOSIS 2009), there is therefore 
enough evidence to convince most African heads of states to be more proactively 
committed to live up on their promises.   
 
Malaria management scheme in the post independence era in Sub-Saharan Africa and 
South East Asia as noted earlier in this thesis have a lot in common in terms of 
geopolitical landscape and epidemiology of the post-independence newly emerged 
malaria endemic states. In Tanzania for instance, the national malaria control 
programmes differs from the rest of Sub-Saharan Africa countries basically due to 
various reasons. Tanzania has a homogenous health system that facilitated the roll out 
malaria control programme as part of the primary Health Care (PHC) system. This was 
supported by evidence-based research emerging from the North-South research 
collaborations. Government and non-state collaborations within Tanzania was key in 
informing the above process. In some cases cross boarder collaboration among 
economic blocks of East Africa and Southern African Development Community (SADC) 
have also provided insights into the control of malaria across nations. Some of the 
novel implementation tools developed and tested in Tanzania, have been applied in the 
rest of Sub-Saharan malaria endemic states and often supported the global campaign 
against malaria.  Political stability and peace for over four decades has also made it 
easy for quick policy change and scale up of control interventions using ACT, which 
could have been different in neighboring nations like Uganda, Sudan, Mozambique and 
Democratic republic of Congo which have experienced civil strife during this period. 
Due to these reasons, Tanzania has emerged as one of the few African countries that 
provided the ground to test some of the most successful malaria control interventions 
for the rest of the world to up-scale.  
As part of a long term malaria related research agenda in Tanzania, social marketing of 
ITN and its resultant effect on child anaemia and mortality have been proven effective 
(Schellenberg, Abdulla et al. 2001; Abdulla, Gemperli et al. 2005). Tanzania is also one 
among few countries in Africa together with South American-Peru and Asia that 
evaluated the effectiveness of IMCI (Armstrong Schellenberg, Bryce et al. 2004). 
Malaria management in children through a novel intermittent preventive treatment in 
infancy strategy was initially tested in Tanzania (Schellenberg, Menendez et al. 2001; 
Schellenberg, Menendez et al. 2005). These are just few on the list of many key 
malaria intervention that have taken place in Ifakara in Tanzania.  
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Ifakara is an area that was initially home to intense perennial malaria endemicity but 
quite opposite today.  Malaria in this region is on the decline and transmission has 
changed significantly (Russell, Lwetoijera et al.). It is worthy to note that, malaria 
endemic Ifakara and Tanzania at large has provided the venue for developing new 
malaria intervention tool and a fertile environment for global anti-malarial policy 
transitions. 
  
8.2 Impact of anti-malarial first line policy on malaria transmission, morbidity and 
under five mortality in rural two districts in Tanzania.  
 
Not long after the launch of a special initiative for Africa to control malaria by the United 
Nations secretary general in 1995, the Kilombero river Valley mosquito bed-net social 
marketing programme (KINET) was launched in Ifakara, in 1996. This launching was 
facilitated by researchers from Ifakara Health Institute, London School of Tropical 
medicine and Hygiene and Swiss Tropical Institute (Schellenberg, Abdulla et al. 1999). 
The social marketing campaign started to focus on distribution of net to the most 
vulnerable to malaria population groups; pregnant women and children under five 
years, and subsequently assessed the medium term impact of the programme in later 
years (Marchant, Schellenberg et al. 2002). This programme in the long-term was 
enhanced by the regional strategies that were being implemented at the national level 
such as the Roll Back Malaria in 1998 that was also supported by the Abuja 
Declaration in 2000.  The introduction of KINET project in Ifakara and subsequent 
launching of DSS was a turning point to succession of upcoming other intervention 
programmes that took place in the region (Schellenberg, Abdulla et al. 1999; 
Schellenberg, Abdulla et al. 2001). It is therefore imperative to note here that, this 
succession of interventions and their resultant medium term changes in transmission 
intensity in Ifakara today stems from past efforts dating fourteen years (Russell, 
Lwetoijera et al.).  
 
It is  therefore a fact that consistent reduction in malaria transmission and all-cause U5 
child mortality that we witness today in Ifakara started to emerge soon after the 
implementation of socially marketed ITNs in the region and support regional 
achievements that  have been accumulated through various implementation platforms 
(Russell, Lwetoijera et al.; Marchant, Schellenberg et al. 2002; Armstrong 
Schellenberg, Bryce et al. 2004; Abdulla, Gemperli et al. 2005; Masanja, Schellenberg 
et al. 2005). On one hand this has to be seen as a secular trend in downturn which is 
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likely due to effect of several interventions that have taken place since mid of last 
decade. On other hand however, the recent sharp decrease in parasite prevalence in 
asymptomatic individuals and the consequential decrease in mortality documented in 
2009 as mentioned in the results section of chapter six of this thesis was influenced 
through the introduction of ACT using AL.  The ALIVE study demonstrated that ACT 
was responsible for 11% annual decreases in U5 mortality when adjusted for other 
interventions like ITN and contextual factors (rainfall and food yields). Additionally since 
its introduction in 2007, ACT with AL has consistently kept the sexual form of malaria 
parasitaemia below 1%.  
 
The introduction of AL as the first line treatment of malaria in Tanzania and in the 
Kilombero river valley in particular coincided with a number of valuable achievements 
on control worthy emulating in similar settings. First AL was introduced in Kilombero at 
a time when SP was readily available in both private and public outlets made possible 
under the community-based social marketing programme for access of malaria 
interventions-ACCSESS project (Hetzel, Msechu et al. 2006). Future malaria 
programmers should pay attention to the accessibility of ACT for better treatment 
outcome (Alba, Hetzel et al.).  The social marketing programme of ACCESS 
programme contributed to the timely accessibility of AL, resulting in comparatively 
fewer cases of fever compared to those before the implementation of ACT policy 
(Khatibu et al., person communication) (Alba, Dillip et al. ; Alba, Hetzel et al.). It is 
crucial to note that during the past three years of ACT policy implementation in Ifakara, 
most malaria fevers at the moment of ascertainment were promptly treated with anti-
malarial on time (Alba, Dillip et al.).  Prompt treatment of malaria related fevers with 
efficacious ACT that could result in severe form of malaria had they been delayed or 
treatment with non-efficacious mono-therapies underlines achievements realized under 
ALIVE. ACT was responsible for nearly 65% reduction in community parasitaemia as 
compared to the baseline in 2006. Secondly AL was introduced in a time Tanzania was 
up-scaling ITN together with bundled or LLITN programme countrywide through- 
NATNETS scheme and ITN coverage in Ifakara has gone beyond global MDGs 
benchmarks (Schellenberg, Abdulla et al. 2001; Kabanywanyi, Macarthur et al. 2008; 
WHO Abuja declaration, 2000). As reported in chapter six of this thesis, it can therefore 
be argued that a good performance of ACT in similar other malaria endemic settings 
will depend on timeliness of implementations and proper monitoring of parallel 
interventions.  
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The consequence of this achievement to the overall health care system at large is an 
exercise that should always attract the attention of several health care partners 
including MDGs scheme evaluators. Because it has been historically acknowledged 
that malaria accounts for a significant majority of outpatient attendances (Maegga, Cox 
et al. 2005) the current positive achievements in the region is likely to be of a major 
health sector importance especially to the local districts health management authorities 
and the overall global extrapolation to the ongoing MGDs scheme.  A recent completed 
study on ACCESS to treatment in the Kilombero river valley (2005-08) estimated a high 
coverage (86% to 96%) of fever treatment with anti-malaria in the public health facilities  
and timely high use of anti-malarial (80% to 93-97%) treatments taken within 24 (Alba, 
Dillip et al.). These findings are peculiar to Tanzania and have never been released in 
other malaria endemic setting in Sub-Saharan Africa. These findings imply that with 
minimal staff, effective interventions including newly introduced malaria rapid 
diagnostic tests could reduce malaria morbidity and mortality considerably and such 
interventions are highly needed in rural Africa (D'Acremont, Lengeler et al. ; 
d'Acremont, Malila et al.).   
 
Another very important consideration in this regard, is the overall implication of the 
impact achieved at the country or regional level especially in the era of malaria 
eradication/elimination. Consistently successions of malaria intervention programmes 
in Ifakara have resulted from integrated research agenda in the region. Because these 
researches sought to address the burden of malaria at the district level in order to 
inform policy, it can be argued that similar outcomes elsewhere are possible through 
defined commitment. High coverage of efficacious interventions with exceeding impact 
has started to project an image of malaria elimination phase in Zanzibar. The same 
implies that similar achievements may happen elsewhere in malaria endemic setting 
given availability of good coverage of political will.  Another similar example of positive 
uptake of efficacious interventions is the scaling up of the Tanzania countrywide bed 
nets-NATNETS programmes and voucher scheme (Magesa, Lengeler et al. 2005; 
Mulligan, Yukich et al. 2008).   
 
Attainment of good coverage of impact interventions is not only due to a long term 
arrangements.  A short term focused programmes can also be successful as the one in 
Bioko island of Equatorial Guinea. In Bioko, it was shown that an integrated malaria 
control programme resulted in to major reduction in entomological indices of malaria 
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transmission prompting to transit to an elimination phase just 4 years after the 
programme (Kleinschmidt, Schwabe et al. 2009; Kleinschmidt, Schwabe et al. 2009).   
 
In general terms, what has been achieved in Ifakara may have already been coming 
along the path in similar localities in the country or elsewhere in the continent. What 
remains is to mobilize available tools, resources and knowledge in order to replicate 
achievements in different regions of Africa and other malaria endemic countries.  
 
8.3 To describe programmatic issues and their implication for anti-malarial first 
line policy and impact assessments 
 
The contribution of AL as first line policy to the reduction of malaria morbidity and 
mortality in children U5 years in the K/U area is described in chapter 6 of this thesis 
under ALIVE study. This is consistent with any success story drawn from the Kilombero 
river valley.  In a conventional applicable definition; a programme success may be 
defined as gain in intervention coverage and in health impact under real world 
conditions when intensity of its implementation is lower than in efficacy trial (Habicht, 
Victora et al. 1999). The Tanzania country-wide ACT introduction with AL as first line 
could be considered as a continuum of a more secular programmatic stepwise phase 
that started back in 2001. The equivalence of policy implementation and subsequent 
evaluation in the framework of Kilombero valley in the IHDSS in particular has different 
picture i.e., regional programmatic evaluation under ALIVE study that is referenced 
here.  Although the country-wide policy implementation by itself is not ecological in 
nature but the Ifakara regional assessment by itself is the case. Malarial intervention 
programmes in Ifakara region date back to the mid 1990s with subsequent phasing out 
of two malaria first line policy; first with CQ in 2001 and later with SP in 2006. Ifakara 
has experienced crucial achievements with respect to malaria morbidity, mortality and 
evidence of changes in malaria transmission. Because changes in malaria 
transmission intensity as documented from asymptomatic individuals in household 
surveys and reduction in children U5 mortality in this area have occurred concurrently 
with anti-malarial policy transitions, the introduction of ACT policy attests to the 
contribution of this effect. The association of less efficacious anti-malarials with child 
mortality in the past during the CQ era was presumed to confound the impact of IMCI 
intervention on mortality in the intervention districts in Tanzania back in 2003. This 
happened despite the fact that IMCI is an efficacious intervention strategy against most 
child health problem (Armstrong Schellenberg, Adam et al. 2004). This particular 
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finding is a crucial background to our findings and supports our extrapolation that ACTs 
have contributed to reduction of U5 child mortality.  
 
Availability of baseline efficacy profile and intensive campaign by stakeholder and 
preparedness among researchers accelerated policy implementation in most part of 
Tanzania (Alba, Dillip et al. ; Kabanywanyi, Mwita et al. 2007). The ACT policy in 
Tanzania was highly acceptable as compared to the SP policy (Kabanywanyi, Lengeler 
et al.). This phenomenon can be explained by consistent stock-outs of AL in most 
public health facilities for a considerable extended period during the early phase of 
implementation that resulted from high uptake of the drug (Alba, Hetzel et al.). The 
experience of mass public campaigns has also contributed to an increase in the 
improvement of most health seeking-parameters (de Savigny, Mayombana et al. 2004). 
A better understanding about causes of malaria among community members in Ifakara 
(from 62% to 84%), an increase in health facility attendance as first treatment option for 
patients older than five years (27% to 52%), higher treatment coverage with anti-
malarial [86% to 96%) and more timely use of anti-malarial (80% to 93-97% treatments 
taken within 24 hrs] (Alba, Dillip et al.) are among important programmatic issues that 
supported ACT policy in K/U.   
 
Monitoring the efficacy and safety of anti-malarial first line policy before and after its full 
implementation is a programmatic aspect that must always be considered as important 
in any successful policy implementation. The richness of evidence that was available 
before the policy with AL when introduced is a good example of worthy emulation in 
similar policy preparedness (Falade, Makanga et al. 2005; Makanga, Premji et al. 
2006; Kabanywanyi, Mwita et al. 2007). In the past it was even difficult for policy 
makers to confidently convince the public that the untoward consequences of treatment 
with SP as compared to treatment with failing anti-malarials were much lower than an 
occurrence of adverse event in one person out of a thousand successfully handled 
patients (Newman, Parise et al. 2003; Mubyazi and Gonzalez-Block 2005). The 
introduction of a safety monitoring framework in the K/U region is another practical 
important step towards gaining local experience to the establishment of a full large 
scale pharmacovigilance reporting system in the region. A good coverage of similar 
experiences in other parts of the country and at the regional level is needed to 
maximize capture of safety information on ACT and other medications in use.  Failure 
to properly assess the safety of anti-malarias in use or new ones that are entering the 
market could result in public misperception and lead to problems with acceptability (SP) 
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(Mubyazi, Bloch et al. 2005). Concerns about SP-related serious adverse skin 
reactions (e.g. Stevens-Johnson syndrome) led to unnecessary delays in the process 
of policy change in several African countries (Mubyazi and Gonzalez-Block 2005).  It is 
also equally important for the relevant drug regulatory authorities to assume more 
responsibility in monitoring drug safety and put in place useful arrangements with local 
regulatory agencies to allow hospitals and pharmacies to enquire more information on 
drug safety and keep vigilance to all drugs that are in use. This will eventually ensure 
accumulation of relevant information on drug safety and increase trust between drug 
users and health authorities or programme authorization holders.  
 
Partnership between the ministry of health, researchers, pharmaceutical industry and 
communities as documented under the ALIVE project in chapter 5 and 7 of this thesis 
is a unique novel example worthy of emulation in similar polices in the future. A 
combination of research experience from IHI and Swiss TPH research communities, 
the local contextual community as well as policy implementation skills from the ministry 
of health in Tanzania and technical expertise plus funding opportunities form Novartis 
Pharma/Novartis Foundation for Sustainable Development has provided a unique 
partnership for programme implementation. This partnership is the first of its kind in 
Sub Saharan Africa. A long time rooted research partisanship and trust between these 
three institutions represented a novel model of health system partnerships.  Safety and 
compliance issues of medicinal products that are deployed at large scale like ACT for 
instance should not and will neither be the responsibility of drug authorizations holder 
nor pharmaceutical industries alone. It is therefore imperative that global health 
partners at present should forge a comprehensive and trustworthy partnership among 
interested parties to implement and upscale anti-malarial drug policies. Lessons on 
partnership and networking from our experience in malaria, reported in this thesis could 
be replicated for other diseases of developing countries.  
 
Capacity building of market and policy implementation holders is very crucial and must 
be considered seriously. Today the Global Fund to fight AIDS, Tuberculosis and 
Malaria and other malarial global partners have massively increased their support for 
malaria treatment and diagnosis. Investments should also be made towards capacity 
building in order to strengthening health sectors of institutions in malaria endemic 
countries. This will further create enabling environment and a critical mass of scientists 
and public health experts to spearhead anti-malaria policy implementations properly 
and monitor their performance on timely a basis.  
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8.4 Implications  
 
(a) Practical 
Isolated success in some benchmarks of the Abuja declarations for 2010 have been 
realized in Ifakara some years ahead of the 2010 target. It is true that not all part of 
Tanzania Mainland has reproduced similar coverage and indicators of success. A 
bigger countrywide and notably continental picture replicated by emulating regional 
based success to a larger scale by undertaking similar implementation strategies in 
other endemic but still lagging behind regions is needed.  
 
Partnership between the ministry of health, researchers and pharmaceutical industry as 
experienced and documented under the ALIVE project of this thesis is a unique 
example worthy of emulation in future policy implementations.  
 
Safety and compliance issues of any medicinal product which is deployed in a large 
scale like the ACT should be the responsibility of several responsible but also 
interested parties.  
 
Capacity building of market and policy implementation holders is another critical aspect 
that should be taken seriously. This will further create an enabling environment and a 
sustainable critical mass of scientists and public health experts to spearhead and 
monitor policies for anti-malaria.  
 
(b) Research related 
At present, in most endemic settings the untoward outcome due to malaria today could 
be avoided because all potential tools to fight malaria such as LLITN and ACT are 
available.  
What is thus needed for the entire community involved is to streamline the thinking and 
to somehow merge the approaches that are at hand very carefully.  
 
In ALIVE programme it has been demonstrated that with high ITNs coverage 
deployment of efficacious drug has the potential to decrease U5 mortality, conversely 
high ITNs coverage with efficacious drug has lowered malaria transmission. This 
attests the argument that deployments of complimentary anti-malarial interventions 
together at a scale produce a huge effect.  For Tanzania it can be expected that, since 
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there is a countrywide distribution of LLTN through NATNETs, then similar assessment 
that will include a large area with different ecological setting notably; different districts 
in order to gain a broad understanding of the actual effect in different administrative 
setting is needed. For this assessment, Tanzania and few other African countries at 
present are well positioned to undertake it through the ongoing formation of the 
Sentinel Panel of Districts (SPD) where the unit of assessment is the district itself and 
not the classic assessment through interventions or programmes. This can also be 
carried out at the continental level with the aim of assessing the health system of 
individual countries on their ability to scale up malaria interventions by including various 
units of measurements for the health system such as governance, human resources, 
services, mechanism of basket funding, intervention delivery infrastructures etc of the 
individual or group of countries. Similar assessment once applied will be a unique 
opportunity for MDGs evaluation since it will provide more granulations on what is 
happening at the regional level for different malaria endemicity and a more complex 
analysis of malaria/HIV synergetic untoward effect on the health system.  
It can thus be hoped that through similar arrangements and sharing experience the 
malaria fighting community truly succeed in the fight that could read to malaria 





Public-private partnerships as exemplified in the ALIVE model of researches represent 
a classical option for the malaria community today.  It is therefore recommended here 
that; global health partners at present be able to forge a comprehensive and 
trustworthy partnership for proper anti-malarial policy implementation. It is also 
recommended that global health financing partners should allocate funds through 
existing funding mechanism tin for capacity building in order to strengthen health 
sectors of institutions in malaria endemic countries. 
8.6 Future work 
 
Where possible in developing countries to include in medical collage’s some syllabuses 
on key issues like safety reporting and policy-based programme implementation. Also 
on job capacity building scheme for programmers and policy implementation holders in 
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order to create enabling environment and a critical mass of scientists and public health 
experts to spearhead anti-malarial policy implementation. 
 
Revival of regional anti-malarial monitoring platforms such as EANMAT is critical now 
at the moment of establishing of efficacy profile of anti-malarial with ACT taking in to 
serious consideration of the emergence of ACT drug resistance in South Eastern Asia. 
8.7 Conclusion 
  
This work has provided evidence that a successful campaign against malaria can be 
realized through combining efforts of researchers, policy makers, global health 
development partners and communities. This partnership has lead to real life time 
achievements in past programmes such as that recorded in the 1940s malaria 
eradication campaigns in Europe.  
8.8 Key message 
 
I. Preparedness for policy inceptions and timely implementation of real time 
focused based operation researches and emulating them in a real practical life 
as outlined in order to address resurgences of global anti-malaria drug 
resistance. 
 
II. Evidence accumulation before and after policy inception is crucial for long life-
span of the new anti-malaria drug policy. 
 
III. Isolated success gained on the impact of well implemented malaria 
interventions in some malaria endemic settings are good examples to emulate 
in other regions. It is moreover crucial that are critically analyzed before 
extrapolations to other regions as it will be crucial to take account of 
heterogeneous nature of health systems in different regions. 
 
IV. Global partnership as exemplified in the ALIVE study represents a classical 
option for malaria combating community today. 
 
V. Capacity building of regulatory and policy decision-makers is a critical aspect 
that should be looked seriously and where possible reasonable part of available 
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global funds be invested to strengthening health sector of most institutions in 
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             Medical Research, Accra Ghana 
 
2002  Certificate of Clinical drug and Vaccine Research, Vienna school of Medical 
Research, Vienna Austria 
 
2001  Certificate of Internship, Muhimbili National Hospital, Tanzania 
 
1999  (MD) Bachelor degree in Medicine, Volgograd Medical academy, Russia 
 
1999   (BA) Bachelor of Arts-Teacher of Russian Language, Volgograd Medical 





1. Efficacy and safety of artemisinin-based antimalarial in the treatment of 
uncomplicated malaria in children in Southern Tanzania: 
http://www.malariajournal.com/content/6/1/146 
Abdunoor M Kabanywanyi, Alex Mwita, Deborah Sumari, Renata Mandike, Kefas 
Mugittu, Salim Abdulla 
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2. Malaria in pregnant women in an area with sustained high coverage of 
insecticide-treated bed nets: http://www.malariajournal.com/content/7/1/133 
Abdunoor M Kabanywanyi, John R MacArthur, Wilma A Stolk, J Dik F Habbema, 
Hassan Mshinda, Peter B Bloland, Salim Abdulla, S Patrick Kachur 
 
3. Residual Antimalarials in Malaria Patients from Tanzania – Implications on 
Drug Efficacy Assessment and Spread of Parasite Resistance   
http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0008184 
Eva Maria Hodel, Abdunoor Mulokozi Kabanywanyi, Aggrey Malila, Boris Zanolari, 
Thomas Mercier, Hans-Peter Beck, Thierry Buclin, Piero Olliaro, Laurent Arthur 
Decosterd, Blaise Genton  
 
4. Adherence to and acceptability of artemether-lumefantrine as first-line anti-
malarial treatment: evidence from a rural community in Tanzania 
http://www.malariajournal.com/content/9/1/48 
Abdunoor M Kabanywanyi, Christian Lengeler, Prudensiana Kasimu, Said 
King’eng’ena, 
Raymond Schlienger, Nathan Mulure, Blaise Genton,   
 
5. Experience of safety monitoring in the context of a prospective observational 
study of artemether-lumefantrine in rural Tanzania: lessons learned for 
pharmacovigilance reporting http://www.malariajournal.com/content/9/1/205 
Abdunoor Mulokozi Kabanywanyi, Nathan Mulure, Christopher Migoha, Aggrey Malila, 




1. Using demographic surveillance system to record early inadvertent exposure 
of antimalarial during pregnancy.  
 
Abdunoor M Kabanywanyi, Aggrey Malila, Mathew Alexander, Honesta 
Mzyangizyangi, Honorati Masanja and Salim Abdulla*  
 
International Meeting and Conferences Presentations 
 
1. November 2009, Using demographic surveillance system to record early inadvertent 
exposure of antimalarial during pregnancy, American Society of Tropical Medicine and 
Hygiene, Washington USA 
[Oral presentation] 
 
2. November 2009, Adherence and safety of artemether/lumefantrine(Coartem®) as 
first-line treatment for uncomplicated malaria in Tanzania, 5th International conference 
for Multilateral Initiative on Malaria (MIM), Nairobi Kenya  [Oral presentation] 
 
 
3. December 2008, Training and implementation of pharmacovigilance in rural sub-
Saharan setting in Tanzania, American Society of tropical medicine and hygiene-New 
Orleans USA [Oral presentation] 
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4. October 2008 Adherence to artemether/lumefantrine(Coartem®) as first-line 
treatment for uncomplicated malaria in Tanzania, 17th International Congress for 




5. November 2007, Risk factors in pregnant women without IPTp protection, American 
Society of tropical medicine and hygiene-Philadelphia, Pennsylvania USA [Oral 
presentation] 
 
6. November 2006, Data Management and statistical issues for Malaria Clinical Trials, 
AMANET workshop of clinical Investigators, Kilifi Kenya [Lecture] 
www.amanet-trust.org/ext/reports/workshops/2006/AMAWS1106.pdf 
 
7. November 2002, Surveillance of antimalarial adverse events, 3rd International 





 Speak Read Write 
Swahili Mother tongue Excellent Excellent 
English Good Good Good 






1. Dr Salim Abdulla 
Director Ifakara Health Institute 
Epidemiologist,  
Senior research scientist,  
Ifakara Health Institute 
P.O Box 78373 
DAR ES SALAAM 
Tel. +255 22 2774714  




2. Prof. Blaise Genton  
Head of Travel Clinic 
Epidemiologist 
Policlinique Médicale Universitaire 
Bugnon 44, 1005 LAUSANNE 
Tel +41 79 556 58 68 
Office Fax +41 21 314 48 57 
E-mail: Blaise.Genton@unibas.ch 
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